[["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes the TAR DNA-binding protein, which is involved in RNA metabolism and the regulation of RNA processing. Mutations in TARDBP have been associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. This pathway involves multiple genes related to complex I of the mitochondrial electron transport chain, suggesting that TARDBP may play a role in mitochondrial function or biogenesis. Disruption of this pathway could lead to impaired energy production, contributing to neuronal dysfunction and degeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes the TAR DNA-binding protein, which is primarily localized in the nucleus but has been found to associate with mitochondria. It plays a role in RNA processing and is involved in the regulation of gene expression. Mutations in TARDBP are associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described, which includes multiple subunits of complex I of the mitochondrial electron transport chain, suggests that TARDBP may influence mitochondrial function or biogenesis, potentially contributing to the mitochondrial dysfunction seen in ALS. This connection underscores the role of mitochondrial impairment in the pathogenesis of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP gene encodes the TAR DNA-binding protein, which is involved in RNA metabolism and is located in the nucleus and mitochondria. Mutations in TARDBP are associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway described includes genes related to complex I of the mitochondrial electron transport chain, which is crucial for ATP production. Disruption of this pathway may lead to impaired mitochondrial function, which is a common feature in neurodegenerative diseases like ALS. TARDBP's role in both nuclear and mitochondrial RNA processing suggests its involvement in maintaining mitochondrial integrity and function. Therefore, the biological effect of this TARDBP allele contributes to amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene encodes the von Hippel-Lindau tumor suppressor protein, which is a key component of an E3 ubiquitin ligase complex involving RBX1, ELOC, ELOB, and CUL2. This complex targets HIF1A for ubiquitination and degradation under normoxic conditions. When VHL is dysfunctional, HIF1A accumulates, leading to the stabilization of the HIF1A-ARNT heterodimer, which activates the transcription of downstream genes such as SLC2A1, VEGFA, TGFB, PDGFB, and TGFA. This results in increased angiogenesis, cell proliferation, and survival. This pathway is commonly dysregulated in VHL disease, leading to the development of hemangioblastomas, renal cell carcinomas, and other tumors. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene encodes a tumor suppressor protein that is part of an E3 ubiquitin ligase complex that targets HIF1A for degradation under normoxic conditions. In the absence of functional VHL, HIF1A accumulates, leading to the activation of genes involved in angiogenesis, cell survival, and glucose metabolism, such as VEGFA, TGFB, and PDGFB. This pathway is central to the hypoxia response and is dysregulated in VHL syndrome. The network defines a pathway where VHL, along with RBX1, ELOC, ELOB, and CUL2, negatively regulates HIF1A, which in turn, when bound to ARNT, activates downstream effectors. Mutations in VHL disrupt this regulation, promoting tumor growth, particularly in the retina, kidney, and adrenal glands. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele is a critical component of the ubiquitin ligase complex (VHL*+RBX1+ELOC+ELOB+CUL2) that targets HIF1A for degradation under normoxic conditions. When VHL is inactivated or mutated, HIF1A accumulates and dimerizes with ARNT, activating downstream hypoxia-responsive genes such as VEGFA, SLC2A1, TGFB, PDGFB, and TGFA. This dysregulated pathway leads to abnormal blood vessel formation, angiogenesis, and cell growth, contributing to the development of von Hippel-Lindau disease. This inherited disorder is characterized by the formation of benign and malignant tumors in various organs, including the retina, kidneys, adrenal glands, and pancreas.\n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that acts as a negative regulator of the cell cycle by inhibiting cyclin-dependent kinases. In the provided pathway, CDKN2A is upstream of MDM2, which negatively regulates TP53. TP53, when activated, induces CDKN1A, which in turn inhibits the cyclin D-CDK4/6 complex, preventing the inactivation of RB1. Active RB1 suppresses E2F, a key transcription factor for cell cycle progression. Loss of CDKN2A function can lead to unchecked cell proliferation due to loss of this regulatory checkpoint. This pathway disruption is commonly observed in several cancers, particularly melanoma, lung cancer, and neuroendocrine tumors. Thus, mutations in CDKN2A contribute to the development of these malignancies.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a cyclin-dependent kinase inhibitor that regulates the cell cycle by inhibiting CDK4/6, preventing the phosphorylation of RB1, and thus blocking the progression from G1 to S phase. Mutations or loss of function in CDKN2A are associated with uncontrolled cell proliferation. In the given pathway, CDKN2A influences the p53 pathway via MDM2 and TP53, which in turn activates CDKN1A to further suppress the cell cycle. Disruption of CDKN2A can lead to dysregulation of the G1/S checkpoint, promoting tumorigenesis. This genetic alteration is implicated in several cancers, most notably melanoma and neurofibromatosis type 1. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that functions as a tumor suppressor. It is part of a critical regulatory pathway involving TP53, MDM2, CDKN1A, RB1, and E2F, which controls cell cycle progression and DNA repair. Mutations in CDKN2A can disrupt this pathway, leading to uncontrolled cell proliferation and genomic instability. This gene is frequently mutated in several cancers, particularly melanoma and certain neuroendocrine tumors. The loss of CDKN2A function contributes to tumorigenesis by inactivating the p53 pathway and allowing cells to bypass checkpoints that normally prevent uncontrolled growth.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele, as described in the provided pathway, is the initiation of a cascade leading to increased intracellular and mitochondrial calcium levels, which can trigger mitochondrial permeability transition pore (MPTP) opening, release of cytochrome c, and ultimately apoptosis. This pathway is closely associated with amyloid-beta (A\u03b2) production, a hallmark of Alzheimer's disease. The activation of mAChR by A\u03b2, followed by downstream signaling through GNAQ, PLCB, and ITPR, highlights the role of calcium dysregulation in neurodegeneration. The involvement of mitochondrial calcium uniporter (MCU) and solute carrier family 25 members further underscores mitochondrial dysfunction, a key feature in Alzheimer's disease. Therefore, this APP allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described begins with the APP (amyloid beta precursor protein) gene, which is central to the production of amyloid-beta (Abeta) peptides. These peptides are implicated in the pathogenesis of Alzheimer's disease. The cascade involving Abeta, mAChR (muscarinic acetylcholine receptors), GNAQ, PLCB, IP3, ITPR, and Ca2+ signaling highlights the role of calcium dysregulation in neuronal dysfunction. The mitochondrial components MCU, MPTP, and CYCS suggest that this pathway leads to mitochondrial calcium overload, potentially triggering apoptosis. This sequence of events is commonly observed in Alzheimer's disease, where accumulation of Abeta contributes to synaptic and neuronal damage. Therefore, the biological effect of this APP allele is most strongly associated with Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway begins with the amyloid beta precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta). Abeta activates muscarinic acetylcholine receptors (mAChR), triggering a cascade involving GNAQ, PLCB, IP3, and ITPR, which elevate intracellular calcium levels. Increased calcium activates the mitochondrial calcium uniporter (MCU), increasing mitochondrial calcium, which can lead to mitochondrial permeability transition pore (MPTP) opening. This leads to the release of cytochrome c (CYCS), promoting apoptosis. This pathway is implicated in Alzheimer's disease, where accumulation of Abeta and subsequent neuronal dysfunction and death are key features.  \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel protein that plays a critical role in neuronal excitability. Mutations in KCNC3 are associated with episodic ataxia, a neurological disorder characterized by recurrent episodes of impaired coordination and balance. This pathway involves extracellular potassium ions (K+), and the dysfunction of the KCNC3 channel can lead to abnormal neuronal firing and impaired signal transmission, contributing to the symptoms of the disease. \n\n\\boxed{Episodic Ataxia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel, which plays a critical role in the regulation of neuronal excitability. Mutations in KCNC3 have been implicated in a rare neurological disorder known as spinocerebellar ataxia type 13 (SCA13). This condition is characterized by progressive cerebellar ataxia, along with a range of neurological symptoms such as nystagmus, dysarthria, and dysphagia. The biological effect of the KCNC3 allele, therefore, is the disruption of normal potassium channel function, leading to impaired neuronal signaling and the development of SCA13.\n\n\\boxed{Spinocerebellar ataxia type 13}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit crucial for neuronal excitability. Mutations in KCNC3 are associated with spinocerebellar ataxia type 13 (SCA13), an autosomal dominant neurodegenerative disorder. This disease is characterized by progressive ataxia, dysarthria, and visual disturbances, resulting from degeneration of cerebellar and brainstem neurons. The biological effect of the KCNC3 allele involves altered potassium channel function, leading to impaired neuronal firing and ultimately neuronal dysfunction and degeneration. \n\n\\boxed{Spinocerebellar Ataxia Type 13}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP allele, specifically involved in the pathway APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS, contributes to the accumulation of amyloid beta (Abeta) peptides, which is a hallmark of Alzheimer's disease. This pathway outlines the progression from amyloid precursor protein (APP) cleavage to the generation of Abeta, activation of muscarinic acetylcholine receptors (mAChR), and subsequent intracellular calcium dysregulation through IP3 and ITPR, leading to mitochondrial calcium overload and the permeability transition pore (MPTP) opening. This causes the release of cytochrome c (CYCS), inducing apoptosis. These events are implicated in neuronal dysfunction and death observed in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway outlines a sequence involving the amyloid precursor protein (APP) and its downstream effects, leading to increased intracellular calcium levels and mitochondrial permeability transition pore (MPTP) activation, which can trigger apoptosis. This pathway is closely associated with Alzheimer's disease (AD). The accumulation of amyloid-beta (A\u03b2) from APP processing is a hallmark of AD and contributes to neurodegeneration. The involvement of muscarinic receptors, GNAQ, PLCB, and inositol trisphosphate receptors further supports the cholinergic hypothesis of AD and calcium dysregulation in the disease. The ultimate effect on mitochondrial function and the release of cytochrome c (CYCS) underscores the role of this pathway in neuronal death seen in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway begins with the APP gene, which encodes the amyloid beta precursor protein. This protein is central to the production of amyloid-beta peptides, which are known to accumulate in the brain and form plaques associated with Alzheimer's disease. The pathway continues through a series of molecular interactions involving cholinergic receptors, G proteins, phospholipase C, inositol trisphosphate, and calcium signaling, ultimately leading to mitochondrial dysfunction and the release of cytochrome c, a key event in apoptosis. These processes are implicated in neurodegeneration. Therefore, the biological effect of this APP allele, particularly when dysregulated, contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes for ataxin-3, a protein involved in the ubiquitin-proteasome system. The pathway described involves calcium signaling, which is critically regulated by the interaction of ITPR1 with ATXN2 and ATXN3. Mutations in ATXN3, particularly those leading to expanded CAG trinucleotide repeats, result in the production of a dysfunctional ataxin-3 protein. This leads to the accumulation of misfolded proteins, neuronal dysfunction, and ultimately neurodegeneration. These mutations are most commonly associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. SCA3 is a progressive neurodegenerative disorder characterized by ataxia, dystonia, and other motor and non-motor symptoms. \n\n\\boxed{Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes a protein involved in the ubiquitin-proteasome system, which is crucial for degrading misfolded or damaged proteins. Mutations in ATXN3, particularly the expansion of a CAG trinucleotide repeat, lead to the production of an aberrant ataxin-3 protein. This dysfunctional protein accumulates in neurons, leading to progressive neurodegeneration. The pathway described involves calcium signaling and mitochondrial dysfunction, both of which are implicated in neuronal cell death. ATXN3 mutations are strongly associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This is a dominantly inherited, progressive neurodegenerative disorder characterized by ataxia, dystonia, and a variety of other neurological symptoms.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes the ataxin-3 protein, which is involved in the ubiquitin-proteasome system and plays a role in maintaining protein homeostasis. In the given pathway, ATXN3 is associated with the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1), suggesting a role in calcium signaling. Mutations in ATXN3 are linked to spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, an inherited neurodegenerative disorder characterized by progressive loss of motor control, ataxia, and other neurological symptoms. The inclusion of ATXN3 in the pathway highlights its potential contribution to calcium dysregulation and mitochondrial dysfunction, which are common features in SCA3. \n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nSOD1 is a key gene in the pathway described, where it activates BIP, leading to a cascade involving EIF2AK3, which phosphorylates EIF2S1, resulting in ATF4 activation and ultimately upregulation of DDIT3. This pathway is involved in the unfolded protein response (UPR) and oxidative stress. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the selective loss of motor neurons. The SOD1 allele, when mutated, leads to misfolding and aggregation of the SOD1 protein, causing toxic effects on motor neurons. This results in progressive muscle weakness and paralysis. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves SOD1, which is linked to BIP, EIF2AK3, and ultimately leads to the activation of DDIT3. This pathway is associated with the unfolded protein response (UPR) in the endoplasmic reticulum (ER). Mutations in SOD1, particularly those that cause misfolding or aggregation, are strongly linked to amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations can lead to ER stress, activation of the UPR, and eventual neuronal death, particularly in motor neurons. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway begins with SOD1, which is a copper/zinc superoxide dismutase involved in scavenging reactive oxygen species. A mutation in the SOD1 gene leads to the production of a toxic, misfolded protein that accumulates in motor neurons, causing oxidative stress and ultimately neuronal death. This process is central to the pathogenesis of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The downstream genes in the pathway\u2014BIP, EIF2AK3, EIF2S1, ATF4, and DDIT3\u2014are all involved in the unfolded protein response (UPR) and stress response mechanisms. The UPR is activated in response to the accumulation of misfolded proteins in the endoplasmic reticulum. In the context of mutant SOD1, this pathway is chronically activated, leading to neuronal dysfunction and degeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is central to the amyloidogenic pathway, where it is cleaved to produce the Abeta peptide. Accumulation of Abeta, particularly in the form of beta-amyloid plaques, is a hallmark of Alzheimer's disease. The proteasome subunits listed are involved in protein degradation and are part of the 26S proteasome complex, which is crucial for degrading damaged or misfolded proteins. Dysfunction in proteasome activity can lead to accumulation of toxic proteins like Abeta, contributing to neurodegeneration. Therefore, the APP allele and its associated pathway contribute to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is central to Alzheimer's disease pathology. It encodes a protein that, through abnormal processing, generates amyloid-beta peptides. These peptides aggregate to form plaques in the brain, a hallmark of Alzheimer's disease. The provided network highlights APP's interaction with the proteasome, which is involved in degrading proteins, including amyloid-beta. Dysfunction in this pathway may impair the clearance of amyloid-beta, contributing to its accumulation. This accumulation is a key factor in the neurodegenerative processes observed in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP gene encodes the amyloid beta precursor protein, which is central to the amyloid pathway. In this network, APP is processed to generate Abeta peptides, which are known to accumulate and form plaques in the brain. These plaques are a hallmark of Alzheimer's disease. The proteasome subunits listed are components of the 26S proteasome, which is responsible for degrading proteins, including Abeta. Dysregulation in this pathway, particularly the accumulation of Abeta, contributes to neurodegeneration. Therefore, the biological effect of the APP allele is primarily associated with Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 allele in this genomic pathway is involved in a signaling cascade that begins with FGFR3 activation, leading through GRB2, SOS, RAS, RAF, MEK, ERK, MSK1, and ultimately to MYC. This pathway is a key part of the RAS/RAF/MEK/ERK (MAPK) signaling pathway, which regulates cell proliferation, differentiation, and survival. Mutations in FGFR3 are frequently associated with certain types of cancer, particularly bladder cancer, and also with genetic disorders like achondroplasia, a form of dwarfism. In the context of cancer, activation of FGFR3 can drive uncontrolled cell growth due to constitutive activation of the downstream pathway. Therefore, the biological effect of this FGFR3 allele can contribute to the development of cancer.\n\n\\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway described involves a signaling cascade starting with FGFR3, which is activated by fibroblast growth factors. This activation leads to downstream signaling through GRB2, SOS, RAS, RAF, MEK, ERK, MSK1, and ultimately MYC, a transcription factor that regulates gene expression essential for cell proliferation and survival. Mutations in FGFR3 are commonly associated with genetic disorders, particularly those involving skeletal dysplasias. Specifically, activating mutations in FGFR3 are known to cause achondroplasia, the most common form of dwarfism. These mutations result in constitutive activation of FGFR3, leading to impaired chondrocyte proliferation and differentiation, which are critical for normal bone growth. Therefore, the biological effect of this FGFR3 allele is the contribution to the development of achondroplasia.\n\n\\boxed{Achondroplasia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 allele in this pathway promotes signal transduction through a network that includes GRB2, SOS, RAS, RAF, MEK, ERK, MSK1, and ultimately MYC. This signaling cascade is part of the RAS/RAF/MEK/ERK pathway, a key regulator of cell proliferation and survival. Mutations in FGFR3 are associated with aberrant signaling, which can lead to uncontrolled cell growth and tumorigenesis. Specifically, FGFR3 mutations are well-documented in bladder cancer, where they contribute to the development and progression of the disease by activating downstream effectors that drive oncogenic processes. \n\n\\boxed{Bladder Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the pathology of Huntington's disease. In this pathway, HTT interacts with STX1A, a syntaxin involved in vesicle trafficking, and influences the function of VGCC (N-type) calcium channels, which modulate intracellular calcium levels. Mutations in HTT, particularly CAG trinucleotide repeat expansions, lead to the production of a toxic mutant huntingtin protein. This disrupts normal cellular functions, including calcium homeostasis, leading to neuronal dysfunction and death. The disease is characterized by progressive motor, cognitive, and psychiatric symptoms. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein involved in various cellular processes. Mutations in HTT, specifically CAG trinucleotide repeat expansions, lead to Huntington's disease. This neurodegenerative disorder is characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. The HTT allele in the described pathway interacts with STX1A and influences VGCC(N-type) calcium channels, affecting intracellular calcium signaling. Dysregulation of calcium homeostasis is implicated in neuronal dysfunction and death. Thus, the HTT allele, when mutated, contributes to the pathogenesis of Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is involved in various cellular processes. In the provided pathway, HTT interacts with STX1A, which is part of the SNARE complex, and this interaction modulates the activity of the N-type voltage-gated calcium channel (VGCC), which is encoded by the CACNA1B gene. This pathway is crucial for calcium signaling, which is essential in synaptic transmission and neuronal function. When the HTT gene is mutated, as in Huntington's disease, the resulting mutant huntingtin protein disrupts this pathway, leading to neurodegeneration. This disruption contributes to the pathogenesis of Huntington's disease, a hereditary neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease. The pathway includes ubiquitin-conjugating enzymes (UBCH7/8) and regulatory components (CDCREL1), indicating its role in protein degradation. The presence of PRKN in this network highlights its involvement in maintaining cellular homeostasis through ubiquitination. Disruption of this pathway can lead to the accumulation of damaged proteins, mitochondrial dysfunction, and neurodegeneration, all hallmarks of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase crucial for the ubiquitin-proteasome system. In this genomic pathway, PRKN is involved in a network that includes UBCH7/8 (E2 enzymes) and CDCREL1, suggesting a role in protein degradation and cellular quality control. Mutations in PRKN are strongly associated with autosomal recessive early-onset Parkinson's disease (PD). These mutations often lead to loss of parkin function, impairing mitochondrial quality control and leading to neurodegeneration in dopaminergic neurons. This pathway's involvement in ubiquitination processes highlights its critical role in maintaining neuronal health. Thus, the PRKN allele in this context contributes to $\\boxed{Parkinson's disease}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, a RBR E3 ubiquitin protein ligase involved in the ubiquitination of target proteins, particularly in the process of mitophagy. Mutations in PRKN are strongly associated with autosomal recessive juvenile Parkinson's disease (ARJPD), also known as PARK2. These mutations often result in loss-of-function of parkin, impairing its ability to label damaged mitochondria for degradation, leading to the accumulation of dysfunctional mitochondria in dopaminergic neurons. This contributes to neuronal degeneration, particularly in the substantia nigra, a hallmark of Parkinson's disease. The ubiquitin conjugating enzymes (UBCH7/8) and CDCREL1 are part of the broader ubiquitination machinery that interacts with parkin to regulate cellular quality control mechanisms. Thus, the PRKN allele contributes to $\\boxed{\\text{Parkinson's disease}}$."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway is a core component of the Wnt/\u03b2-catenin signaling pathway. AXIN1 is a negative regulator of this pathway, functioning to promote the degradation of \u03b2-catenin (CTNNB1) through the formation of a destruction complex that includes GSK3B and APC. If AXIN1 is mutated or inactivated, \u03b2-catenin accumulates, leading to the activation of TCF/LEF transcription factors, which in turn upregulate the expression of target genes such as MYC and CCND1. This constitutive activation of the Wnt pathway is a well-known driver of colorectal cancer. Thus, mutations in AXIN1 contribute to the development of colorectal cancer by dysregulating Wnt signaling.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nAXIN1 is a key component of the Wnt/\u03b2-catenin signaling pathway, which regulates cell proliferation, differentiation, and survival. In this pathway, AXIN1 interacts with GSK3B and APC to regulate the phosphorylation and degradation of CTNNB1 (\u03b2-catenin). A mutation or loss of function in AXIN1 can lead to the stabilization and accumulation of \u03b2-catenin, which then translocates to the nucleus and activates downstream target genes such as MYC and CCND1 through TCF/LEF transcription factors. This dysregulation of Wnt signaling can promote uncontrolled cell growth and tumorigenesis. Mutations in AXIN1 have been implicated in colorectal cancer, where they contribute to the inappropriate activation of the Wnt pathway. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is a core component of the Wnt/\u03b2-catenin signaling pathway. AXIN1 is a negative regulator of this pathway, promoting the degradation of CTNNB1 (\u03b2-catenin) when the pathway is inactive. A mutation in AXIN1 that disrupts its function could result in stabilization of CTNNB1, leading to constitutive activation of the Wnt pathway. This can cause aberrant activation of TCF/LEF transcription factors, which in turn upregulate target genes such as MYC and CCND1, promoting cell proliferation and survival. Such dysregulation is a hallmark of several cancers, particularly colorectal cancer. Therefore, mutations in AXIN1 are implicated in the pathogenesis of colorectal cancer.\n\n\\boxed{Colorectal cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) gene is central to the androgen signaling pathway, which influences the expression of KLK3, a prostate-specific antigen (PSA). Variants in the AR gene can affect androgen sensitivity and signaling efficiency. In the context of this pathway, an altered AR allele may lead to dysregulated androgen signaling, contributing to the development and progression of prostate cancer. This disease is characterized by uncontrolled growth of prostate cells, often driven by hormonal factors, including androgens like DHT. The AR's role in mediating androgen effects makes it a key player in prostate cancer etiology.\n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) gene plays a central role in the genomic pathway involving androgen signaling, as indicated by the network definition and the effect on KLK3, a gene associated with prostate-specific antigen (PSA) production. Mutations or specific alleles in the AR gene can lead to altered androgen signaling, which is strongly linked to the development and progression of prostate cancer. This disease is characterized by uncontrolled growth of prostate cells, often driven by androgen stimulation. The AR allele in question likely contributes to increased sensitivity or resistance to androgens, affecting tumor progression. \n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR allele in this genomic pathway is involved in the androgen signaling cascade, which is critical for prostate development and function. The pathway includes androgens (T, DHT), estrogens (E2), progesterone (P4), and other regulatory molecules influencing AR activity. AR activation leads to KLK3 expression, a key component in prostate fluid production. Dysregulation of this pathway, particularly through AR mutations or overactivation, is a major contributor to **prostate cancer**. This disease arises from uncontrolled cell proliferation and resistance to apoptosis in prostate tissues, often driven by persistent androgenic stimulation. The AR allele\u2019s influence on KLK3 and other downstream targets makes it a central player in prostate cancer progression.\n\n\\boxed{Prostate Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a component of the gamma-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). These mutations disrupt normal APP processing, leading to increased production of amyloid-beta (A\u03b2) peptides, which accumulate as plaques in the brain. This pathway involves calcium signaling, with PSEN1 influencing intracellular calcium levels through its interaction with ITPR and other calcium channels. Dysregulation of calcium homeostasis, as indicated by the network, can lead to mitochondrial dysfunction and apoptosis. These events are closely linked to neurodegenerative processes in AD. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the processing of the amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). This pathway highlights the involvement of PSEN1 in calcium signaling, which is dysregulated in AD. PSEN1 modulates intracellular calcium release through the ITPR family, leading to increased cytosolic and mitochondrial calcium levels via MCU. Excessive calcium can trigger MPTP opening, releasing CYCS and initiating apoptosis. This dysregulation contributes to neuronal dysfunction and degeneration in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes a spectrin beta non-erythrocytic 2 protein, which is involved in the pathway: SPTBN2 -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+. This pathway suggests a role in calcium signaling through the metabotropic glutamate receptor 1 (GRM1) and phospholipase C beta (PLCB), leading to inositol trisphosphate (IP3) production and subsequent intracellular calcium release via inositol 1,4,5-trisphosphate receptors (ITPR). Disruption of this pathway might affect neuronal function and calcium homeostasis. Given the involvement of calcium signaling and the genes implicated, this allele may contribute to a neurodegenerative disorder, specifically spinocerebellar ataxia type 11. \n\n\\boxed{Spinocerebellar Ataxia Type 11}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway begins with SPTBN2, which interacts with GRM1, leading to a cascade involving GNAQ, PLCB, IP3, and ITPR, ultimately resulting in the release of Ca\u00b2\u207a. This signaling pathway is associated with calcium signaling and synaptic transmission. Mutations in SPTBN2 are linked to intellectual disability and microcephaly. These neurological conditions suggest that the biological effect of this SPTBN2 allele contributes to neurodevelopmental disorders, specifically impairing brain development and function.\n\n\\boxed{Microcephaly}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the SPTBN2 allele in the given pathway involves the activation of GRM1, which triggers a cascade through GNAQ, PLCB (multiple isoforms), IP3, and ITPR, ultimately leading to an increase in intracellular calcium (Ca2+). This pathway is associated with cellular signaling and response to neurotransmitters. Mutations in SPTBN2, which encodes a critical component of the cytoskeleton, can lead to impaired cellular function and neurodevelopmental defects. This disruption may contribute to a rare neurodevelopmental disorder known as autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). \n\n\\boxed{Autosomal recessive spastic ataxia of Charlevoix-Saguenay}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of the voltage-gated calcium channel, which is crucial for calcium ion influx into neurons. Mutations in CACNA1A are associated with various neurological disorders, particularly those involving dysfunctional calcium signaling. These mutations can lead to abnormal neuronal excitability and impaired signal transmission. A specific disease linked to CACNA1A mutations is spinocerebellar ataxia type 1 (SCA1), which is an autosomal dominant neurodegenerative disorder characterized by progressive loss of coordination and balance. Additionally, CACNA1A mutations have been implicated in episodic ataxia and familial hemiplegic migraine. Therefore, the biological effect of the CACNA1A allele is primarily related to neurological dysfunction, with a key contribution to the development of spinocerebellar ataxia type 1.\n\n\\boxed{Spinocerebellar Ataxia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha-1A subunit of the P/Q-type voltage-gated calcium channel, which plays a key role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with a range of neurological disorders, most notably with episodic ataxia type 2, which is characterized by brief episodes of incoordination and impaired balance. These mutations can also contribute to spinocerebellar ataxia type 6 (SCA6), a progressive neurodegenerative disorder affecting the cerebellum. Additionally, some CACNA1A mutations have been implicated in familial hemiplegic migraine, a type of migraine with transient motor weakness. These findings highlight the gene's critical role in calcium signaling within the nervous system.\n\n\\boxed{Spinocerebellar Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha-1A subunit of the P/Q-type voltage-gated calcium channel, which is critical for neurotransmitter release in the nervous system. Mutations in CACNA1A are associated with several neurological disorders, including spinocerebellar ataxia type-6 (SCA6), episodic ataxia type-2, and familial hemiplegic migraine. These conditions are characterized by impaired motor coordination, recurrent episodes of ataxia, and, in the case of migraine, severe headaches. The biological effect of CACNA1A alleles, particularly those with pathogenic mutations, involves dysfunctional calcium signaling in neurons, leading to the aforementioned clinical manifestations.\n\n\\boxed{Spinocerebellar Ataxia Type 6}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including GLB1, GBA, and GALC. Mutations in PSAP can lead to the reduced activity of these enzymes, resulting in the accumulation of substrates that these enzymes normally break down. This pathway is implicated in the lysosomal storage disorders, particularly in the context of metachromatic leukodystrophy (MLD). However, specific mutations in PSAP are more closely associated with a different disorder known as saposin deficiency, which is a rare autosomal recessive disorder. In this condition, the deficiency of saposins leads to abnormal myelination and progressive neurological deterioration. The provided network, involving PSAP, GBA, and GALC, is biologically relevant to lysosomal storage diseases, and PSAP is most directly linked to metachromatic leukodystrophy. \n\n\\boxed{Metachromatic leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including GBA and GALC. Mutations in PSAP can lead to a deficiency in saposins, impairing the function of these enzymes. This impairment results in the accumulation of lipids within cells, particularly in the nervous system. The biological effect of a PSAP allele with mutations is associated with a lysosomal storage disorder known as saposin deficiency, which can manifest as a severe neurological disease. This condition is closely linked to metachromatic leukodystrophy (MLD), a neurodegenerative disorder caused by the deficiency of arylsulfatase A, but PSAP mutations are also implicated in an atypical form of the disease known as late-infantile metachromatic leukodystrophy. \n\n\\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including GBA and GALC. Mutations in PSAP can lead to a deficiency in saposins, impairing the function of these enzymes. This deficiency results in the accumulation of specific lipids in lysosomes, leading to cellular dysfunction. The specific disease associated with PSAP mutations is **Saposin-Deficient Metachromatic Leukodystrophy (SAPL)**. This inherited disorder affects the nervous system, causing progressive neurological deterioration. The network definition (PSAP* // (GBA,GALC)) highlights the interplay between PSAP and the enzymes it activates, implicating it in lysosomal storage diseases. \n\n\\boxed{Saposin-Deficient Metachromatic Leukodystrophy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with the neurodegenerative disorder spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. ATXN3 is involved in the ubiquitin-proteasome system and autophagy, which are crucial for the degradation of misfolded proteins. The provided pathway includes genes involved in autophagy, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, which are part of the class III phosphatidylinositol 3-kinase complex essential for autophagosome formation. Dysfunctional ATXN3 may impair autophagy, leading to the accumulation of toxic proteins and subsequent neuronal degeneration. This impairment may exacerbate the disease pathology. Therefore, the ATXN3 allele contributes to $\\boxed{\\text{Spinocerebellar Ataxia Type 3}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is a gene associated with the ubiquitin-proteasome system and plays a role in autophagy, which is regulated by the network including BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1. Mutations in ATXN3 are primarily linked to spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of motor control, oculomotor dysfunction, and other neurological symptoms. The ATXN3 allele with expansion of CAG repeats leads to toxic protein accumulation, impairing neuronal function and contributing to the pathological features of SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with the neurodegenerative disease Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph disease. This condition is caused by the expansion of a CAG trinucleotide repeat within the ATXN3 gene, leading to the production of an abnormally long poly-glutamine tract in the ataxin-3 protein. This results in protein misfolding, aggregation, and neuronal dysfunction, primarily affecting the cerebellum and brainstem. The pathway defined includes genes involved in autophagy, a process critical for the degradation of misfolded proteins. Dysfunctional autophagy, as suggested by the network of BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, may exacerbate the accumulation of toxic ataxin-3 aggregates, contributing to disease progression. \n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele in this genomic pathway contributes to the development of **Creutzfeldt-Jakob Disease (CJD)**. This pathway involves the prion protein (PRNP), which, when misfolded, can trigger a chain of events leading to neurodegeneration. The pathway includes interactions with caveolins (CAV1-3), FYN kinase, PI3K, PRKCD, and ultimately ROS production via NOX2. These biological processes are implicated in the pathogenesis of prion diseases, where the misfolded PRNP protein leads to neuronal damage and eventual disease manifestation. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the mutant forms of the PRNP gene, is associated with prion diseases, a group of rare, degenerative, and often fatal neurologic disorders. These diseases result from the misfolding of the prion protein (PrP) into a pathogenic form, leading to neuronal damage and loss of brain function. The pathway provided involves a series of molecular interactions that may contribute to the pathogenesis of these diseases by influencing oxidative stress and signaling cascades. ROS production via the NOX2 pathway, for instance, could exacerbate neuronal damage. This pathway may also be involved in the propagation of prion diseases through cellular interactions and signaling events.\n\n\\boxed{Prion disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the pathogenic variants of the PRNP gene, is primarily associated with prion diseases, a group of fatal neurodegenerative disorders. These diseases include Creutzfeldt-Jakob disease (CJD), Gerstmann-Str\u00e4ussler-Scheinker syndrome (GSS), and Fatal Familial Insomnia (FFI). The PRNP gene encodes the prion protein (PrP), and mutations in this gene can lead to the misfolding of PrP into a pathological form (PrPSc), which accumulates in the brain and causes neuronal damage. This pathway, involving PRNP, CAV, FYN, PI3K, PRKCD, NOX2, and ROS, may contribute to the oxidative stress and neurodegeneration characteristic of these disorders. The PRNP allele's effects are thus primarily linked to prion-related diseases.\n\n\\boxed{Prion disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway outlines a signaling cascade starting with NRAS and KRAS, which activate PI3K, leading to the production of PIP3 and subsequent activation of AKT. This pathway is crucial for cell survival and proliferation. Mutations in NRAS, particularly in the GTPase domain, can result in constitutive activation of this pathway, promoting uncontrolled cell growth. This aberrant signaling is a well-documented driver in various cancers. Specifically, NRAS mutations are frequently observed in melanoma, leading to the unregulated activation of downstream effectors like AKT, which in turn phosphorylate and inactivate BAD, a pro-apoptotic protein. This contributes to resistance to cell death and tumor progression. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS-PI3K-AKT signaling cascade, which plays a critical role in cell proliferation, survival, and differentiation. Mutations in NRAS, a key component of this pathway, can lead to constitutive activation of downstream effectors such as AKT, promoting uncontrolled cell growth. This aberrant signaling is frequently associated with various cancers, particularly melanoma, where NRAS mutations are common and contribute to tumor development and progression.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway describes a signaling cascade involving NRAS and KRAS, which activate PI3K. PI3K phosphorylates PIP3, which in turn activates AKT. AKT inhibits BAD, a pro-apoptotic protein, thereby promoting cell survival. Mutations in NRAS, particularly activating ones, can lead to constitutive activation of this pathway, promoting uncontrolled cell proliferation and survival. This aberrant signaling is commonly observed in various cancers, especially melanoma, leukemia, and certain solid tumors. Therefore, the biological effect of an activating NRAS allele is the promotion of tumorigenesis. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described outlines a calcium signaling cascade initiated by glutamate binding to GRM1, leading to increased intracellular calcium through IP3 and ITPR1, and further regulated by ATXN2 and ATXN3. ATXN3 is a gene that, when mutated, is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of motor control, ophthalmoplegia, and other neurological symptoms due to the toxic accumulation of mutant ATXN3 protein. The involvement of ATXN3 in calcium regulation suggests its role in the disruption of neuronal calcium homeostasis, contributing to neurodegeneration.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes a protein involved in maintaining cellular health through its role in ubiquitin-mediated protein degradation. Mutations in ATXN3, particularly those leading to expanded polyglutamine tracts, are associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of motor control, ophthalmoplegia, and other neurological symptoms. The ATXN3 allele in the given pathway may contribute to the dysfunction of calcium signaling, which is implicated in the neurodegenerative processes of SCA3. \n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the metabotropic glutamate receptor GRM1, which activates GNAQ and subsequently PLCB, leading to IP3 production. IP3 binds to ITPR1, releasing Ca\u00b2\u207a, which enters the mitochondrion via MCU. This Ca\u00b2\u207a influx can trigger MPTP opening, leading to CYCS release and apoptosis. ATXN3 is part of a complex with ITPR1, suggesting it modulates IP3-mediated Ca\u00b2\u207a release. Mutations in ATXN3 are known to cause spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disorder. ATXN3's role in Ca\u00b2\u207a regulation may contribute to neuronal dysfunction and death in SCA3. \n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. A loss-of-function PTEN allele leads to constitutive activation of AKT, promoting cell survival, proliferation, and inhibition of apoptosis. This dysregulation contributes to uncontrolled cell growth, a hallmark of cancer. Mutations in PTEN are frequently observed in various cancers, including endometrial, glioblastoma, and certain types of breast and prostate cancers. The most well-characterized condition associated with PTEN mutations is Cowden syndrome, an autosomal dominant disorder predisposing individuals to multiple types of cancer. \n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3, thereby inhibiting AKT activation. Mutations or loss of PTEN function can lead to constitutive activation of the AKT pathway, promoting cell survival, proliferation, and resistance to apoptosis. This dysregulation is implicated in the development of various cancers. PTEN mutations are frequently observed in conditions such as Cowden syndrome, a hereditary cancer predisposition syndrome, and are also associated with glioblastoma, endometrial cancer, and other malignancies. The loss of PTEN function disrupts normal cellular control mechanisms, contributing to tumorigenesis.\n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. In the provided network, PTEN* (likely a mutated or dysfunctional allele) fails to inhibit PIP3, leading to increased AKT activation. This results in uncontrolled cell proliferation and survival, contributing to tumorigenesis. Mutations in PTEN are strongly associated withCowden syndrome, a hereditary condition that predisposes individuals to various cancers, including breast, thyroid, and endometrial cancers. \n\n\\boxed{Cowden syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive degeneration of the cerebellum and brainstem, leading to ataxia, dysarthria, and other motor and non-motor symptoms. The provided pathway involves components of the autophagy machinery, which is crucial for cellular homeostasis. Mutations in ATXN3, particularly those involving expansion of a CAG trinucleotide repeat, result in a polyglutamine-expanded protein that is toxic and aggregates, leading to neuronal dysfunction and death. The interaction with autophagy-related genes such as BECN1, ATG14, and AMBRA1 suggests that impaired autophagy may contribute to the pathogenesis of the disease. \n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is a gene involved in autophagy, a cellular process crucial for maintaining cellular health. The given network includes autophagy-related genes, suggesting ATXN3 plays a role in this pathway. Mutations in ATXN3, particularly expansions of CAG trinucleotide repeats, lead to the production of a toxic protein that disrupts normal cellular functions. This is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. SCA3 is a neurodegenerative disorder characterized by progressive loss of motor control, speech difficulties, and other neurological symptoms. The involvement of ATXN3 in the autophagy pathway implies that impaired autophagy may contribute to the pathogenesis of this disease.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of coordination, muscle stiffness, and other neurological symptoms. The ATXN3 protein is involved in autophagy, a cellular process that degrades and recycles damaged components. The provided pathway highlights ATXN3 interacting with components of the autophagy machinery, including BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, underlining its role in autophagic processes. Dysfunction in this pathway may contribute to the accumulation of misfolded proteins and neuronal degeneration seen in SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a critical component of the gamma-secretase complex, involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). The given pathway highlights a stress response network initiated by PSEN1, leading to the activation of ATF4 and DDIT3, which are involved in the unfolded protein response (UPR). This suggests PSEN1's role in endoplasmic reticulum (ER) stress response, a known contributor to neurodegenerative diseases. The biological effect of PSEN1 mutations includes impaired APP processing, leading to increased amyloid-beta production, a hallmark of Alzheimer's disease. This pathway underscores how PSEN1 dysfunction can contribute to neurodegeneration through both amyloidogenic processing and ER stress mechanisms.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex and is critically involved in the processing of amyloid precursor protein (APP) into amyloid-beta peptides. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). The given pathway, involving PSEN1, EIF2AK3, EIF2S1, ATF4, and DDIT3, reflects the unfolded protein response (UPR) pathway, which is activated under endoplasmic reticulum (ER) stress. ER stress and the UPR are implicated in the progression of Alzheimer's disease, where PSEN1 mutations lead to increased amyloid-beta production and subsequent neurodegeneration. Therefore, this PSEN1 allele contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in amyloid precursor protein (APP) processing. The given pathway illustrates a stress response pathway, where PSEN1* (a mutant allele) likely affects the unfolded protein response (UPR) by influencing EIF2AK3, leading to the activation of ATF4 and DDIT3. This suggests that PSEN1 mutations may contribute to endoplasmic reticulum (ER) stress, a mechanism implicated in neurodegenerative diseases. Specifically, mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. These mutations result in abnormal APP processing, leading to increased production of amyloid-beta peptides, a hallmark of Alzheimer's pathology.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD). In the given pathway, PSEN1 influences ERN1, which activates XBP1, a transcription factor important in the unfolded protein response (UPR). Dysregulation of this pathway may contribute to endoplasmic reticulum (ER) stress, a hallmark of neurodegenerative diseases like Alzheimer's. Thus, the PSEN1 allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the processing of amyloid precursor protein (APP). A mutation in PSEN1 can lead to the production of abnormal amyloid-\u03b2 peptides, which accumulate to form amyloid plaques in the brain. This pathway involves ERN1 (IRE1), which activates XBP1 in response to endoplasmic reticulum (ER) stress. ER stress is implicated in neurodegeneration. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease (AD), contributing to the pathogenesis by disrupting normal amyloid processing and inducing ER stress responses. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a protein involved in the gamma-secretase complex, which processes amyloid precursor protein (APP) to produce amyloid-beta peptides. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. In the provided pathway, PSEN1 activates ERN1, which in turn activates XBP1, a transcription factor involved in the unfolded protein response (UPR). Dysregulation of this pathway due to PSEN1 mutations may lead to endoplasmic reticulum (ER) stress and contribute to neurodegeneration. Therefore, the PSEN1 allele is implicated in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in autophagy and the ubiquitin-proteasome system. Mutations in SQSTM1 have been implicated in neurodegenerative diseases, particularly in the context of Parkinson's disease. SQSTM1 functions as an adaptor protein that links ubiquitinated proteins to autophagosomes, facilitating their degradation. When SQSTM1 is dysregulated or mutated, it can disrupt the clearance of damaged proteins and organelles, including mitochondria, leading to the accumulation of toxic proteins and cellular dysfunction. In the context of the PINK1-PRKN pathway, which is critical for mitophagy, a malfunctioning SQSTM1 could impair the degradation of damaged mitochondria, contributing to the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in autophagy and the ubiquitin-proteasome system. Mutations in SQSTM1 are associated with neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). SQSTM1 plays a role in the PINK1-PRKN pathway, which is involved in mitochondrial quality control. Pathogenic variants in SQSTM1 can impair autophagy and lead to the accumulation of damaged mitochondria, contributing to neuronal dysfunction and death. This dysfunction is implicated in the progression of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nSQSTM1 is a gene involved in the ubiquitin-proteasome system and autophagy, functioning as an adaptor protein that links ubiquitinated proteins to the autophagy machinery. Mutations in SQSTM1 have been implicated in neurodegenerative disorders, particularly amyotrophic lateral sclerosis (ALS). These mutations can lead to the accumulation of misfolded or aggregated proteins, impairing cellular clearance mechanisms and contributing to neuronal degeneration. Given its role in the PINK1-PRKN pathway, which is critical for mitophagy, dysfunction of SQSTM1 can disrupt mitochondrial quality control, exacerbating neurodegenerative processes. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway involves the RAS-PI3K-AKT signaling cascade, a critical pathway in cell survival, growth, and proliferation. Mutations in NRAS, a member of the RAS family of GTPases, can result in its constitutive activation, leading to uncontrolled signal transduction through PI3K (catalyzed by PIK3CA, PIK3CB, or PIK3CD) and subsequent activation of AKT. This persistent activation promotes cell survival and proliferation by inhibiting BAD, a pro-apoptotic protein. Such alterations are commonly observed in various cancers, including melanoma, leukemia, and solid tumors. Therefore, NRAS mutations contribute to tumorigenesis and progression of cancer.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a signaling cascade initiated by NRAS and KRAS, which activate PI3K, leading to PIP3 production, AKT activation, and ultimately, BAD phosphorylation, which inhibits apoptosis. Mutations in NRAS, particularly in the G12 or Q61 codons, can lead to constitutive activation of this pathway, promoting uncontrolled cell growth and survival. This dysregulation is a known driver in several cancers. Specifically, NRAS mutations are frequently observed in melanoma, and are also implicated in other malignancies such as chronic myeloid leukemia, acute myeloid leukemia, and certain types of lymphomas. The persistent activation of the PI3K/AKT pathway due to NRAS mutations contributes to tumor progression and resistance to therapy.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS/MAPK and PI3K/AKT signaling cascades, which are central to cell growth, survival, and proliferation. Mutations in NRAS, particularly activating mutations, can lead to constitutive activation of these pathways, driving uncontrolled cell growth. NRAS is a key player in the RAS family of proto-oncogenes, and its mutations are commonly associated with various cancers, including melanoma, leukemia, and thyroid cancer. In this context, the NRAS allele contributes to the development of **melanoma**.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor involved in the ubiquitin-proteasome system, specifically in the assembly of an E3 ubiquitin ligase complex that targets the HIF (hypoxia-inducible factor) transcription factors for degradation. When VHL is dysfunctional, HIF is stabilized, leading to the transcription of genes like VEGFA, CXCL8, SLC2A1, and EPO, which promote angiogenesis, cell proliferation, and survival. This pathway is crucial in the pathogenesis of von Hippel-Lindau disease (VHL), a hereditary cancer syndrome characterized by the development of benign and malignant tumors in various organs, including the kidneys, brain, and adrenal glands. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele is part of a pathway that regulates hypoxia-inducible factor (HIF) through the ubiquitination and degradation of HIF-\u03b1 subunits. When VHL is mutated or inactivated, HIF-\u03b1 accumulates, leading to the activation of genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO, which are involved in angiogenesis, inflammation, and erythropoiesis. This dysregulation contributes to the development of clear-cell renal cell carcinoma (ccRCC), a common type of kidney cancer. The pathway involves components like CUL2, RBX1, ELOC, and ELOB, which function as part of the VHL E3 ubiquitin ligase complex, and EPAS1 (also known as HIF-2\u03b1), which dimerizes with ARNT to drive transcriptional activation. \n\n\\boxed{Clear-cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor gene involved in the regulation of hypoxia-inducible factor (HIF) through the ubiquitination of HIF-1\u03b1. In the provided pathway, VHL interacts with RBX1, ELOC, ELOB, and CUL2 to form an E3 ubiquitin ligase complex that targets EPAS1 (a HIF-1\u03b1-like protein) for degradation. Under normal oxygen conditions, EPAS1 is degraded, but under hypoxia, it dimerizes with ARNT to activate the transcription of downstream genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO, which promote angiogenesis, cell proliferation, and erythropoiesis. Mutations in VHL lead to accumulation of EPAS1 and activation of these genes, promoting tumor growth. This contributes to the development of von Hippel-Lindau disease, a hereditary cancer syndrome characterized by the formation of benign and malignant tumors in multiple organs.\n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in mitochondrial quality control through the ubiquitin-proteasome system. Mutations in PRKN are a major cause of early-onset Parkinson's disease (PD), specifically autosomal recessive juvenile parkinsonism (ARJP). Parkin plays a critical role in mitophagy, the selective degradation of damaged mitochondria. When PRKN is dysfunctional, impaired mitophagy leads to the accumulation of defective mitochondria, resulting in neuronal degeneration, particularly in dopamine-producing neurons in the substantia nigra. This contributes to the motor symptoms characteristic of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of proteins in the proteasome degradation pathway. It plays a critical role in mitochondrial quality control and autophagy. Mutations in PRKN are a common cause of autosomal recessive early-onset parkinsonism. These mutations often result in loss of parkin function, leading to the accumulation of damaged mitochondria and impaired neuronal function. The pathway involving PRKN and MFN1/2, which are involved in mitochondrial fusion, is essential for maintaining mitochondrial dynamics and function. Disruption of this pathway is implicated in neurodegenerative diseases. Specifically, mutations in PRKN are strongly associated with Parkinson's disease, particularly the juvenile form. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in mitochondrial quality control via the ubiquitin-proteasome system. Mutations in PRKN are a common cause of autosomal recessive early-onset Parkinson's disease (PD). The PRKN pathway, along with MFN1/2, plays a critical role in mitochondrial dynamics, including fusion and fission. Disruption of this pathway can impair mitochondrial function, leading to neuronal degeneration. Specifically, loss-of-function mutations in PRKN are strongly associated with PD, contributing to the degeneration of dopaminergic neurons in the substantia nigra. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 gene is part of a genomic pathway that regulates the cell cycle. Specifically, the interaction (CCND+CDK4*) -> RB1 // E2F indicates that CDK4, along with cyclin D proteins, phosphorylates RB1, leading to the release and activation of E2F transcription factors. This pathway is crucial for cell cycle progression from G1 to S phase. Mutations or overexpression of CDK4 can lead to uncontrolled cell proliferation by disrupting the normal regulation of the cell cycle, increasing the risk of cancer. This pathway is commonly dysregulated in various cancers, particularly in melanoma and other solid tumors. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction of cyclin D (CCND) with CDK4, leading to the phosphorylation of RB1, which subsequently releases E2F proteins. This process is critical for cell cycle progression, particularly the transition from G1 to S phase. Dysregulation of this pathway can lead to uncontrolled cell proliferation. Mutations or overexpression of CDK4, especially when it results in constitutive activation of this pathway, can contribute to cancer development. Specifically, such alterations are commonly associated with melanoma and certain types of leukemia and lymphoma. These mutations can lead to resistance to growth suppression signals, promoting tumor growth.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele participates in a signaling pathway that regulates the cell cycle. Specifically, CDK4 interacts with cyclin D proteins (CCND1, CCND2, CCND3) to phosphorylate RB1, which releases E2F transcription factors to promote cell cycle progression. Mutations in CDK4 or its regulatory components can lead to uncontrolled cell proliferation. When CDK4 is overactive or dysregulated, it can contribute to the development of cancer by driving cells into the S phase of the cell cycle without proper regulation. This aberrant pathway activity is commonly observed in various malignancies, particularly melanoma and cancers of the head and neck. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway outlines a key signaling cascade involving NRAS and KRAS, both of which are members of the RAS family of GTPases. These proteins activate PI3K, leading to the production of PIP3, which in turn activates AKT. AKT phosphorylates BAD, promoting cell survival by inhibiting apoptosis. Mutations in NRAS, especially activating ones, can result in constitutive activation of this pathway, promoting uncontrolled cell growth and proliferation. Such mutations are commonly associated with various cancers. Specifically, NRAS mutations are frequently observed in melanoma, hematologic malignancies, and some solid tumors. They contribute to tumor initiation and progression by sustaining oncogenic signaling.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS-MAPK and PI3K-AKT signaling cascades, which are central to cell survival, proliferation, and differentiation. NRAS is a small GTPase that, when mutated, can constitutively activate downstream effectors like PI3K, leading to sustained AKT activation. This results in uncontrolled cell growth and resistance to apoptosis, particularly impacting the BAD protein, which is a pro-apoptotic factor. Mutations in NRAS are commonly associated with various cancers, including melanoma, leukemia, and solid tumors. The persistent activation of this pathway due to NRAS mutations contributes to oncogenesis.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a signaling cascade initiated by NRAS (and KRAS) activating PI3K, leading to PIP3 production and subsequent AKT activation, which phosphorylates BAD, promoting cell survival. Mutations in NRAS, particularly in this pathway, can lead to constitutive activation of the PI3K/AKT axis, resulting in uncontrolled cell proliferation and survival. This is a known mechanism in several cancers, especially those involving hematopoietic cells. NRAS mutations are frequently observed in cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin lymphoma. \n\n\\boxed{Cutaneous T-cell lymphoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including GBA and GALC. Mutations in PSAP can lead to a deficiency in these enzymes, affecting the degradation of complex lipids. This pathway is involved in lysosomal storage diseases. Specifically, mutations in PSAP are associated with a rare inherited metabolic disorder called **Saposin A deficiency**, which contributes to a broader category of diseases known as **Saposinopathies**. These conditions are characterized by the accumulation of sphingolipids due to impaired lysosomal enzyme function. The disease may present with a range of neurological and systemic symptoms, depending on the specific enzyme affected. \n\n\\boxed{Saposinopathy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including GBA and GALC. Mutations in PSAP can lead to a deficiency in saposins, impairing the function of these enzymes. This results in the accumulation of substrates that these enzymes normally break down, leading to lysosomal storage diseases. Specifically, mutations in PSAP are associated with a form of metachromatic leukodystrophy (MLD), a rare, autosomal recessive disorder characterized by progressive neurological deterioration due to the buildup of sulfatides. \n\n\\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of lysosomal enzymes such as GBA and GALC. Mutations in PSAP can lead to a deficiency in these saposins, impairing the function of these enzymes. This contributes to the pathogenesis of a rare lysosomal storage disorder known as **Saposin Deficiency** or **Schaumann Disease**. This condition is associated with neurological manifestations, including developmental delay, hypotonia, and seizures. The disease is also related to the broader group of lysosomal storage diseases, particularly those involving sphingolipid metabolism. \n\n\\boxed{Schaumann Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, specifically the MET proto-oncogene, is a receptor tyrosine kinase that plays a role in cellular proliferation, survival, and migration. In the provided pathway, MET activates downstream signaling through GAB1, PI3K, PIP3, and AKT, leading to the phosphorylation of BAD, a pro-apoptotic protein, thereby promoting cell survival. Mutations or amplifications in MET can lead to constitutive activation of this pathway, contributing to uncontrolled cell growth and tumor progression. This aberrant signaling is implicated in several cancers, including non-small cell lung cancer (NSCLC), gastric cancer, and others. The dysregulation of the MET pathway is a known oncogenic driver in these diseases. \n\n\\boxed{Non-Small Cell Lung Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, as part of the described pathway on chromosome 7, is involved in the MET receptor tyrosine kinase signaling cascade, which includes downstream effectors like GAB1, PI3K, PIP3, and AKT. This pathway is crucial for cell proliferation, survival, and migration. Mutations or overactivation of MET can lead to uncontrolled cell growth, a hallmark of cancer. Specifically, aberrant MET signaling has been associated with several cancers, including non-small cell lung cancer, gastric cancer, and some pediatric tumors. The activation of AKT and its downstream target BAD is linked to anti-apoptotic effects, further promoting tumor progression.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, involving the MET receptor tyrosine kinase and downstream effectors like GAB1, PI3K, PIP3, AKT, and BAD, is critical in cell proliferation, survival, and migration. Mutations or overactivation of MET can lead to uncontrolled signaling, promoting tumor growth and progression. This pathway is frequently dysregulated in various cancers. MET amplification or mutations are implicated in cancers such as non-small cell lung cancer, gastric cancer, and others. This aberrant signaling contributes to tumorigenesis by enhancing cell survival and resistance to apoptosis. \n\n\\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene is central to the BCR-ABL fusion protein, a hallmark of chronic myeloid leukemia (CML). This fusion results from a reciprocal translocation between chromosomes 9 and 22, forming the Philadelphia chromosome. The BCR-ABL fusion protein is a constitutively active tyrosine kinase that drives uncontrolled cell proliferation and inhibits apoptosis, contributing to leukemogenesis. The pathway involves downstream effectors such as CRKL, CBL, CRK, PI3K, PIP3, AKT, and BAD, which regulate cell survival and growth. ABL1 is also implicated in other leukemias and lymphomas. The dysregulation of this pathway is a key molecular mechanism in CML.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when constitutively activated through fusion with BCR (as in BCR-ABL), plays a central role in the pathogenesis of chronic myeloid leukemia (CML). This fusion leads to continuous activation of downstream signaling pathways, including the PI3K-AKT axis, which promotes uncontrolled cell proliferation and survival. The pathway involves CRKL, CBL, and CRK as adaptor proteins that relay the signal from BCR-ABL to PI3K, resulting in PIP3 production and subsequent activation of AKT. AKT then phosphorylates BAD, preventing apoptosis. This aberrant signaling contributes to the malignant transformation of hematopoietic cells, leading to CML. \n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that is central to the BCR-ABL fusion protein, a hallmark of chronic myeloid leukemia (CML). In this pathway, ABL1 activates CRKL, CBL, and CRK, which in turn activate PI3K, leading to PIP3 production and subsequent activation of AKT. AKT phosphorylates BAD, preventing apoptosis. The constitutive activation of this pathway due to the BCR-ABL fusion protein promotes uncontrolled cell proliferation and survival, contributing to the development of CML. \n\n\\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of damaged proteins, particularly in mitochondrial quality control. Mutations in PRKN are associated with early-onset autosomal recessive Parkinson's disease (PD). The pathway described involves PRKN interacting with PLCG1, leading to IP3 production, which binds to ITPR receptors, resulting in Ca\u00b2\u207a release. This pathway is crucial for intracellular signaling and calcium homeostasis. Disruption of PRKN function can impair this signaling, contributing to neuronal dysfunction and degeneration. This supports the role of PRKN in PD pathogenesis.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of proteins. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism, also known as Parkinson disease (PD) type 2. The pathway described includes PRKN, which likely functions in regulating cellular processes that, when disrupted, can lead to neurodegeneration. This pathway involves calcium signaling, a process critical for neuronal function. Dysregulation of calcium homeostasis due to PRKN mutations might contribute to the degeneration of dopaminergic neurons, a hallmark of Parkinson's disease. \n\n\\boxed{Parkinson disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a major cause of early-onset autosomal recessive Parkinson's disease. Parkin is part of a signaling pathway that includes PLCG1, IP3, and ITPR, which regulate intracellular calcium levels. Disruption of this pathway may contribute to neuronal dysfunction and death observed in Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is normally a non-pathogenic protein found on the surface of neurons. However, certain mutations in the PRNP gene can lead to misfolding of the prion protein, triggering a chain reaction that results in the accumulation of pathological prion proteins. This accumulation is associated with neurodegenerative diseases known as transmissible spongiform encephalopathies. In humans, mutations in PRNP are the primary cause of Creutzfeldt-Jakob disease (CJD), a rapidly progressive and fatal neurodegenerative disorder. The NOTCH1 gene, while involved in various developmental and signaling pathways, does not directly contribute to prion disease pathology. Therefore, the biological effect of the PRNP allele, particularly in the context of disease, is primarily linked to prion-related neurodegenerative conditions.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to prion diseases. A specific PRNP allele, such as the 129 methionine (M) or valine (V) polymorphism, can influence susceptibility to prion-related diseases. Particularly, the PRNP codon 129 polymorphism is associated with the risk of developing Creutzfeldt-Jakob disease (CJD), especially when combined with other genetic or environmental factors. The NOTCH1 gene is involved in cell signaling pathways and is not directly linked to prion diseases. However, the pathway definition PRNP* -> NOTCH1 suggests a hypothetical or research-based interaction. The biological effect of the PRNP allele primarily relates to the development of prion diseases, such as CJD.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is involved in the pathogenesis of prion diseases. When mutated, PRNP can lead to the conversion of normal prion proteins into misfolded, pathogenic isoforms. This results in progressive neurodegeneration. The interaction with NOTCH1, a receptor involved in cell communication and development, may influence the progression or cellular response to prion-induced damage. The biological effect of the PRNP allele, particularly when mutated, is the development of prion diseases such as Creutzfeldt-Jakob disease.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele is part of a signaling pathway that regulates hypoxia-inducible factor (HIF) stability. Under normal conditions, the VHL protein, along with RBX1, ELOC, ELOB, and CUL2, forms an E3 ubiquitin ligase complex that targets HIF-1\u03b1 (represented here by EPAS1) for degradation. When VHL is dysfunctional, HIF-1\u03b1 accumulates and activates downstream genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO, which are involved in angiogenesis, inflammation, and erythropoiesis. This leads to abnormal blood vessel growth and is a hallmark of von Hippel-Lindau disease, a hereditary tumor syndrome. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor involved in the ubiquitin-proteasome system, specifically in the VHL-Elongin C-Elongin B-CUL2 (VBC) complex, which targets hypoxia-inducible factor (HIF) for degradation. When VHL is mutated or inactivated, HIF accumulates, leading to activation of the HIF-1\u03b1/ARNT complex. This complex upregulates genes involved in angiogenesis, such as VEGFA and EPO, and inflammatory responses like CXCL8. The pathway described is central to the hypoxia response and is dysregulated in VHL syndrome, leading to the development of clear cell renal cell carcinoma (ccRCC), among other tumors. \n\n\\boxed{Clear Cell Renal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor gene involved in the ubiquitin-proteasome system, specifically in the assembly of an E3 ubiquitin ligase complex that targets the hypoxia-inducible factor (HIF) for degradation. In the provided pathway, the VHL allele is part of a complex that regulates HIF activity, which is central to the hypoxia response. When VHL is non-functional, HIF-1\u03b1 accumulates, leading to the activation of downstream genes such as VEGFA, CXCL8, SLC2A1 (GLUT1), and EPO, which are involved in angiogenesis, inflammation, and erythropoiesis. This dysregulation contributes to the development of clear cell renal cell carcinoma (ccRCC), a common type of kidney cancer. \n\n\\boxed{Clear Cell Renal Cell Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, associated with Huntington's disease, encodes the huntingtin protein. In this pathway, HTT interacts with DLG4, which is involved in NMDA receptor (NMDAR) signaling. Activation of NMDAR leads to calcium influx, which is transported into mitochondria via MCU. Elevated mitochondrial calcium can trigger the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS) and initiating the apoptotic cascade through APAF1, CASP9, and CASP3. This process contributes to neuronal degeneration. Huntington's disease is characterized by progressive neurodegeneration, particularly in the striatum and cerebral cortex, leading to movement disorders, cognitive decline, and psychiatric symptoms. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, associated with the huntingtin protein, is involved in a pathway that leads to neuronal apoptosis. HTT interacts with DLG4, which is part of the NMDA receptor (NMDAR) complex, facilitating calcium influx. Calcium entry through NMDAR activates MCU, importing calcium into the mitochondria, which can trigger the mitochondrial permeability transition pore (MPTP). This leads to the release of cytochrome c (CYCS), activating APAF1 and the caspase cascade (CASP9 and CASP3), ultimately causing cell death. This pathway is implicated in neuronal loss, particularly in the striatum and cortex, characteristic of Huntington's disease. The mutant HTT protein disrupts normal cellular function, leading to progressive neurodegeneration.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the HTT gene, which encodes huntingtin, a protein whose mutation leads to Huntington's disease. The pathway outlines a sequence involving NMDA receptors, calcium influx, mitochondrial calcium uptake via MCU, and ultimately, apoptosis through the caspase cascade. This sequence is consistent with the pathophysiology of Huntington's disease, where mutant huntingtin disrupts calcium homeostasis and induces excitotoxicity and apoptosis in neurons. HTT alleles with expanded CAG repeats cause this neurodegenerative disorder.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which is critical for regulating neuronal excitability. Mutations in KCNC3 can lead to dysfunctional potassium channels, disrupting normal neuronal firing patterns. This dysfunction is strongly associated with a dominantly inherited form of episodic ataxia, specifically episodic ataxia type 6 (EA6). The condition is characterized by brief, recurrent episodes of ataxia, often triggered by stress or fatigue, and may also include myokymia or other neurological symptoms. The KCNC3 allele contributes to this disease by impairing the function of the potassium channel, leading to hyperexcitability in the cerebellum and related brain regions. \n\n\\boxed{Episodic Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nKCNC3 encodes a voltage-gated potassium channel subunit that plays a critical role in the repolarization of cardiac and neuronal action potentials. Mutations in KCNC3 have been implicated in long QT syndrome (LQTS), a cardiac arrhythmia condition that can lead to sudden cardiac death. Specifically, these mutations may disrupt normal potassium channel function, prolonging the QT interval on the electrocardiogram and increasing the risk of life-threatening arrhythmias. The pathway involving KCNC3 and extracellular potassium is essential for proper channel function and cardiac rhythm regulation.\n\n\\boxed{Long QT Syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a potassium voltage-gated channel subunit, which plays a critical role in the regulation of neuronal excitability. Mutations in KCNC3 have been implicated in spinocerebellar ataxia type 13 (SCA13), a neurodegenerative disorder characterized by progressive ataxia, dystonia, and other motor impairments. This disease results from dysfunctional potassium channels, leading to altered neuronal firing and degeneration in the cerebellum and other brain regions. The specific allele in question likely contributes to the disruption of normal ion flux, thereby impairing neuronal function and ultimately leading to the clinical manifestations of SCA13.\n\n\\boxed{Spinocerebellar Ataxia Type 13}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination and degradation of damaged proteins. Mutations in PRKN are strongly associated with autosomal recessive early-onset Parkinson's disease (PD). In the provided pathway, PRKN likely initiates a cascade through PLCG1, leading to intracellular calcium (Ca2+) signaling via IP3 and ITPR receptors. Dysregulation of this pathway due to PRKN mutations may disrupt cellular calcium homeostasis, contributing to neuronal degeneration characteristic of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of proteins, particularly in the process of mitochondrial quality control. Mutations in PRKN are among the most common causes of early-onset autosomal recessive Parkinson's disease. The pathway described connects PRKN to PLCG1, IP3, and ITPR, which are involved in calcium signaling. Impairment in this pathway may disrupt calcium homeostasis, leading to neuronal dysfunction and degeneration. These mechanisms are implicated in the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of proteins, particularly in mitochondrial quality control. Mutations in PRKN are a common cause of autosomal recessive juvenile Parkinson's disease. The pathway described\u2014starting with PRKN and leading to Ca\u00b2\u207a release via IP3 and ITPR\u2014suggests a role in calcium signaling, which is crucial for neuronal function. Disruption of this pathway may lead to mitochondrial dysfunction and neuronal degeneration. Therefore, the PRKN allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway begins with PRNP, the prion protein, and involves molecular chaperones and stress response elements. The network includes HSPA5 (BIP), EIF2AK3 (PERK), EIF2S1, ATF4, and DDIT3 (CHOP), which are central to the unfolded protein response (UPR) in the endoplasmic reticulum. PRNP is associated with prion diseases, which are neurodegenerative disorders caused by misfolded prion proteins. These proteins can induce conformational changes in normal PRNP, leading to cellular dysfunction and neurotoxicity. The pathway reflects the cellular stress response to misfolded proteins, highlighting PRNP's role in prion-related pathologies.\n\n\\boxed{Prion disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the gene encoding the prion protein, is central to the progression of prion diseases. These are neurodegenerative disorders resulting from misfolding of the prion protein into a pathogenic form. The provided pathway suggests that PRNP interacts with the unfolded protein response (UPR) pathway, which is activated under conditions of endoplasmic reticulum (ER) stress. This pathway involves HSPA5 (BIP), EIF2AK3, EIF2S1, ATF4, and DDIT3. The UPR is a cellular stress response that, when dysregulated, can lead to neurodegeneration. In the context of prion disease, the PRNP allele may contribute to the misfolding and aggregation of prion proteins, leading to neuronal dysfunction and death. This pathway is implicated in the progression of neurodegenerative diseases.\n\n\\boxed{Prion disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the PRNP gene, which encodes the prion protein. The pathway illustrates a stress response network where PRNP interacts with BIP (a chaperone protein), leading to the activation of EIF2AK3, which phosphorylates EIF2S1. This results in the induction of ATF4, a transcription factor that activates DDIT3, a stress response gene. This pathway is associated with the unfolded protein response in the endoplasmic reticulum. Mutations in PRNP are known to cause prion diseases, such as Creutzfeldt-Jakob disease (CJD). These diseases are characterized by the misfolding of the prion protein, leading to neurodegenerative effects. The PRNP allele contributes to the development of prion-related neurodegenerative disorders.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of the voltage-gated calcium channel, which plays a critical role in calcium ion influx into cells. Mutations in CACNA1A are linked to several neurological disorders, including episodic ataxia, hemiplegic migraine, and spinocerebellar ataxia type 6. These conditions are characterized by impaired motor coordination, recurrent episodes of ataxia, and migraine headaches. The dysfunction of calcium channels due to CACNA1A mutations disrupts normal neuronal excitability and signaling, leading to the observed clinical symptoms. \n\n\\boxed{Spinocerebellar Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of the P/Q-type voltage-gated calcium channel, crucial for neurotransmitter release and neuronal excitability. Mutations in CACNA1A are implicated in a variety of neurological disorders, including episodic ataxia, hemiplegic migraine, and spinocerebellar ataxia type 6. These conditions are characterized by impaired motor coordination, recurrent episodes of ataxia, and sometimes seizures. The allele's dysfunction disrupts normal calcium influx, leading to altered neuronal signaling and synaptic transmission. This disruption underlies the clinical manifestations of these neurological diseases.\n\n\\boxed{Spinocerebellar Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with several neurological disorders, primarily episodic ataxia and hemiplegic migraine. These disorders are characterized by episodes of loss of coordination (ataxia) and, in some cases, transient weakness on one side of the body (hemiplegia). The CACNA1A allele contributes to these conditions by altering calcium channel function, thereby affecting synaptic transmission and neuronal firing. This genomic pathway illustrates the movement of extracellular calcium into the cell via the CACNA1A channel, which is vital for normal neuronal function. Disruption of this pathway can lead to the pathophysiological mechanisms underlying these diseases.\n\n\\boxed{Episodic Ataxia and Hemiplegic Migraine}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 allele, as part of the described autophagy pathway involving LC3-II, plays a critical role in the recognition and clearance of damaged or aggregated proteins through selective autophagy. Mutations in TBK1 can impair its kinase activity, leading to defective autophagy and accumulation of substrates such as ubiquitinated proteins. This dysfunction is implicated in neurodegenerative disorders, particularly amyotrophic lateral sclerosis (ALS). TBK1 is essential for the recruitment of autophagy receptors like SQSTM1 and OPTN, and its malfunction disrupts this process, contributing to cellular toxicity and neurodegeneration.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 pathway, as defined, is involved in autophagy regulation through the interaction with SQSTM1, OPTN, NDP52, TAX1BP1, and NBR1, leading to LC3-II formation. TBK1 is a critical kinase in the autophagy process, particularly in selective autophagy. Mutations in TBK1 can impair this process, leading to the accumulation of damaged proteins and organelles. This dysfunction is implicated in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). TBK1 mutations have been linked to both familial and sporadic forms of ALS, contributing to motor neuron degeneration by disrupting autophagy and stress response pathways.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 allele is involved in the autophagy signaling pathway, where it phosphorylates SQSTM1, OPTN, NDP52, TAX1BP1, and NBR1 to recruit LC3-II, an essential component of the autophagosome. Mutations in TBK1 can impair this pathway, leading to defective autophagy. This dysfunction has been linked to the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS). \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is involved in the regulation of synaptic vesicle trafficking. Mutations or overexpression of SNCA are associated with the accumulation of misfolded alpha-synuclein, leading to the formation of Lewy bodies. This pathology is a hallmark of Parkinson's disease. The SNCA allele in the provided network is linked to complex I (CxI) of the mitochondrial electron transport chain, which is critical for ATP production. Dysfunction in this pathway can contribute to neuronal damage and death, exacerbating the neurodegenerative process. Thus, the biological effect of this SNCA allele is primarily linked to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a key component in the formation of Lewy bodies, abnormal protein aggregates found in the brain. Mutations or overexpression of SNCA have been implicated in the pathogenesis of Parkinson's disease. The pathway described, involving SNCA and components of complex I (CxI) of the mitochondrial electron transport chain, suggests a potential link between mitochondrial dysfunction and alpha-synuclein pathology. This interplay may contribute to neurodegeneration observed in Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the synuclein alpha protein, which is a key component in the formation of Lewy bodies \u2014 a hallmark of Parkinson's disease. The SNCA allele, particularly when mutated or overexpressed, contributes to the development of Parkinson's disease by disrupting normal cellular function, leading to neurodegeneration in dopaminergic neurons. This pathway, defined with SNCA acting on complex I (CxI), highlights its role in mitochondrial dysfunction, which is a central feature in Parkinson's pathogenesis. Thus, SNCA is strongly associated with Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPARK7 (also known as DJ1) is associated with early-onset Parkinson's disease. The pathway described involves DJ1 interacting with the DAXX and ASK1 proteins, which activate the JNK pathway. JNK is a key player in stress responses and apoptosis. Mutations in PARK7 can disrupt this pathway, leading to neuronal degeneration, a hallmark of Parkinson's disease. Therefore, the biological effect of this PARK7 allele is its contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves PARK7 (DJ1), which is linked to the regulation of the JNK signaling cascade through interactions with DAXX and ASK1 (MAP3K5). Mutations in PARK7 are associated with early-onset Parkinson's disease. This allele likely contributes to neurodegeneration by disrupting the normal function of DJ1, which plays a role in stress response and mitochondrial function. Impairment in this pathway could lead to neuronal death characteristic of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the gene *PARK7* (also known as DJ1), which is associated with Parkinson's disease. The network includes interactions leading to the activation of JNK via DAXX and ASK1. Mutations in *PARK7* can disrupt this pathway, contributing to neurodegeneration. Specifically, *PARK7* is a known susceptibility gene for Parkinson's disease. It plays a role in protecting neurons from oxidative stress and maintaining mitochondrial function. Dysfunctional DJ1 may lead to increased neuronal vulnerability and the progressive loss of dopaminergic neurons characteristic of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase involved in the MAPK/ERK signaling pathway, which regulates cell growth and differentiation. Mutations in BRAF, such as V600E, result in constitutive activation of the BRAF kinase, leading to continuous activation of the MEK-ERK pathway. This uncontrolled signaling promotes cell proliferation and survival, contributing to the development of various cancers. Specifically, BRAF mutations are frequently observed in melanoma, thyroid cancer, and colorectal cancer. The persistent activation of the ERK pathway due to mutant BRAF is a key driver in these malignancies.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene is a key component of the MAPK/ERK signaling pathway, which regulates cell growth and proliferation. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the pathway, promoting uncontrolled cell division. This aberrant signaling is commonly observed in several cancers, most notably melanoma. The pathway activation due to BRAF mutations contributes to tumor progression and resistance to apoptosis. The presence of BRAF mutations is a significant biomarker for targeted therapies, such as BRAF inhibitors.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene is part of the mitogen-activated protein kinase (MAPK) signaling pathway, which regulates cell growth and survival. A mutation in BRAF, such as the V600E mutation, leads to constitutive activation of the MAPK pathway, promoting uncontrolled cell proliferation. This pathway is defined by BRAF \u2192 MEK \u2192 ERK, where BRAF phosphorylates MEK, which in turn activates ERK. The activation of ERK can drive tumor development. Mutations in BRAF are commonly found in melanoma, a type of skin cancer, and also in other cancers like colorectal and thyroid cancers. This aberrant signaling underlies the malignant transformation of cells and is a key factor in the progression of these diseases.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT gene encodes adenine phosphoribosyltransferase, an enzyme involved in the salvage pathway of purine synthesis. A mutation in this gene leads to a deficiency in APRT activity, impairing the body's ability to recycle adenine into adenosine monophosphate (AMP). This results in the accumulation of 2,8-dihydroxyadenine, which can form crystals and lead to the development of kidney stones. The condition is known as 2,8-dihydroxyadenine urolithiasis, or more specifically, adenine phosphoribosyltransferase deficiency. This disease is rare and typically presents with recurrent kidney stones, hematuria, and, in severe cases, renal failure. The enzyme deficiency is usually inherited in an autosomal recessive manner.\n\n\\boxed{Adenine phosphoribosyltransferase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT gene encodes adenine phosphoribosyltransferase, an enzyme involved in the salvage pathway of purine nucleotide synthesis. A deficiency in this enzyme leads to the accumulation of adenine derivatives, which can crystallize and cause damage to the urinary tract. This condition is known as adenine phosphoribosyltransferase deficiency, also called APRT deficiency. It is a rare autosomal recessive disorder that primarily results in kidney stones and, in severe cases, chronic kidney disease. The biological effect of a pathogenic APRT allele is thus the development of this metabolic disorder, which can lead to significant renal complications.\n\n\\boxed{Adenine Phosphoribosyltransferase Deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT gene encodes adenine phosphoribosyltransferase, an enzyme involved in the salvage pathway of purine nucleotide synthesis. Mutations in the APRT gene can lead to a deficiency in this enzyme, impairing the body's ability to recycle adenine into adenosine monophosphate (AMP). This results in the accumulation of 2,8-dihydroxyadenine, which can form crystals and lead to kidney damage. The condition is known as 2,8-dihydroxyadenine urolithiasis or adenine phosphoribosyltransferase deficiency. It is a rare autosomal recessive disorder often associated with recurrent kidney stones and, in severe cases, kidney failure. \n\n\\boxed{Adenine phosphoribosyltransferase deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene is a tumor suppressor gene involved in the regulation of the cell cycle, primarily through its interaction with E2F transcription factors. The RB1 allele, when mutated or inactivated, leads to the dysregulation of the G1/S checkpoint, promoting uncontrolled cell proliferation. This disruption in cell cycle control is a key feature in the development of retinoblastoma, a rare childhood eye cancer. The network definition involving RB1 and E2F proteins underscores the critical role of RB1 in repressing E2F activity, which, when impaired, contributes to tumorigenesis. \n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a tumor suppressor that regulates the cell cycle by inhibiting E2F transcription factors. Mutations in RB1 lead to uncontrolled cell proliferation by disrupting its ability to inhibit E2F, which promotes DNA synthesis and cell division. This disruption is a key event in the development of retinoblastoma, a rare childhood eye cancer. Additionally, RB1 mutations are associated with an increased risk of other cancers, such as osteosarcoma and melanoma. The interaction between RB1 and E2F proteins is central to the regulation of the G1/S checkpoint in the cell cycle.\n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates the cell cycle by inhibiting E2F transcription factors. When RB1 is inactivated or mutated, E2F proteins are released and activate genes involved in DNA replication, leading to uncontrolled cell proliferation. This pathway is critical in preventing cancer. Mutations in RB1 are strongly associated with retinoblastoma, a childhood eye cancer, and also contribute to other cancers such as osteosarcoma and small cell lung cancer. The interaction between RB1 and E2F proteins is central to the regulation of the G1/S checkpoint in the cell cycle.\n\n\\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of coordination, muscle stiffness, and other neurological symptoms. The pathway provided highlights the involvement of ATXN3 in calcium signaling, a process that is crucial for neuronal function and survival. Dysregulation of calcium homeostasis, potentially influenced by ATXN3 dysfunction, may contribute to the neurodegeneration seen in SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the metabotropic glutamate receptor GRM1, which initiates a cascade leading to intracellular calcium release and mitochondrial calcium uptake, ultimately influencing mitochondrial permeability transition pore (MPTP) activity and cytochrome c (CYCS) release. ATXN3 is part of a complex with ITPR1, which modulates calcium signaling. Mutations in ATXN3 are linked to spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive dysfunction of the cerebellum and other brain regions, leading to ataxia, dystonia, and other motor impairments. The involvement of ATXN3 in calcium signaling suggests its role in neuronal integrity and the pathogenesis of SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with Machado-Joseph disease (also known as spinocerebellar ataxia type 3), a neurodegenerative disorder characterized by progressive ataxia, dysarthria, and other neurological symptoms. The inclusion of ATXN3 in the described pathway suggests a role in calcium signaling, which is implicated in neuronal dysfunction and cell death. The presence of ATXN3 in the context of calcium and mitochondrial dynamics may further indicate its contribution to the pathogenesis of Machado-Joseph disease through mechanisms involving calcium homeostasis disruption and mitochondrial dysfunction.\n\n\\boxed{Machado-Joseph disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves SOD1, which is a key component of the endoplasmic reticulum (ER) stress response. SOD1, when mutated, can lead to misfolding and aggregation, triggering ER stress and subsequent activation of the unfolded protein response (UPR), including the ATF6 and DDIT3 pathways. This pathway is implicated in neurodegenerative diseases. Specifically, mutations in the SOD1 gene are a major cause of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies reactive oxygen species. The provided pathway highlights its interaction with BIP (HSPA5) and ATF6, leading to the activation of DDIT3, which is involved in stress responses and apoptosis. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. These mutations can lead to toxic protein aggregation and mitochondrial dysfunction, contributing to neuronal death. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, playing a crucial role in protecting cells from oxidative damage. Mutations in SOD1 are implicated in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. In this pathway, SOD1 may influence the endoplasmic reticulum stress response through its interaction with BIP (a chaperone protein) and ATF6, which activates DDIT3, a gene involved in cellular stress responses. Dysfunctional SOD1 can lead to the accumulation of misfolded proteins, triggering endoplasmic reticulum stress and contributing to neuronal degeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene is a tumor suppressor that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. In the given pathway, PTEN* (a mutated or non-functional allele) would lose its ability to dephosphorylate PIP3, leading to increased PIP3 levels. This results in the activation of AKT kinases (AKT1, AKT2, AKT3), which promote cell survival, proliferation, and growth. Loss of PTEN function is strongly associated with the development of various cancers, particularly those involving the PI3K/AKT pathway. One disease specifically linked to PTEN mutations is Cowden syndrome, a hereditary condition that predisposes individuals to multiple types of cancer, including breast, thyroid, and endometrial cancers.\n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. Loss of PTEN function leads to increased AKT activation, promoting cell survival, proliferation, and resistance to apoptosis. This contributes to uncontrolled cell growth and tumorigenesis. Germline mutations in PTEN are associated with Cowden syndrome, a hereditary condition characterized by an increased risk of benign and malignant tumors, including breast, thyroid, and endometrial cancers. Somatic mutations in PTEN are commonly found in various cancers, such as glioblastoma, endometrial carcinoma, and melanoma. \n\n\\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPTEN is a tumor suppressor gene that negatively regulates the PI3K/AKT signaling pathway by dephosphorylating PIP3. Loss-of-function mutations in PTEN lead to constitutive activation of AKT, promoting cell survival, proliferation, and resistance to apoptosis. This dysregulation contributes to uncontrolled cell growth and is implicated in various cancers. Specifically, PTEN mutations are commonly observed in cancers such as endometrial, prostate, and glioblastoma. \n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele initiates a pathological cascade leading to neurodegenerative disease. Activated PRNP interacts with NMDAR, increasing intracellular Ca\u00b2\u207a, which then enters mitochondria via MCU. This mitochondrial Ca\u00b2\u207a overload triggers MPTP opening, releasing CYCS and initiating the apoptotic cascade through APAF1, CASP9, and CASP3. This pathway contributes to neuronal apoptosis and is implicated in prion diseases, specifically Creutzfeldt-Jakob disease.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele is associated with prion diseases, a group of neurodegenerative disorders caused by the misfolding of the prion protein (PrP). This pathway involves PRNP initiating a chain reaction through NMDAR and calcium influx, which can lead to mitochondrial calcium overload and ultimately apoptosis via the mitochondrial permeability transition pore (MPTP), releasing cytochrome c and activating caspases. This process is implicated in neuronal death. The PRNP allele contributes to diseases like Creutzfeldt-Jakob disease (CJD), a rapidly progressive and fatal neurodegenerative disorder.\n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, specifically the pathogenic variants of the PRNP gene, is primarily associated with prion diseases. These are a group of rare, neurodegenerative disorders characterized by the misfolding of the prion protein (PrP^Sc), leading to neuronal dysfunction and death. The mentioned pathway involves the activation of NMDA receptors, influx of calcium ions, mitochondrial dysfunction via the MCU complex, and eventual induction of apoptosis through the caspase cascade. These molecular events are commonly linked to neurodegenerative processes, such as those observed in prion diseases like Creutzfeldt-Jakob disease (CJD). Thus, the PRNP allele contributes to the development of prion-related neurodegenerative diseases.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described outlines a sequence of events leading to apoptosis, starting with SOD1, which is a key antioxidant enzyme. When SOD1 is dysfunctional or mutated, it leads to an accumulation of reactive oxygen species (ROS), which can promote mitochondrial damage. This damage triggers the release of cytochrome c (CYCS), activating the apoptotic cascade via APAF1, CASP9, and CASP3. BCL2 normally inhibits apoptosis, but its suppression by BAX and BAK1 allows the pathway to proceed. Mutations in SOD1 are specifically associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The disruption of SOD1 function contributes to oxidative stress and subsequent neuronal death. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway illustrates a sequence from the SOD1 gene, which encodes superoxide dismutase 1, an antioxidant enzyme. Mutations in SOD1 are linked to a specific neurodegenerative disorder. The pathway shows that SOD1 negatively regulates BCL2, which in turn inhibits pro-apoptotic proteins BAX and BAK1. This leads to the release of cytochrome c (CYCS), activation of APAF1, and the subsequent caspase cascade involving CASP9 and CASP3, leading to apoptosis. This sequence is central to programmed cell death, and malfunction in SOD1 can lead to excessive apoptosis in neurons. SOD1 mutations are known to cause amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, a progressive neurological condition that leads to the degeneration of motor neurons.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway illustrates a sequence of events in the intrinsic apoptotic pathway. SOD1 is shown to negatively regulate BCL2, which in turn inhibits BAX and BAK1, preventing the release of cytochrome c (CYCS) from mitochondria. The release of CYCS activates APAF1, leading to caspase 9 (CASP9) activation, which then activates caspase 3 (CASP3), the executioner caspase. Mutations in SOD1 are associated with familial amyotrophic lateral sclerosis (ALS). These mutations lead to misfolding and aggregation of SOD1, causing toxic effects on motor neurons. This disruption in the apoptotic pathway may contribute to neuronal death observed in ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, as part of the described pathway, initiates a signaling cascade from MET to CCND1. This pathway involves key components such as GRB2, SOS, RAS, RAF, MEK, and ERK, which are crucial in regulating cell growth, proliferation, and survival. Dysregulation of this pathway, particularly through MET overactivation, can lead to uncontrolled cell proliferation and tumor formation. MET is frequently implicated in various cancers, especially those involving aberrant activation or overexpression of the MET receptor tyrosine kinase. This contributes to the development and progression of cancer by promoting oncogenic signaling. \n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway involves a series of molecular interactions starting with the MET receptor tyrosine kinase, which, when activated, triggers a cascade through GRB2, SOS, RAS (HRAS, KRAS, or NRAS), RAF (BRAF, ARAF, or RAF1), MEK (MAP2K1 or MAP2K2), ERK (MAPK1 or MAPK3), and finally CCND1. This pathway is critical for cell proliferation, survival, and migration. Mutations or overactivation of MET can lead to uncontrolled cell growth and are implicated in various cancers. Notably, MET dysregulation is frequently observed in non-small cell lung cancer (NSCLC), glioblastoma, and some gastrointestinal cancers. The MET allele, when aberrantly activated, contributes to tumor progression and resistance to therapy.\n\n\\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, starting from MET and proceeding through GRB2, SOS, RAS, RAF, MEK, ERK, and finally CCND1, is a critical signaling cascade involved in cell growth, survival, and proliferation. Mutations or overactivation of MET can lead to constitutive activation of this pathway, promoting uncontrolled cell division. This aberrant signaling is frequently observed in various cancers, particularly in gastric cancer, where MET amplification or mutation is associated with tumor progression and poor prognosis. Additionally, MET alterations are implicated in lung cancer, glioblastoma, and some hematologic malignancies. The pathway's role in cyclin D1 regulation further links it to cell cycle control, a hallmark of cancer.\n\n\\boxed{Gastric Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism, also known as Parkinson disease 5 (PD5). This pathway involves PRKN and monoamine oxidases (MAO A and B), which are involved in the degradation of monoamines such as dopamine. The pathway MAO -> DOPAL suggests a role in dopamine metabolism. Impairment in this pathway, particularly through PRKN dysfunction, leads to the accumulation of damaged proteins and mitochondrial dysfunction, contributing to the degeneration of dopaminergic neurons in the substantia nigra. This neuronal loss is a hallmark of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive early-onset Parkinson's disease. The pathway described includes PRKN, which is linked to MAO (monoamine oxidase) through the metabolite DOPAL (3,4-dihydroxyphenylacetaldehyde). This pathway suggests a connection between parkin and monoamine metabolism, which may influence dopaminergic neuron function. Since PRKN is a known causative gene for a subset of Parkinson's disease cases, the biological effect of a PRKN allele with a pathogenic mutation would be contributing to the development of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in mitochondrial quality control and proteasomal degradation. Mutations in PRKN are a common cause of autosomal recessive early-onset Parkinson's disease (PD). The pathway described includes PRKN, which is linked to MAOA and MAOB, enzymes that metabolize monoamines like dopamine. MAOA and MAOB metabolize dopamine into DOPAL, a neurotoxic compound. PRKN's role in mitochondrial function and protein degradation suggests that its dysfunction may lead to dopaminergic neuron death, a hallmark of Parkinson's disease. Therefore, the biological effect of this PRKN allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, encodes the p53 protein, a critical tumor suppressor involved in initiating apoptosis, cell cycle arrest, and DNA repair. The provided pathway highlights TP53's regulatory role over genes such as CDKN1A, GADD45A/B/G, BAX, BAK1, DDB2, and POLK, all of which are key players in DNA damage response and apoptosis. Mutations in TP53 can disrupt these processes, leading to uncontrolled cell proliferation and genomic instability. Such dysregulation is a hallmark of various cancers. Germline mutations in TP53 are specifically associated with Li-Fraumeni syndrome, a hereditary condition that greatly increases the risk of developing multiple types of malignancies, including breast cancer, leukemia, lymphoma, and sarcomas, at an early age.\n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the p53 protein, a critical tumor suppressor involved in regulating the cell cycle, DNA repair, and apoptosis. In the given pathway, TP53 regulates genes such as CDKN1A, GADD45A/B/G, BAX, BAK1, DDB2, and POLK, all of which are involved in stress response, DNA repair, and programmed cell death. Mutations in TP53 can lead to loss of function, preventing the cell from undergoing apoptosis or repairing DNA damage, thereby increasing the risk of cancer. Specifically, germline mutations in TP53 are associated with Li-Fraumeni syndrome, a hereditary condition that predisposes individuals to a wide range of cancers, including breast cancer, sarcomas, and brain tumors. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the p53 protein, a critical tumor suppressor that regulates the DNA damage response, apoptosis, and cell cycle arrest. In the provided pathway, TP53 activates downstream targets such as CDKN1A (p21), GADD45 family members, BAX, BAK1, DDB2, and POLK, all of which are involved in DNA repair, apoptosis, and cell cycle regulation. Mutations in TP53 that disrupt its function can lead to genomic instability and uncontrolled cell proliferation. This loss of tumor suppression is strongly associated with a variety of cancers, particularly Li-Fraumeni syndrome, a hereditary condition characterized by a high predisposition to multiple types of cancer, including breast cancer, leukemia, and sarcomas.\n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway begins with the amyloid beta precursor protein (APP), which is cleaved to generate amyloid-beta (Abeta). Accumulation of Abeta is a hallmark of Alzheimer's disease. The pathway continues through a series of intracellular signaling events, ultimately leading to apoptosis via activation of caspase 3. This cascade is implicated in neuronal dysfunction and death, which are central to the pathogenesis of Alzheimer's disease. The involvement of mitochondrial calcium regulation and the apoptotic cascade further supports a role in neurodegeneration.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway involves the amyloid beta precursor protein (APP), which is central to Alzheimer's disease pathology. APP is cleaved to produce Abeta, a peptide that aggregates into amyloid plaques. These plaques contribute to neurodegeneration by disrupting calcium homeostasis, activating apoptotic pathways, and leading to neuronal dysfunction. The pathway includes GRM5, GNAQ, PLCB, IP3, ITPR, and MCU, all involved in calcium signaling. Excessive intracellular calcium and mitochondrial dysfunction trigger MPTP opening, release of cytochrome c, and activation of caspases, culminating in apoptosis. This chain of events is a hallmark of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway involves the amyloid precursor protein (APP), which is proteolytically processed to generate amyloid-beta (A\u03b2) peptides. These peptides are central to the pathogenesis of Alzheimer's disease (AD). The pathway describes a sequence of events starting with APP, leading through G protein-coupled signaling, calcium signaling via IP3 and IPRs, mitochondrial calcium uptake via MCU, and ultimately to the release of cytochrome c and activation of caspases, which are hallmarks of apoptosis. This cascade is implicated in neuronal dysfunction and cell death in Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele, through its role in the described pathway, contributes to the activation of the mitochondrial permeability transition pore (MPTP), leading to the release of cytochrome c and subsequent apoptosis. This pathway begins with PRNP, which can be misfolded in certain genetic variations, initiating a cascade that includes calcium dysregulation and mitochondrial dysfunction. These processes are central to the pathogenesis of prion diseases. The misfolding and aggregation of the prion protein PRNP are directly associated with neurodegeneration. Specifically, the described pathway aligns with mechanisms seen in Creutzfeldt-Jakob disease (CJD), a neurodegenerative disorder caused by prion protein dysfunction.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP allele is associated with prion diseases, a group of transmissible neurodegenerative disorders. The pathway outlined shows how the prion protein (PRNP) activates calcium release through RYR and ITPR channels, leading to mitochondrial calcium overload via MCU. This overload can trigger the mitochondrial permeability transition pore (MPTP), resulting in the release of cytochrome c (CYCS), which initiates the apoptotic cascade through APAF1, CASP9, and CASP3. This sequence of events leads to neuronal death, a hallmark of prion diseases such as Creutzfeldt-Jakob disease (CJD). \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to the pathogenesis of prion diseases. The provided pathway outlines a sequence involving calcium signaling and apoptosis, starting with PRNP and leading to caspase-3 activation. This pathway suggests that the PRNP allele may contribute to neurodegenerative diseases through dysregulation of calcium homeostasis and induction of apoptosis. Specifically, mutations in PRNP are strongly associated with Creutzfeldt-Jakob disease (CJD), a rare, rapidly progressive, and fatal neurodegenerative disorder caused by misfolded prion proteins.\n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway involves SOD1, which is known to be associated with amyotrophic lateral sclerosis (ALS). SOD1 is a copper-zinc superoxide dismutase that normally functions to detoxify reactive oxygen species. Mutations in the SOD1 gene have been implicated in inherited forms of ALS. The pathway describes a protein degradation process involving ubiquitination and proteasomal degradation, which is relevant to the pathological mechanisms in ALS where misfolded or mutant SOD1 proteins may accumulate and form aggregates, leading to motor neuron degeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described involves SOD1 interacting with DERL1, leading to the ubiquitination of proteins via the ubiquitin-proteasome system, potentially contributing to protein degradation and neuronal dysfunction. This network highlights the role of SOD1 in maintaining cellular homeostasis, and its dysfunction can lead to the accumulation of toxic proteins and subsequent neurodegeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that plays a critical role in protecting cells from oxidative damage by catalyzing the conversion of superoxide radicals to hydrogen peroxide and oxygen. Mutations in the SOD1 gene are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. This neurodegenerative disorder is characterized by the progressive loss of motor neurons, leading to muscle weakness, paralysis, and eventually death. The SOD1 mutations lead to the production of misfolded SOD1 protein, which may cause oxidative stress, mitochondrial dysfunction, and neuroinflammation, thereby contributing to the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is part of the NRG // ERBB4* pathway, which involves neuregulins (NRG1-4) and the ERBB4 receptor. This pathway is crucial in neurodevelopment, particularly in the formation and function of neural circuits. Dysregulation or mutations in ERBB4 can impair its ability to interact with neuregulins, leading to disruptions in neuronal migration, synaptic connectivity, and myelination. These disruptions are associated with neurodevelopmental disorders, particularly those involving autism spectrum disorders (ASD). ERBB4 is highly expressed in the brain, and its dysfunction has been linked to altered social behaviors and cognitive deficits observed in ASD. Therefore, the ERBB4 allele contributes to the development of autism spectrum disorder.\n\n\\boxed{Autism Spectrum Disorder}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a key role in various signaling pathways, including those involving the NRG (neuregulin) ligands. Mutations or dysregulation of ERBB4 have been implicated in several diseases. Specifically, ERBB4 has been associated with schizophrenia, as studies have identified genetic variants in ERBB4 that are linked to increased susceptibility to the disorder. These variants may disrupt normal neuronal function and synaptic connectivity, contributing to the pathogenesis of schizophrenia. Therefore, the biological effect of this ERBB4 allele is its contribution to the development of schizophrenia. \n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase involved in cell signaling pathways crucial for development and function of the nervous system and mammary glands. The NRG (neuregulin) ligands activate ERBB4, influencing processes such as myelination, synaptic plasticity, and organ development. Mutations or dysregulation of the ERBB4 pathway, particularly in the context of neuregulins, have been implicated in neurodevelopmental and psychiatric disorders. Specifically, alterations in ERBB4 have been associated with schizophrenia, a complex mental disorder characterized by impaired cognition, affective dysfunction, and perceptual disturbances. These findings suggest that the ERBB4 allele contributes to the etiology of schizophrenia through its role in neural development and signaling.\n\n\\boxed{Schizophrenia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the molecular pathway HTT* -> MLK2 -> MKK7 -> JNK. Mutations in the HTT gene, particularly CAG trinucleotide repeat expansions, lead to the production of an abnormal huntingtin protein. This dysfunctional protein disrupts cellular processes, leading to the degeneration of neurons, especially in the brain. The disease associated with HTT mutations is Huntington's disease. This neurodegenerative disorder is characterized by motor, cognitive, and psychiatric symptoms. The pathway involving HTT, MLK2, MKK7, and JNK may contribute to the neuroinflammatory and apoptotic responses observed in affected neurons. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, and pathogenic expansions in the CAG trinucleotide repeat within this gene lead to Huntington's disease. The given pathway\u2014HTT* -> MLK2 -> MKK7 -> JNK\u2014suggests that mutant HTT (HTT*) may dysregulate the JNK signaling cascade, contributing to neuronal dysfunction and cell death. This pathway is implicated in stress responses and apoptosis, which are key features of Huntington's disease pathology. Thus, the HTT allele, when mutated, contributes to Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the pathway HTT* \u2192 MLK2 \u2192 MKK7 \u2192 JNK. This pathway is involved in stress response and apoptosis. Mutations in the HTT gene, specifically expansions of CAG repeats, lead to the production of an abnormal huntingtin protein. This results in the neurodegenerative disease Huntington's disease, characterized by motor, cognitive, and psychiatric symptoms. The abnormal protein disrupts cellular functions, leading to the progressive loss of neurons, particularly in the striatum and cerebral cortex.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that is involved in various signaling pathways, including those related to neural development and function. When activated by ligands such as NRG1-4, ERBB4 plays a role in cell proliferation, differentiation, and survival. Mutations or dysregulation of ERBB4 have been implicated in several diseases, most notably in schizophrenia. Studies have shown that genetic variations in ERBB4 contribute to the risk of developing schizophrenia, possibly through disrupted neural connectivity and synaptic function. ERBB4 is also associated with other neurological and psychiatric disorders, but its strongest and most consistent link is to schizophrenia.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in various cellular processes, including development and signaling. Its interaction with NRG (neuregulin) ligands is essential in pathways affecting neural development, mammary gland function, and immune responses. Mutations or dysregulation of ERBB4 can lead to impaired signaling, contributing to disorders such as schizophrenia. This pathway is also implicated in certain cancers, but the specific allele in question most directly contributes to schizophrenia through its impact on neurodevelopment and synaptic function.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that is part of the ERBB family, which is involved in cellular signaling pathways regulating growth, differentiation, and survival. When activated by ligands such as neuregulins (NRG1-4), ERBB4 participates in various physiological processes, including neural development and mammary gland morphogenesis. Genetic variations or mutations in ERBB4 can lead to dysregulation of these pathways. This dysregulation has been implicated in several diseases, including certain types of breast cancer. Specifically, alterations in the ERBB4 pathway have been linked to the progression and prognosis of breast cancer.\n\n\\boxed{Breast Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and degradation of misfolded proteins. Mutations in PRKN are associated with early-onset autosomal recessive Parkinson's disease. The pathway described includes PRKN and MAO enzymes, which are involved in dopamine metabolism. Dysfunction in this pathway, particularly related to PRKN, can lead to the accumulation of damaged proteins and dopaminergic neuron degeneration. This contributes to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and degradation of proteins. Mutations in PRKN are associated with early-onset Parkinson's disease (PD), an inherited neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra. The pathway includes MAOA and MAOB, which metabolize neurotransmitters like dopamine into DOPAL, a neurotoxin. Loss of functional parkin disrupts protein quality control and leads to accumulation of toxic proteins, contributing to neuronal death. This genetic defect is a known cause of autosomal recessive juvenile Parkinsonism.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and degradation of misfolded proteins. Mutations in PRKN are a common cause of autosomal recessive early-onset Parkinson's disease. The pathway described involves PRKN, MAOA, and MAOB, which are related to the metabolism of dopamine. MAO enzymes (A and B) catalyze the breakdown of dopamine into DOPAL. PRKN's role in protein quality control suggests that its dysfunction may lead to the accumulation of toxic proteins, particularly in dopaminergic neurons, contributing to neuronal degeneration. This is a key mechanism in Parkinson's disease pathogenesis. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves SOD1, which is implicated in a neurodegenerative disorder. SOD1 encodes superoxide dismutase 1, an enzyme that normally detoxifies reactive oxygen species. Mutations in SOD1 are known to cause amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the loss of motor neurons. The pathway shown reflects a stress response involving ER stress and the unfolded protein response, which is relevant in ALS pathology. SOD1 mutations can lead to misfolded proteins, triggering the ER stress pathway, ultimately leading to neuronal death.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the unfolded protein response (UPR) in the endoplasmic reticulum (ER), triggered by oxidative stress and ER stress. SOD1 (superoxide dismutase 1) is a key player in mitigating oxidative stress by converting superoxide radicals to hydrogen peroxide. In this context, the pathway involves SOD1, which, when dysfunctional, leads to increased oxidative stress and ER stress. This initiates a signaling cascade through the PERK pathway (EIF2AK3), leading to the phosphorylation of EIF2S1 and subsequent activation of ATF4, which upregulates DDIT3 (CHOP), a pro-apoptotic gene. Chronic activation of this pathway results in ER stress-mediated apoptosis. Mutations in SOD1 are strongly associated with Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease characterized by motor neuron death. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway illustrates a molecular network involving SOD1, which is linked to the unfolded protein response (UPR) through its interaction with BIP and downstream effectors such as EIF2AK3, EIF2S1, ATF4, and DDIT3. SOD1 is a key enzyme involved in the detoxification of superoxide radicals. Mutations in the SOD1 gene are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. These mutations can lead to the misfolding and aggregation of SOD1, which may trigger cellular stress responses and ultimately contribute to neuronal death. \n\n\\boxed{Amyotrophic lateral sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive early-onset Parkinson's disease (PD). This allele contributes to the pathogenesis of Parkinson's disease by impairing the normal function of parkin, which is essential for the degradation of damaged proteins and maintaining mitochondrial health. Disruption of this pathway can lead to the accumulation of misfolded proteins and mitochondrial dysfunction, hallmark features of PD.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are strongly associated with early-onset autosomal recessive Parkinson's disease. Parkin plays a critical role in mitochondrial quality control by tagging damaged mitochondria for degradation via mitophagy. Loss-of-function mutations in PRKN impair this process, leading to the accumulation of dysfunctional mitochondria and subsequent neuronal degeneration, particularly in dopaminergic neurons of the substantia nigra. This contributes to the characteristic motor symptoms of Parkinson's disease, such as bradykinesia, rigidity, and resting tremor.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile Parkinson's disease (AR-JP). This pathway includes genes involved in ubiquitination and protein degradation, such as UBCH7/8 (ubiquitin-conjugating enzymes) and UBE2L3/UBE2L6, and is connected to PRKN, which plays a role in mitochondrial quality control and apoptosis. SNCAIP, which interacts with alpha-synuclein, is also included, linking this pathway to processes relevant to Parkinson's disease pathology. The presence of this PRKN allele suggests a predisposition or causation of Parkinson's disease, particularly the early-onset form.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a major cause of autosomal recessive early-onset Parkinson's disease (PD). The pathway described involves components of the ubiquitin system, including UBCH7/8 (E2 enzymes), PRKN (E3 ligase), and PAELR, which is involved in the unfolded protein response. UBE2L3 and UBE2L6 are also E2 enzymes, supporting the role of ubiquitination in this network. Dysfunction in this pathway, particularly involving PRKN, can lead to impaired protein degradation and mitochondrial dysfunction, both of which are implicated in neurodegeneration. Thus, the PRKN allele contributes to \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with early-onset autosomal recessive Parkinson's disease. The pathway includes genes involved in ubiquitination, such as UBCH7/8 (E2 enzymes) and PAELR, which functions in ubiquitin ligase activity. PRKN mutations lead to impaired protein degradation, mitochondrial dysfunction, and neuronal degeneration. This contributes to the progressive loss of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism (also known as Parkinson disease 4, PD4). This disease is characterized by early-onset Parkinson's symptoms, including bradykinesia, rigidity, and resting tremor. The pathway described involves components of the ubiquitin-proteasome system, including UBCH7/8 (E2 enzymes), PRKN (E3 ligase), and PAELR, suggesting a role in protein degradation and quality control. Dysfunctional parkin may disrupt mitochondrial quality control and lead to neurodegeneration. \n\n\\boxed{Parkinson disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene is a key component of the MAPK/ERK signaling pathway, which is crucial for cell growth and survival. Mutations in BRAF, specifically the V600E mutation, lead to constitutive activation of the BRAF kinase, which in turn continuously activates MEK and ERK downstream. This uncontrolled activation promotes unregulated cell proliferation and can lead to the development of cancer. BRAF mutations are frequently observed in melanoma, a type of skin cancer, as well as in thyroid, colorectal, and other cancers. The persistent activation of this pathway is a major driver of tumorigenesis in these malignancies.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that is a key component of the MAPK/ERK signaling pathway. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the kinase, resulting in uncontrolled cell proliferation. This pathway is crucial for cell growth and differentiation. In the context of the given pathway (BRAF \u2192 MEK \u2192 ERK), a mutated BRAF allele would continuously activate MEK and ERK, promoting cellular proliferation and survival. This dysregulated signaling is a common driver in several cancers, most notably melanoma. The BRAF V600E mutation is frequently observed in melanoma and other malignancies, contributing to tumor development and progression.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that is a key component of the mitogen-activated protein kinase (MAPK) signaling pathway, which is crucial for cell growth and differentiation. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the BRAF-ERK signaling cascade, promoting uncontrolled cell proliferation. This aberrant activation is a common feature in several cancers, most notably melanoma. The pathway defined\u2014BRAF* (mutant) \u2192 MEK \u2192 ERK\u2014represents the activated MAPK/ERK pathway, which drives tumor progression. BRAF mutations are also found in thyroid cancer, colorectal cancer, and other malignancies. The biological effect of a mutant BRAF allele is the promotion of tumorigenesis through persistent MAPK signaling.  \n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor protein that is cleaved into saposins, which are essential for the activity of several lysosomal enzymes, including GBA and GALC. Mutations in PSAP are associated with a rare autosomal recessive disorder called **Saposin deficiency**, also known as **Saposin A deficiency** or **SAP-A deficiency**. This condition leads to impaired lysosomal function, resulting in the accumulation of certain lipids and the progressive degeneration of the nervous system, primarily affecting the central and peripheral nerves. It is a form of **metachromatic leukodystrophy (MLD)**, though distinct from the more common arylsulfatase A-deficient form. The network definition provided links PSAP with GBA and GALC, highlighting its functional relationship with these enzymes in lipid metabolism and lysosomal function.  \n\\boxed{Saposin deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the function of lysosomal enzymes such as GBA (glucosylceramidase beta) and GALC (galactosylceramidase). Mutations in PSAP can lead to a deficiency in saposins, impairing the activity of these enzymes. This enzymatic deficiency results in the accumulation of their substrates, such as glucosylceramide and galactosylceramide, in lysosomes, causing cellular dysfunction. This pathway is associated with lysosomal storage disorders. Specifically, mutations in PSAP are linked to a condition known as **Saposin A deficiency**, which contributes to **Krabbe disease**. Krabbe disease is a severe neurodegenerative disorder characterized by early-onset symptoms, including developmental delay, seizures, and progressive neurological deterioration.\n\n\\boxed{Krabbe disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP gene encodes prosaposin, a precursor to saposins, which are essential for the activity of several lysosomal enzymes, including GBA and GALC. Mutations in PSAP lead to a deficiency in saposins, impairing the function of these enzymes. This results in the accumulation of glycosphingolipids in lysosomes, causing cellular dysfunction. The clinical manifestation of this condition is a rare, inherited lysosomal storage disease known as **Saposin-Deficient Lysosomal Storage Disease (SD-LSD)**, also referred to as **Neuronal Ceroid Lipofuscinosis Type 1 (NCL1)**. This disease leads to progressive neurological decline, visual impairment, and cognitive deficits. \n\n\\boxed{Neuronal Ceroid Lipofuscinosis Type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the metabotropic glutamate receptor GRM1, which activates a signaling cascade leading to intracellular calcium release through IP3 and ITPR1. ATXN3 is part of this pathway, possibly modulating the function of ITPR1. Mutations or altered function of ATXN3, particularly in the context of expanded polyQ tracts, are associated with neurodegenerative disorders. Specifically, ATXN3 is a causative gene for Machado-Joseph disease (also known as Spinocerebellar Ataxia Type 3). This autosomal dominant disorder leads to progressive ataxia, dystonia, and other neurological symptoms due to the toxic effects of mutant ATXN3 protein.  \n\n\\boxed{Machado-Joseph disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes for ataxin-3, a protein involved in DNA repair and maintenance of the nervous system. The provided pathway details a calcium signaling cascade initiated by glutamate, involving G-protein coupled receptors and ultimately leading to mitochondrial calcium uptake and cytochrome c release. Mutations in ATXN3 are associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive ataxia, dystonia, and other movement disorders due to the toxic gain-of-function of mutant ataxin-3, which leads to neuronal dysfunction and death. The role of ATXN3 in calcium signaling may further contribute to the pathophysiology of SCA3.\n\n\\boxed{Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes the ataxin-3 protein, which is primarily associated with the neurodegenerative disorder known as spinocerebellar ataxia type 3 (SCA3), also called Machado-Joseph disease. The pathway described highlights the role of ATXN3 in calcium signaling, a process crucial for neuronal function. Abnormalities in this pathway, particularly those involving ATXN3, can lead to dysregulation of intracellular calcium levels, mitochondrial dysfunction, and ultimately, neurodegeneration. The presence of ATXN3 in this pathway underscores its involvement in the regulation of calcium homeostasis, which is critical in the pathogenesis of SCA3. \n\n\\boxed{Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the tumor suppressor protein p53, which is central to the DNA damage response and apoptosis. In the given pathway, TP53 regulates genes such as CDKN1A, GADD45A/B/G, BAX, BAK1, DDB2, and POLK\u2014genes involved in cell cycle arrest, DNA repair, and apoptosis. Mutations in TP53 can lead to loss of function, impairing these critical processes and allowing genomic instability and uncontrolled cell growth. This is strongly associated with Li\u2013Fraumeni syndrome, a hereditary cancer predisposition syndrome characterized by a high risk of developing various cancers, including breast cancer, sarcomas, brain tumors, leukemia, and adrenocortical tumors, often at an early age.\n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the tumor protein p53, a critical regulator of apoptosis, cell cycle arrest, and DNA repair. The pathway described includes TP53 and downstream effectors like CDKN1A, GADD45 family members, BAX, BAK1, DDB2, and POLK, all involved in stress response, DNA repair, and apoptosis. Mutations in TP53 can disrupt these vital functions, leading to uncontrolled cell proliferation and tumor development. Germline mutations in TP53 are associated with Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome characterized by a high risk of multiple types of cancer, including sarcomas, breast cancer, and brain tumors.\n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, encodes the p53 protein, a critical tumor suppressor involved in regulating the cell cycle, DNA repair, and apoptosis. Mutations in TP53 can lead to loss of function, disrupting its ability to prevent uncontrolled cell growth. The defined pathway includes genes like CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which are involved in cell cycle arrest, DNA repair, and apoptosis. Dysfunctional TP53 can result in failure to activate these pathways, contributing to tumorigenesis. This loss of tumor suppression is strongly associated with various cancers, especially Li-Fraumeni syndrome, a hereditary condition characterized by a high risk of developing multiple types of cancers at an early age.\n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPSEN1 (presenilin 1) is a key component of the gamma-secretase complex, which is involved in the proteolytic processing of the amyloid precursor protein (APP). This processing generates amyloid-beta peptides, which are the primary constituents of amyloid plaques found in Alzheimer's disease (AD). Mutations in the PSEN1 gene are strongly linked to early-onset familial Alzheimer's disease. These mutations disrupt the normal function of gamma-secretase, altering the cleavage of APP and increasing the production of toxic amyloid-beta 42 peptides. The resulting accumulation of amyloid-beta leads to neurodegeneration and cognitive decline. The pathway described, involving GSK3B and the KIF5+KLC complex, suggests a connection to intracellular transport and tau phosphorylation, both of which are implicated in AD pathology.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involving PSEN1, GSK3B, and the KIF5+KLC complex is implicated in Alzheimer's disease. PSEN1 encodes presenilin 1, a protein involved in amyloid precursor protein (APP) processing, which leads to the formation of amyloid-beta plaques, a hallmark of Alzheimer's. GSK3B is associated with tau phosphorylation, contributing to neurofibrillary tangles. KIF5 and KLC proteins are involved in intracellular transport, and their dysregulation may affect neuronal function. Mutations in PSEN1 are a well-known cause of early-onset familial Alzheimer's disease. Thus, the PSEN1 allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the proteolytic processing of amyloid precursor protein (APP). This pathway, defined by PSEN1 \u2192 GSK3B -| (KIF5+KLC), suggests a functional connection between PSEN1 and the regulation of GSK3B, which is known to influence tau phosphorylation and amyloid-beta processing. The KIF5 and KLC genes are components of the kinesin motor complex, which is involved in intracellular transport. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease, contributing to the accumulation of amyloid-beta plaques and neurofibrillary tangles. These pathological changes disrupt neuronal function and lead to progressive cognitive decline. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the alpha subunit of the Gs protein, which is a critical component in the cAMP signaling pathway. Mutations in GNAS can lead to constitutive activation of the pathway, resulting in overproduction of cAMP. This overactivation can dysregulate downstream effectors like PKA and CREB, leading to abnormal cellular responses. In the context of the given pathway, persistent activation of this signaling cascade may contribute to the development of multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome characterized by tumors in multiple endocrine glands. Alternatively, it may also be associated with McCune-Albright syndrome, which is characterized by endocrinopathies, fibrous dysplasia, and precocious puberty.\n\n\\boxed{McCune-Albright syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the Gs alpha subunit, a key component of the G protein-coupled receptor signaling pathway. When activated, GNAS stimulates adenylate cyclase (ADCY), leading to cAMP production, which in turn activates PKA, CREB, and other downstream effectors, ultimately influencing gene expression and various cellular functions. Mutations or aberrant activity in GNAS can disrupt this pathway, contributing to disorders such as pseudohypoparathyroidism and Albright hereditary osteodystrophy. These conditions are characterized by resistance to parathyroid hormone and other endocrine signals, due to defective Gs alpha function. Additionally, GNAS mutations are implicated in certain tumor syndromes, including McCune-Albright syndrome, where constitutively active GNAS alleles drive uncontrolled signaling. \n\n\\boxed{McCune-Albright syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS gene encodes the Gs alpha subunit, which is a key component of the G protein-coupled receptor signaling pathway. The pathway described, starting with GNAS and proceeding through ADCY, cAMP, PKA, CREB, and ACTH, is central to intracellular signaling. Mutations in GNAS can lead to aberrant activation of this pathway, resulting in conditions like pseudohypoparathyroidism or fibrous dysplasia. These disorders are characterized by resistance to parathyroid hormone and abnormal bone development, respectively. The GNAS allele in question likely contributes to a disease involving dysregulation of this pathway, affecting intracellular signaling and hormone responsiveness. \n\n\\boxed{Pseudohypoparathyroidism}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the \u03b3-secretase complex, which is involved in the proteolytic cleavage of amyloid precursor protein (APP). This pathway, defined by the interaction PSEN1* -> GSK3B -| (KIF5+KLC), suggests that PSEN1 influences GSK3B activity, which in turn regulates the KIF5 and KLC proteins involved in intracellular transport. Mutations in PSEN1 are strongly associated with early-onset Alzheimer\u2019s disease, as they lead to abnormal processing of APP and increased production of amyloid-beta peptides, a hallmark of Alzheimer's pathology. This contributes to the accumulation of amyloid plaques and neurofibrillary tangles, leading to neuronal dysfunction and degeneration.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in the proteolytic processing of amyloid precursor protein (APP). This pathway, as defined, involves PSEN1 influencing GSK3B, which phosphorylates Tau protein, and through a regulatory mechanism involving KIF5 and KLC proteins, contributes to the transport of Tau and other substrates within neurons. Aberrant activity in this pathway leads to the accumulation of toxic Tau aggregates and amyloid-beta plaques, both hallmarks of Alzheimer's disease. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer\u2019s disease. Thus, the biological effect of this PSEN1 allele is the contribution to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway involves PSEN1, which is a key component of the gamma-secretase complex responsible for the proteolytic cleavage of the amyloid precursor protein (APP). This cleavage is central to the production of amyloid-beta peptides, which are implicated in the pathogenesis of Alzheimer's disease. The pathway also includes GSK3B, a known kinase involved in various cellular processes, and the KIF5 and KLC proteins, which are components of the kinesin motor complex involved in intracellular transport. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease, as they lead to abnormal processing of APP and increased production of amyloid-beta. This contributes to the accumulation of amyloid plaques, a hallmark of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that functions as a tumor suppressor by inhibiting cyclin-dependent kinases, thereby regulating the cell cycle. In the given pathway, CDKN2A is involved in the regulation of the G1/S checkpoint through its interaction with the p53 pathway. Mutations or deletions in CDKN2A can lead to uncontrolled cell proliferation. This gene is frequently mutated in several types of cancer. Specifically, germline mutations in CDKN2A are strongly associated with melanoma, as well as other cancers such as neurofibromatosis type 1 and certain types of lymphomas. The loss of CDKN2A function can disrupt the normal cell cycle checkpoints and contribute to tumorigenesis.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein, p16INK4a, which inhibits cyclin-dependent kinases CDK4 and CDK6, preventing the phosphorylation of RB1. Inactivation or mutation of CDKN2A leads to loss of this inhibitory function, allowing uncontrolled cell cycle progression. This contributes to the development of melanoma and certain neuroendocrine tumors. The pathway described highlights the role of CDKN2A in regulating the G1/S checkpoint via the p53-MDM2-CDKN1A and cyclin D/CDK4/6-RB1-E2F axes. Disruption of CDKN2A therefore disrupts normal cell cycle control, promoting tumorigenesis. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that plays a critical role in cell cycle regulation and tumor suppression. Mutations in CDKN2A are associated with an increased risk of developing certain types of cancer, particularly melanoma and neurofibromatosis type 1. The pathway described involves the regulation of the G1/S phase of the cell cycle, where CDKN2A inhibits cyclin-dependent kinases, preventing cell cycle progression. Disruption of this pathway can lead to uncontrolled cell division and tumorigenesis. Given the role of CDKN2A in cell cycle control and its association with oncogenic pathways, mutations in this gene are strongly linked to melanoma.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes the Wnt/\u03b2-catenin (CTNNB1) signaling cascade, where stabilization of CTNNB1 due to inactivation of the destruction complex (GSK3B, AXIN, APC) leads to its translocation to the nucleus, where it interacts with TCF/LEF transcription factors to regulate downstream genes (BIRC5, MYC, CCND1). This pathway is crucial for cell proliferation and differentiation. Dysregulation, such as through mutations in APC or CTNNB1, leads to aberrant activation of the Wnt pathway, promoting uncontrolled cell growth. This is a well-known mechanism in colorectal cancer. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway illustrates the Wnt/\u03b2-catenin signaling cascade. CTNNB1 (\u03b2-catenin) is a central component of this pathway. When the destruction complex (GSK3B, AXIN, APC) is inhibited or dysfunctional, CTNNB1 accumulates in the nucleus and binds to TCF/LEF transcription factors, leading to the activation of target genes such as BIRC5, MYC, and CCND1. These genes are involved in cell proliferation and survival. Dysregulation of this pathway is a hallmark of several cancers, particularly colorectal cancer. Mutations or inactivation of APC, AXIN, or GSK3B can lead to constitutive activation of \u03b2-catenin, promoting uncontrolled cell growth. This aberrant signaling contributes to tumorigenesis.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is part of the Wnt/\u03b2-catenin signaling cascade. CTNNB1 (\u03b2-catenin) is a central component of this pathway. When the complex (GSK3B+AXIN+APC) is active, it promotes the degradation of \u03b2-catenin. However, if this complex is inactivated or absent, \u03b2-catenin accumulates and translocates to the nucleus, where it binds to TCF/LEF transcription factors to activate downstream target genes such as BIRC5, MYC, and CCND1. This leads to increased cell proliferation and survival. Dysregulation of this pathway is a hallmark of several cancers, particularly colorectal cancer. Mutations in APC, AXIN, or GSK3B that prevent \u03b2-catenin degradation lead to aberrant activation of this pathway and are associated with tumorigenesis.  \n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 gene encodes a protein involved in calcium signaling and mitochondrial function. In the provided pathway, SIGMAR1 is a central node that influences intracellular calcium dynamics through its interaction with ITPR and other calcium transporters. Disruption of this pathway may lead to dysregulation of calcium homeostasis, which is crucial for numerous cellular processes, including apoptosis and mitochondrial function. Aberrant calcium signaling is implicated in neurodegenerative disorders. Given that SIGMAR1 is directly involved in pathways affecting mitochondrial calcium uptake and release, its malfunction may contribute to diseases such as Alzheimer's disease, where mitochondrial dysfunction and calcium dysregulation are key features.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 gene encodes a sigma non-opioid intracellular receptor 1, which is involved in calcium signaling pathways. In the presented genomic pathway, SIGMAR1 influences calcium (Ca\u00b2\u207a) dynamics via ITPR, MCU, and other mitochondrial calcium regulatory proteins, ultimately affecting MPTP and CYCS, key players in apoptosis. Dysregulation of mitochondrial Ca\u00b2\u207a homeostasis and the permeability transition pore can lead to mitochondrial dysfunction and cell death. Given the involvement of these genes, SIGMAR1's malfunction may contribute to neurodegenerative disorders, particularly those with mitochondrial calcium dysregulation and apoptosis, such as Alzheimer\u2019s disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 gene encodes sigma non-opioid intracellular receptor 1, which is involved in calcium signaling and mitochondrial function. In the given pathway, SIGMAR1 interacts with ITPR (inositol 1,4,5-trisphosphate receptor), contributing to Ca\u00b2\u207a release and subsequent mitochondrial Ca\u00b2\u207a uptake via MCU. Dysregulation of this pathway can lead to mitochondrial dysfunction and increased risk of apoptosis. Impairment in mitochondrial calcium handling is implicated in several neurodegenerative and metabolic diseases. Specifically, mutations or dysfunction in SIGMAR1 have been associated with neurological disorders, including Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in a genomic pathway that includes key players in apoptosis, such as HTRA2, TRAP1, CYCS, APAF1, CASP9, and CASP3. PINK1 is known to play a critical role in the mitochondrial quality control pathway. Mutations in the PINK1 gene are associated with Parkinson's disease, as PINK1 helps protect neurons from degeneration by promoting mitochondrial integrity and function. When PINK1 is defective or nonfunctional, the pathway may not properly initiate protective responses, leading to increased neuronal death and the pathological features of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves PINK1, which is a serine/threonine kinase involved in mitochondrial quality control and protection against apoptosis. The network indicates that PINK1 interacts with HTRA2 and TRAP1, which are associated with proteolytic and chaperone functions. When PINK1 is absent or nonfunctional, it leads to cytochrome c (CYCS) release, which activates APAF1, initiating the caspase cascade (CASP9 -> CASP3), ultimately leading to apoptosis. Mutations in PINK1 are known to cause Parkinson's disease due to impaired mitochondrial function and increased susceptibility to neuronal apoptosis. These defects result in the degeneration of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe genomic pathway defined includes PINK1, which is involved in mitochondrial quality control through the PINK1-Parkin pathway. The network shows PINK1 interacting with components of the intrinsic apoptotic pathway, including APAF1, CASP9, and CASP3, suggesting a role in apoptosis regulation. Mutations in PINK1 are associated with autosomal recessive early-onset parkinsonism. This disease is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra, leading to motor symptoms such as tremors, rigidity, and bradykinesia. The contribution of PINK1 to this disease is through its role in mitochondrial dysfunction and impaired clearance of damaged mitochondria, which can lead to neuronal death.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with the neurodegenerative disorder Spinocerebellar Ataxia Type 3 (SCA3), also known as Machado-Joseph disease. This condition is caused by the expansion of a trinucleotide (CAG) repeat in the ATXN3 gene, leading to the production of an abnormal ATXN3 protein. This protein accumulates in neurons, causing progressive degeneration of the cerebellum and other brain regions, which results in ataxia, dystonia, and other neurological symptoms. The provided pathway includes autophagy-related genes, suggesting a possible role of impaired autophagy in the disease pathology. ATXN3 is involved in ubiquitin-dependent proteolysis and may interact with the autophagy machinery, thus its dysfunction could contribute to the accumulation of misfolded proteins and neurodegeneration.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of coordination, muscle stiffness, and oculomotor abnormalities. ATXN3 encodes a protein involved in ubiquitin-mediated proteolysis and autophagy. The pathway described includes components of the autophagy-related machinery, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, which are essential for autophagosome formation. Dysfunctional ATXN3, particularly through CAG trinucleotide repeat expansions, may impair autophagy and lead to the accumulation of toxic proteins, thus contributing to neuronal dysfunction and the pathogenesis of SCA3.\n\n\\boxed{Spinocerebellar ataxia type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is involved in the ubiquitin-proteasome system and is part of a network associated with autophagy, including BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1. Mutations in ATXN3, particularly the expansion of a CAG trinucleotide repeat, lead to the production of a toxic, aggregation-prone protein. This contributes to the degeneration of Purkinje cells in the cerebellum and is the primary cause of spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. \n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when aberrantly activated, contributes to the development of cancer, particularly in conditions like non-small cell lung cancer (NSCLC), gastric cancer, and glioblastoma. The pathway MET \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK \u2192 CCND1 represents the MET-driven signaling cascade that promotes cell proliferation and survival through the mitogen-activated protein kinase (MAPK) pathway. MET activation can occur due to gene amplification, mutation, or overexpression, leading to uncontrolled cell growth. This pathway is crucial in tumorigenesis and is often targeted in precision oncology for therapeutic intervention.\n\n\\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, as defined, involves the MET receptor tyrosine kinase, which, when activated, initiates a signaling cascade through GRB2, SOS, RAS, RAF, MEK, ERK, and ultimately CCND1. This cascade is part of the MAPK/ERK pathway, which regulates cell proliferation and survival. Mutations or overactivation of MET can lead to uncontrolled cell growth. MET gene aberrations, including amplifications, mutations, or fusions, are implicated in various cancers, particularly in non-small cell lung cancer (NSCLC), glioblastoma, and some sarcomas. These alterations contribute to tumor progression by promoting cell proliferation, migration, and resistance to apoptosis.\n\n\\boxed{Non-Small Cell Lung Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, starting with the MET proto-oncogene, is involved in cell growth, survival, and motility. Activation of MET leads to the downstream signaling through GRB2, SOS, RAS, RAF, MEK, and ERK, ultimately resulting in the upregulation of CCND1, which promotes cell cycle progression. Dysregulation of this pathway, particularly through MET activation, has been implicated in the development of various cancers. MET overexpression or mutations can lead to uncontrolled cell proliferation and tumor progression. This pathway is commonly activated in several malignancies, including non-small cell lung cancer, gastric cancer, and some types of leukemia.\n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that inhibits the activity of cyclin-dependent kinases (CDK4/6), thereby regulating the cell cycle. In the provided pathway, CDKN2A inhibits the CDK4/6-cyclin D complex, which in turn prevents the inactivation of RB1. Active RB1 represses E2F transcription factors, which are crucial for cell cycle progression. Mutations or deletions in CDKN2A can lead to uncontrolled cell division by allowing CDK4/6 to inactivate RB1, thus derepressing E2F and promoting cell cycle progression. This dysregulation contributes to the development of cancer. Specifically, mutations in CDKN2A are strongly associated with melanoma. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that inhibits the G1/S transition of the cell cycle by blocking the activity of cyclin D-CDK4/6 complexes, which in turn prevents the phosphorylation of RB1. When CDKN2A is mutated or inactivated, the cyclin D-CDK4/6 complex can phosphorylate RB1, leading to the release of E2F transcription factors, which promote cell cycle progression. Loss of CDKN2A function is associated with uncontrolled cell proliferation, a hallmark of cancer. This genetic alteration is strongly linked to melanoma, a type of skin cancer, and also contributes to the development of certain neuroendocrine tumors and other cancers. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that inhibits the activity of cyclin-dependent kinases (CDK4/6), preventing the phosphorylation of the RB1 protein. When CDKN2A is inactivated or mutated, it leads to uncontrolled cell cycle progression through the G1 phase, as RB1 cannot be inactivated, and E2F transcription factors are released to promote cell division. This loss of tumor suppression is a hallmark of certain cancers. The CDKN2A pathway is crucial for regulating cell cycle control, and its dysfunction is associated with melanoma and other malignancies. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, when mutated, can lead to constitutive activation of the MAPK signaling pathway. This pathway is crucial for cell proliferation and survival. In the given pathway, NRAS (or KRAS) activates RAF, leading through MEK and ERK to the transcription of CCND1, which promotes the cell cycle. Mutations in NRAS that result in continuous pathway activation can lead to uncontrolled cell growth, a hallmark of cancer. This pathway dysregulation is commonly observed in various cancers, including melanoma, leukemia, and others. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is part of the RAS-RAF-MAPK signaling cascade, which plays a critical role in cell growth, differentiation, and survival. Mutations in NRAS, particularly activating mutations, can lead to constitutive activation of this pathway, promoting uncontrolled cell proliferation. This aberrant signaling is a well-known driver of various cancers, including melanoma, leukemia, and solid tumors. The presence of an NRAS mutation, especially in the context of this pathway, contributes to oncogenesis by bypassing normal growth regulatory mechanisms. Therefore, this NRAS allele is associated with the development of cancer.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, when mutated, can constitutively activate the RAS-RAF-MEK-ERK signaling pathway, leading to uncontrolled cell proliferation. This pathway is critical for cell growth and survival. In the given genomic pathway, NRAS and KRAS both activate RAF, which in turn phosphorylates MEK, leading to ERK activation. ERK then promotes the expression of CCND1, a cyclin involved in the progression of the cell cycle. Mutations in NRAS can result in continuous signaling through this pathway, bypassing normal growth controls. This aberrant signaling is a common feature in several cancers, particularly in tumors such as melanoma, leukemia, and some solid tumors. The constitutive activation of this pathway contributes to tumorigenesis by promoting cell growth and division.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that is central to the BCR-ABL fusion protein, a hallmark of chronic myeloid leukemia (CML). This fusion results from a chromosomal translocation (t(9;22)), creating the Philadelphia chromosome. The BCR-ABL fusion protein is constitutively active, leading to uncontrolled cell proliferation and survival. The downstream pathway (BCR-ABL \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK) is involved in promoting cell growth and division. This aberrant signaling contributes to the pathogenesis of CML and other leukemias. Targeted therapies, such as tyrosine kinase inhibitors, have been developed to treat these diseases by inhibiting BCR-ABL activity.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when constitutively activated through chromosomal translocation (e.g., BCR-ABL fusion), drives uncontrolled cell proliferation. This aberrant signaling is a hallmark of chronic myeloid leukemia (CML). The BCR-ABL fusion gene activates downstream survival pathways, including the RAS-RAF-MEK-ERK cascade, promoting leukemogenesis. ABL1 is central to this pathway, initiating the chain of events that lead to the disease. \n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a tyrosine kinase that, when fused with BCR (breakpoint cluster region) due to a chromosomal translocation (t(9;22)), forms the BCR-ABL fusion protein. This fusion protein is constitutively active, leading to uncontrolled cell proliferation. The pathway involves activation of GRB2, SOS, RAS, RAF, MEK, and ERK, which are key components of the MAPK signaling cascade. This continuous activation contributes to the development of chronic myeloid leukemia (CML). The BCR-ABL fusion gene is a hallmark of CML and is targeted by tyrosine kinase inhibitors such as imatinib.\n\n\\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in mitochondrial quality control via the ubiquitin-proteasome system. Mutations in PRKN are a major cause of autosomal recessive Parkinson's disease (PD), particularly early-onset PD. These mutations can lead to loss of function in parkin, impairing mitochondrial dynamics and leading to the accumulation of damaged mitochondria, which contributes to neurodegeneration. The pathway involving PRKN and MFN1/2, which are key regulators of mitochondrial fusion, underscores the role of mitochondrial dysfunction in the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in mitochondrial quality control through mitophagy. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease. The PRKN pathway, including MFN1 and MFN2, regulates mitochondrial dynamics and function. Disruption of this pathway impairs mitochondrial integrity and leads to neuronal dysfunction. This contributes to the degeneration of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in mitochondrial quality control through the process of mitophagy. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease. The pathway involving PRKN and MFN1/2 is crucial for mitochondrial fusion and function. Disruption of this pathway can lead to impaired mitochondrial dynamics and function, contributing to neuronal degeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is primarily associated with Huntington's disease. This neurodegenerative disorder is caused by a CAG trinucleotide repeat expansion in the HTT gene, leading to the production of a mutant huntingtin protein. This mutant protein disrupts normal cellular functions, particularly in neurons, resulting in progressive motor, cognitive, and psychiatric symptoms. The provided pathway indicates that the HTT protein interacts with CREB family members and TAF4 to regulate the expression of PPARGC1A, a coactivator involved in mitochondrial biogenesis and energy metabolism. Dysregulation of this pathway may contribute to the cellular dysfunction observed in Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the pathogenesis of Huntington's disease. In the provided pathway, HTT interacts with CREB family members and TAF4 to regulate the expression of PPARGC1A, a coactivator involved in mitochondrial biogenesis and energy metabolism. Mutations in HTT, particularly CAG trinucleotide repeats, lead to the production of a toxic mutant huntingtin protein that disrupts normal cellular functions, contributing to neurodegeneration. This disruption affects multiple pathways, including those related to transcription, mitochondrial function, and protein clearance, ultimately leading to the characteristic clinical features of Huntington's disease, such as motor dysfunction, cognitive decline, and psychiatric symptoms.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to a genetic pathway involving CREB family members and TAF4, leading to the activation of PPARGC1A. Mutations in HTT, specifically CAG trinucleotide repeat expansions, result in the production of a mutant huntingtin protein that is toxic to neurons. This leads to progressive degeneration of motor neurons and other brain regions, primarily in the basal ganglia and cortex. The disease is known as Huntington's disease, an inherited neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. \n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene is a key player in mitochondrial quality control and apoptosis regulation. In the provided pathway, PINK1 interacts with PRKN (Parkin), which together are involved in mitophagy\u2014removal of damaged mitochondria. The pathway also includes BAX, CYCS, APAF1, CASP9, and CASP3, all of which are central to the intrinsic apoptotic pathway. Mutations in PINK1 are strongly associated with autosomal recessive early-onset Parkinson's disease. These mutations disrupt mitochondrial function and the clearance of damaged mitochondria, leading to neuronal dysfunction and degeneration characteristic of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway is involved in the process of apoptosis, specifically the intrinsic mitochondrial pathway. PINK1 is a serine/threonine kinase that plays a critical role in maintaining mitochondrial integrity and preventing oxidative stress. The pathway suggests that PINK1 may be involved in stabilizing or activating PRKN (parkin), which is known to target damaged mitochondria for autophagy. Disruption of PINK1 function may lead to the accumulation of damaged mitochondria and increased oxidative stress, contributing to neurodegenerative processes. Given the genes involved, particularly PINK1 and PRKN, this pathway is closely associated with Parkinson's disease. Mutations in PINK1 are linked to early-onset Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene encodes a serine/threonine protein kinase involved in the mitochondrial quality control pathway. When functional, PINK1 interacts with PRKN (parkin) to initiate mitophagy, the selective degradation of damaged mitochondria. The given pathway illustrates PINK1's role in apoptosis: PINK1 activates PRKN, which in turn promotes BAX activation, leading to the release of CYCS (cytochrome c), which activates APAF1, forming the apoptosome. This triggers a caspase cascade involving CASP9 and CASP3, leading to apoptosis. Mutations in PINK1 disrupt this process, impairing mitochondrial function and leading to the accumulation of damaged mitochondria. This contributes to neurodegeneration, specifically Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, a protein involved in redox regulation and cellular signaling. In the given pathway on chromosome 17, NXN interacts with DVL1, DVL2, and DVL3, which are key components of the Wnt/\u03b2-catenin signaling pathway critical for embryonic development and tissue homeostasis. Mutations in NXN have been implicated in the development of certain cancers, particularly in the context of tumor angiogenesis and progression. These mutations may disrupt the normal regulatory functions of nucleoredoxin, leading to dysregulated signaling and potentially contributing to oncogenic processes. \n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, which is involved in redox regulation and has been implicated in various cellular processes, including apoptosis and oxidative stress response. In the context of the given pathway, NXN interacts with DVL proteins, which are central components of the Wnt signaling pathway. Mutations or dysregulation of NXN may affect Wnt signaling, contributing to abnormal cell proliferation and differentiation. Aberrant Wnt signaling is associated with several diseases, particularly cancers. Research suggests that alterations in NXN may be linked to tumorigenesis, specifically in cancers where Wnt signaling plays a critical role, such as colorectal cancer. However, direct evidence linking NXN mutations to a specific disease remains limited, and more studies are required for a definitive conclusion. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, a protein involved in redox regulation and cellular signaling. In the given pathway (NXN -| DVL), NXN likely modulates the activity of DVL proteins, which are central to the Wnt signaling pathway. Disruption of this pathway can lead to aberrant cell proliferation and differentiation. Mutations in NXN have been associated with congenital heart defects, specifically atrial septal defects and other cardiac abnormalities. These defects arise due to impaired cardiac development during embryogenesis. Thus, mutations in the NXN allele contribute to cardiovascular diseases, particularly those involving structural heart malformations.\n\n\\boxed{Congenital Heart Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the SOD1 gene, which encodes superoxide dismutase 1, an enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide. In the provided network, SOD1 is upstream and appears to regulate BIP (also known as HSPA5), which is involved in the unfolded protein response. This pathway leads to the activation of ATF6, which in turn promotes the expression of DDIT3, a gene associated with cellular stress responses. Mutations in SOD1 are strongly linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. These mutations can lead to misfolding and aggregation of the SOD1 protein, contributing to neuronal dysfunction and death. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves SOD1, which is known to be associated with amyotrophic lateral sclerosis (ALS). SOD1 is a copper/zinc superoxide dismutase that normally detoxifies superoxide radicals. Mutations in the SOD1 gene can lead to misfolding of the protein, triggering a cascade involving the unfolded protein response (UPR) through the pathway involving BIP, ATF6, and DDIT3. This leads to endoplasmic reticulum (ER) stress and ultimately neuronal degeneration. Therefore, the biological effect of this SOD1 allele is the contribution to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, playing a critical role in protecting cells from oxidative damage. Mutations in SOD1 have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the loss of motor neurons. In the given pathway, SOD1 is connected to HSPA5 (BIP), which is involved in the unfolded protein response (UPR), and through ATF6, it leads to the activation of DDIT3, which is associated with cellular stress responses. This pathway highlights the role of SOD1 in mitochondrial and endoplasmic reticulum stress, which are key features in ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves glutamate signaling through GRM1, leading to calcium (Ca\u00b2\u207a) mobilization via the inositol trisphosphate (IP3) receptor ITPR1, modulated by ATXN2 and ATXN3. ATXN3 is implicated in the pathogenesis of spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive ataxia, dystonia, and other neurological symptoms due to the toxic effects of the mutant ATXN3 protein, which causes neuronal dysfunction and death.\n\n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is involved in a genomic pathway that begins with glutamate and proceeds through a series of signaling events ending in mitochondrial Ca\u00b2\u207a release and cytochrome c release, which are associated with apoptosis. ATXN3 is known to be mutated in Spinocerebellar Ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive ataxia, ophthalmoplegia, and other clinical features due to the toxic effects of expanded polyglutamine tracts in the ATXN3 protein. The inclusion of ATXN3 in this pathway suggests its role in calcium signaling and mitochondrial dysfunction, which are implicated in the pathogenesis of SCA3.\n\n\\boxed{Spinocerebellar Ataxia type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, which is involved in the ubiquitin-proteasome system. In the provided pathway, ATXN3 is associated with ITPR1, contributing to calcium signaling and mitochondrial dysfunction. Mutations in ATXN3, particularly those leading to expanded CAG repeats, result in spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive ataxia, dystonia, and other neurological symptoms due to the toxic accumulation of mutant ataxin-3 protein, leading to neuronal death. \n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the VHL tumor suppressor gene, which is part of a ubiquitin ligase complex (VHL*+RBX1+ELOC+ELOB+CUL2) that regulates the stability of HIF-\u03b1 proteins. When VHL is dysfunctional, HIF-\u03b1 accumulates and activates downstream targets such as EPAS1, which dimerizes with ARNT to induce the expression of genes like VEGFA, CXCL8, GLUT1, and EPO. These genes are involved in angiogenesis, inflammation, and erythropoiesis. Mutations in VHL lead to the loss of this regulatory function, contributing to the development of von Hippel-Lindau disease, a hereditary cancer syndrome characterized by the formation of hemangioblastomas, pheochromocytomas, and other tumors.\n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor that plays a critical role in the ubiquitin-proteasome system by targeting hypoxia-inducible factors (HIFs), such as EPAS1, for degradation. In the given pathway, VHL is part of a complex with RBX1, ELOC, ELOB, and CUL2, which marks EPAS1 for degradation. Under normal oxygen conditions, EPAS1 is degraded, preventing its interaction with ARNT and subsequent activation of downstream genes like VEGFA, CXCL8, SLC2A1, and EPO. Loss of functional VHL leads to stabilization of EPAS1, which dimerizes with ARNT to activate these genes, promoting angiogenesis and cell survival. This dysregulation is a hallmark of von Hippel-Lindau disease, a hereditary cancer syndrome characterized by the development of benign and malignant tumors in multiple organs.\n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL gene is a tumor suppressor that plays a critical role in the ubiquitin-proteasome system by targeting the HIF (hypoxia-inducible factor) complex for degradation. When the VHL allele is mutated or inactivated, HIF-\u03b1 proteins accumulate and activate transcription of genes involved in angiogenesis, cell proliferation, and survival, such as VEGFA, CXCL8, and EPO. This pathway is defined by the interaction (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO), indicating the VHL complex's role in inhibiting the HIF-ARNT-EPAS1 complex. Loss of VHL function leads to uncontrolled activation of these genes, contributing to the development of clear-cell renal cell carcinoma (ccRCC). This dysregulation supports tumor growth by promoting vascularization and metabolic adaptation.\n\n\\boxed{clear-cell renal cell carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway depicts a signaling cascade initiated by NRAS and KRAS, which activate PI3K, leading to PIP3 production and subsequent activation of AKT. AKT phosphorylates BAD, inhibiting its pro-apoptotic function and promoting cell survival. Mutations in NRAS, particularly in this pathway, lead to constitutive activation of the PI3K/AKT signaling axis, resulting in uncontrolled cell proliferation and resistance to apoptosis. This aberrant signaling is commonly observed in various cancers, including melanoma, where NRAS mutations are well-documented oncogenic drivers. Thus, the biological effect of this NRAS allele is tumorigenesis, specifically contributing to the development of melanoma.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the activation of RAS proteins (KRAS and NRAS), which phosphorylate PI3K, leading to the production of PIP3. This activates AKT, which in turn phosphorylates and inactivates BAD, a pro-apoptotic protein. This signaling cascade promotes cell survival and proliferation. Mutations in NRAS can lead to constitutive activation of this pathway, contributing to uncontrolled cell growth. NRAS mutations are commonly associated with several cancers, including melanoma, leukemia, and some solid tumors. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS (KRAS and NRAS) signaling cascade, which activates PI3K, leading to PIP3 production and subsequent AKT activation. AKT phosphorylates BAD, inhibiting apoptosis. Mutations in NRAS, particularly those that result in constitutive activation, can drive uncontrolled cell proliferation and survival. This aberrant signaling contributes to the development of various cancers, including melanoma, leukemia, and certain solid tumors. NRAS mutations are frequently associated with melanoma, especially in cases where BRAF is wild-type. Therefore, the biological effect of an activating NRAS allele is the promotion of tumorigenesis.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the APP gene, which encodes the amyloid beta precursor protein. The pathway proceeds through the production of Abeta, which is a key component of amyloid plaques. These plaques are a hallmark of Alzheimer's disease. The pathway then involves PPID, which interacts with MPTP, leading to the release of CYCS, a factor in mitochondrial dysfunction and apoptosis. The presence of various VDAC and SLC25 family members suggests a role in mitochondrial permeability and function. This sequence of events is strongly associated with the pathogenesis of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) allele is central to the amyloidogenic pathway, leading to the production of Abeta peptides. Accumulation of Abeta contributes to the formation of amyloid plaques, a hallmark of Alzheimer's disease. The pathway described involves APP \u2192 Abeta \u2192 PPID \u2192 MPTP \u2192 CYCS, which links to mitochondrial dysfunction and apoptosis. Genes like VDAC1-3 and SLC25A family members are involved in mitochondrial permeability and transport, further implicating this pathway in neuronal damage. This genetic and biochemical cascade is strongly associated with Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is central to the amyloid pathway, which is implicated in Alzheimer's disease. The given pathway illustrates a sequence where APP is cleaved to produce Abeta, leading to downstream effects such as PPID activation, MPTP formation, and ultimately the release of CYCS, which is involved in apoptosis. The presence of multiple VDAC and SLC25 family members suggests a role in mitochondrial dysfunction and calcium regulation, which are also linked to neurodegeneration. This pathway is consistent with the pathogenesis of Alzheimer's disease, characterized by amyloid plaque formation, mitochondrial impairment, and neuronal death. Therefore, the biological effect of the APP allele in this context is its contribution to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves SOD1, which is known to be involved in the degradation of misfolded or damaged proteins through the ubiquitin-proteasome system. The SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies superoxide radicals. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the production of misfolded SOD1 proteins, which are targeted for degradation by the proteasome. However, the process can become impaired or dysregulated, leading to the accumulation of toxic SOD1 species and subsequent neurodegeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 (superoxide dismutase 1) gene, located on chromosome 21, is involved in the pathway that includes DERL1, ubiquitination (Protein+UB), and proteasomal degradation (26S \u2192 Peptide). Mutations in SOD1 have been strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by progressive degeneration of motor neurons. The mutant SOD1 proteins are misfolded and accumulate, leading to toxicity and dysfunction in motor neurons. The pathway described here, involving ubiquitination and proteasome processing, is crucial for the degradation of misfolded proteins. Dysfunction in this pathway can lead to the accumulation of toxic SOD1 aggregates, contributing to the pathogenesis of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an antioxidant enzyme that converts superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the production of misfolded SOD1 proteins, which accumulate in motor neurons, causing toxicity and cell death. The provided pathway highlights the involvement of SOD1 in a network that includes ubiquitination and 26S proteasome activity, which are critical for protein degradation. Dysfunction of this pathway may impair the clearance of misfolded SOD1, contributing to neurodegeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the \u03b3-secretase complex, which is involved in the cleavage of amyloid precursor protein (APP) to produce amyloid-beta (A\u03b2) peptides. Accumulation of A\u03b2 is a hallmark of Alzheimer\u2019s disease (AD). The pathway described involves PSEN1 and PSEN2 influencing calcium signaling through RYR3, MCU, and other mitochondrial calcium transporters, ultimately leading to apoptosis via the intrinsic pathway involving CYCS, APAF1, and CASP9. Dysregulation of this pathway can result in neuronal dysfunction and death, characteristic of AD. Therefore, mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in the proteolytic processing of amyloid precursor protein (APP). This pathway leads to the production of amyloid-beta peptides, which accumulate and form plaques in Alzheimer's disease. The provided pathway illustrates how PSEN1 and PSEN2 mutations can lead to increased calcium influx and mitochondrial dysfunction, promoting apoptosis through the intrinsic pathway, involving CYCS, APAF1, and caspases. These events are central to neurodegeneration. Thus, mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 allele is involved in a genomic pathway that contributes to apoptosis through the regulation of calcium signaling. PSEN1 and PSEN2 are part of the gamma-secretase complex, which processes the amyloid precursor protein (APP), generating amyloid-beta peptides. These peptides accumulate in the brain, leading to the formation of amyloid plaques, a hallmark of Alzheimer's disease. The pathway described includes mitochondrial calcium uptake and release, which can trigger the mitochondrial permeability transition pore (MPTP), leading to cytochrome c release and subsequent caspase activation, culminating in apoptosis. Abnormal PSEN1 function is strongly associated with early-onset familial Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 pathway, involving FLT3, STAT5, and PIM1/2, is critical in hematopoiesis and cell survival. Mutations in FLT3, particularly internal tandem duplications (ITD) in the juxtamembrane domain, lead to constitutive activation of the kinase, promoting uncontrolled cell proliferation and survival. This aberrant signaling contributes to the development of acute myeloid leukemia (AML). FLT3-ITD mutations are associated with poor prognosis, increased resistance to therapy, and relapse. The persistent activation of downstream effectors like STAT5 and PIM1/2 further enhances leukemogenic potential by promoting cell growth and apoptosis resistance.\n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 allele in this genomic pathway contributes to the activation of the JAK-STAT signaling cascade through phosphorylation of STAT5, leading to the downstream activation of PIM1 and PIM2. This pathway is often dysregulated in hematological malignancies, particularly acute myeloid leukemia (AML). Mutations in FLT3, especially internal tandem duplications (ITD) in the kinase domain, are associated with poor prognosis and resistance to therapy in AML. These mutations result in constitutive activation of FLT3, driving uncontrolled cell proliferation and survival. The aberrant signaling through this pathway is a key driver in the pathogenesis of AML.\n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 gene encodes a receptor tyrosine kinase involved in cell survival and proliferation. Mutations in FLT3, particularly internal tandem duplications (ITD) in the juxtamembrane domain, are commonly found in acute myeloid leukemia (AML). These mutations lead to constitutive activation of FLT3, resulting in uncontrolled cell growth and survival, contributing to leukemogenesis. The pathway FLT3 \u2192 STAT5 \u2192 PIM1/2 is part of the signaling cascade that promotes myeloid cell proliferation and transformation. This aberrant signaling is a key driver in AML pathogenesis. \n\n\\boxed{Acute Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway involves LRRK2, a gene associated with Parkinson's disease, and includes components of the intrinsic apoptosis pathway (CYCS, APAF1, CASP9, CASP3). Mutations in LRRK2 are known to contribute to the pathogenesis of Parkinson's disease by affecting mitochondrial function and increasing oxidative stress, which can lead to neuronal death. The pathway suggests that LRRK2 may influence apoptosis, potentially contributing to the neurodegeneration observed in Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves LRRK2, a kinase associated with Parkinson\u2019s disease, and proceeds through intrinsic apoptotic signaling via CYCS, APAF1, CASP9, and CASP3. This indicates that the LRRK2 allele may influence apoptosis regulation. Mutations in LRRK2 are strongly linked to late-onset Parkinson\u2019s disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. The activation of the apoptotic pathway through this pathway could contribute to neuronal death observed in Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway outlines a sequence involving LRRK2, which is known to phosphorylate and regulate the activity of CYCS, a key player in the intrinsic apoptosis pathway. The activation of APAF1 by CYCS leads to the formation of the apoptosome, which in turn activates CASP9 and subsequently CASP3, promoting apoptosis. Mutations in LRRK2 are strongly associated with Parkinson's disease, where it may contribute to the degeneration of dopaminergic neurons. The biological effect of this LRRK2 allele likely involves dysregulation of apoptosis, contributing to neurodegeneration.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes a subunit of the voltage-gated calcium channel, which plays a critical role in regulating calcium influx into cells. Mutations in CACNA1A are associated with various neurological disorders, including episodic ataxia, hemiplegic migraine, and spinocerebellar ataxia type 6. These conditions are characterized by abnormal neuronal excitability and impaired motor coordination. The gene's role in calcium channel function is vital for proper nerve signal transmission and muscle control. Dysfunctional CACNA1A alleles can lead to abnormal calcium signaling, contributing to neurological symptoms. \n\n\\boxed{Spinocerebellar Ataxia Type 6}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha-1A subunit of the P/Q-type voltage-gated calcium channel, which is critical for neuronal excitability and neurotransmitter release. Mutations in CACNA1A are associated with a range of neurological disorders, including episodic ataxia, familial hemiplegic migraine, and spinocerebellar ataxia type 6. These conditions are characterized by impaired motor coordination, seizures, and migraine headaches. The calcium channels play a key role in various cellular processes, and their dysfunction can lead to excitotoxicity and neuronal dysfunction. Therefore, the CACNA1A allele contributes to the development of neurological diseases related to calcium channel dysfunction.\n\n\\boxed{Familial hemiplegic migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha-1A subunit of the P/Q-type calcium channel, which plays a critical role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with various neurological disorders, including episodic ataxia, hemiplegic migraine, and spinocerebellar ataxia type 6. These conditions are characterized by impaired motor control and neurologic dysfunction. The dysfunction of calcium channels disrupts normal neuronal signaling, contributing to the pathophysiology of these diseases. Therefore, the CACNA1A allele contributes to $\\boxed{\\text{spinocerebellar ataxia type 6}}$."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function. In the given pathway, SNCA interacts with BIP (also known as GRP78), a chaperone protein, and is part of the ER stress response pathway that includes ERN1 and XBP1. Dysregulation of this pathway may contribute to endoplasmic reticulum stress, which has been implicated in neurodegenerative diseases. Mutations or increased expression of SNCA are strongly associated with Parkinson\u2019s disease, a progressive neurological disorder characterized by motor dysfunction and loss of dopaminergic neurons. The involvement of SNCA in ER stress signaling further supports its role in the pathogenesis of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. In the defined pathway, SNCA interacts with BIP (a chaperone protein) and influences ERN1, which activates XBP1, a transcription factor involved in the unfolded protein response. Dysregulation of this pathway may lead to endoplasmic reticulum stress and subsequent neuronal dysfunction. Accumulation of misfolded alpha-synuclein is a hallmark of Parkinson's disease, contributing to the degeneration of dopaminergic neurons. Thus, the SNCA allele is strongly associated with Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes \u03b1-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. In the provided pathway, SNCA interacts with BIP (a chaperone protein) and ERN1 (which activates XBP1), suggesting involvement in the unfolded protein response. Aberrant \u03b1-synuclein accumulation is a hallmark of Parkinson's disease and may disrupt endoplasmic reticulum function, leading to neurodegeneration. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a major cause of autosomal recessive juvenile Parkinson's disease (PD). This pathway, involving UBCH7/8, PRKN, and PAELR, is associated with the regulation of mitochondrial quality control and protein degradation. The PRKN allele, when mutated, impairs these processes, leading to the accumulation of damaged proteins and dysfunctional mitochondria, particularly in dopaminergic neurons. This neuronal dysfunction underlies the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease (PD). Parkin plays a critical role in mitochondrial quality control, and its dysfunction leads to accumulation of damaged mitochondria and neuronal degeneration, particularly in dopaminergic neurons of the substantia nigra. This pathway, involving UBE2L3, UBE2L6, PRKN, and GPR37, suggests a role in ubiquitination and protein degradation processes. The involvement of PRKN in this network highlights its contribution to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system and mitochondrial quality control. Mutations in PRKN are associated with early-onset autosomal recessive Parkinson's disease (PD). These mutations often result in loss of parkin function, leading to impaired mitochondrial function and subsequent neuronal degeneration, particularly in dopaminergic neurons of the substantia nigra. The provided pathway, involving ubiquitin conjugating enzymes (UBCH7/8) and ubiquitin ligase PRKN, highlights its role in protein degradation. The presence of PAELR and GPR37 further implicates this pathway in cellular stress responses. Thus, the PRKN allele contributes to \\boxed{Parkinson's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in the regulation of synaptic vesicle trafficking. In the given pathway, SNCA is connected to the 26S proteasome, which is crucial for protein degradation. Mutations or overexpression of SNCA are associated with the accumulation of misfolded alpha-synuclein, leading to the formation of Lewy bodies. This pathological hallmark is a key feature of Parkinson's disease. The interaction of SNCA with the proteasome suggests that impaired proteasome function may contribute to the neurodegenerative process in Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein associated with the formation of Lewy bodies, which are pathological hallmarks of Parkinson's disease. The 26S proteasome, a multi-subunit complex including both 20S and 19S/26S subunits, is involved in proteolytic degradation. Dysregulation or dysfunction of the proteasome can lead to the accumulation of misfolded or damaged proteins, including alpha-synuclein. This accumulation is a key factor in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA can enhance this process, contributing to neurodegeneration. Therefore, the SNCA allele contributes to \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is a key component of Lewy bodies, abnormal protein aggregates found in the brains of patients with Parkinson's disease. The 26S proteasome, composed of 20S and 19S (or 26S) subunits, is essential for degrading misfolded or damaged proteins. A dysfunction in proteasome activity may lead to the accumulation of alpha-synuclein, contributing to neurodegenerative processes. Mutations or overexpression of SNCA, along with impaired proteasome function, are strongly implicated in the pathogenesis of Parkinson's disease. This pathway highlights the interplay between SNCA and proteasome subunits, which may influence the progression of the disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene is involved in the amyloid precursor protein (APP) processing pathway, which affects the production of amyloid-beta peptides. Mutations in PSEN2 are associated with early-onset Alzheimer's disease (AD). In the provided pathway, PSEN2 contributes to the activation of the mitochondrial apoptotic pathway through its influence on calcium signaling and mitochondrial permeability transition. This can lead to increased cellular apoptosis and neurodegeneration, processes central to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a protein involved in the processing of amyloid precursor protein (APP), which is critical in the formation of amyloid-beta peptides. The pathway described is linked to apoptosis and calcium dysregulation. PSEN2 mutations are associated with early-onset Alzheimer's disease. These mutations can disrupt normal calcium homeostasis and mitochondrial function, leading to neuronal dysfunction and death. The pathway involves mitochondrial calcium import via MCU and the release of cytochrome c, triggering apoptosis. Therefore, PSEN2 mutations contribute to Alzheimer's disease by promoting amyloidogenesis and inducing neurodegeneration through apoptotic mechanisms.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway illustrates a mechanism involving PSEN1 and PSEN2, which are aspartyl proteases involved in \u03b3-secretase activity. These genes play a key role in the processing of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Accumulation of amyloid-\u03b2 is a hallmark of Alzheimer's disease. PSEN2 mutations are linked to early-onset Alzheimer's disease. The pathway further shows the release of calcium ions and subsequent apoptotic cascade, which is also relevant to neurodegenerative processes. Hence, the PSEN2 allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is implicated in Huntington's disease (HD). In the provided pathway, HTT interacts with ITPR to modulate calcium release, which is central to mitochondrial function and apoptosis. Mutations in HTT, particularly CAG trinucleotide repeat expansions, lead to abnormal huntingtin protein that disrupts cellular processes, including calcium homeostasis and mitochondrial function. This leads to progressive neurodegeneration, primarily affecting the basal ganglia and cortex. The disease manifests with motor, cognitive, and psychiatric symptoms. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the pathological process in Huntington's disease. Mutations in HTT, particularly the expansion of a CAG trinucleotide repeat, lead to the production of a mutant huntingtin protein. This mutant protein causes toxic gain-of-function effects, including impaired intracellular signaling, mitochondrial dysfunction, and disruption of calcium homeostasis\u2014consistent with the pathway described, where HTT interacts with ITPR to regulate Ca\u00b2\u207a levels. The malfunction of HTT contributes to neuronal degeneration, especially in the striatum and cerebral cortex, ultimately resulting in motor, cognitive, and psychiatric symptoms. This genetic alteration is the primary cause of Huntington's disease.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, and mutations in this gene, particularly CAG trinucleotide repeat expansions, are the primary cause of Huntington's disease. This neurodegenerative disorder is characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. In the given pathway, HTT is involved in the regulation of Ca\u00b2\u207a release and signaling, which is crucial for neuronal function. Dysfunctional HTT can disrupt Ca\u00b2\u207a homeostasis, leading to mitochondrial dysfunction, apoptosis, and ultimately neuronal death. These effects contribute to the progressive pathology observed in Huntington's disease.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to the pathogenesis of prion diseases. When the PRNP allele is involved in a pathological context, it can lead to the misfolding of prion proteins, resulting in neurodegenerative disorders such as Creutzfeldt-Jakob disease (CJD). The NOTCH1 gene, which is part of the same pathway, plays a role in cell signaling and development, but its direct involvement in prion disease is not well established. The primary biological effect of the PRNP allele in the context of this pathway is the contribution to prion-mediated neurodegeneration.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which plays a critical role in the pathogenesis of transmissible spongiform encephalopathies (TSEs), a group of progressive, degenerative diseases of the central nervous system. Mutations in the PRNP gene are strongly associated with fatal neurodegenerative disorders such as Creutzfeldt-Jakob disease (CJD). Specifically, the PRNP allele with certain genetic variants can lead to the production of misfolded prion proteins that accumulate in the brain, causing neuronal damage and dysfunction. This pathway, involving PRNP and NOTCH1, may highlight molecular interactions that contribute to disease progression. The biological effect of the PRNP allele is thus closely linked to prion-related diseases, especially CJD.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which is central to the pathology of prion diseases. These are a group of rare, neurodegenerative disorders characterized by the misfolding of the prion protein into a pathogenic form, leading to progressive brain damage. The NOTCH1 gene is involved in cell signaling pathways important for development and homeostasis. While the direct interaction between PRNP and NOTCH1 is not well-established, the presence of PRNP in this genomic pathway may influence prion disease progression through signaling interactions. The PRNP allele is primarily associated with prion diseases such as Creutzfeldt-Jakob disease. \n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, which is involved in the deubiquitination of proteins, playing a role in ubiquitin homeostasis. Mutations in UCHL1 have been associated with Parkinson's disease. Specifically, a common missense mutation (P158L) in UCHL1 has been linked to an increased risk of developing Parkinson's disease, likely due to impaired proteasomal function and altered ubiquitin recycling. This disruption can lead to the accumulation of misfolded or damaged proteins, contributing to neurodegeneration characteristic of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, a deubiquitinating enzyme involved in the ubiquitin-proteasome system. This system regulates protein degradation and is essential for various cellular processes, including cell cycle control and apoptosis. UCHL1 is part of a pathway involving ubiquitin (UB) and its processing enzymes, such as UBA52, UBB, UBC, and RPS27A. Mutations in UCHL1 have been implicated in neurodegenerative diseases. Specifically, a common polymorphism in the UCHL1 gene, known as the Ser189Ala variant, has been associated with an increased risk of Alzheimer\u2019s disease. This variant may contribute to the disease by reducing UCHL1 activity, leading to impaired proteasome function and accumulation of misfolded proteins, which are hallmarks of Alzheimer\u2019s pathology.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme that regulates the ubiquitin-proteasome system by cleaving ubiquitin from proteins. The pathway described involves ubiquitin (UB) conjugation and processing, with UCHL1 playing a role in recycling ubiquitin. Mutations or alterations in UCHL1 may disrupt this cycle, leading to impaired protein degradation and accumulation of damaged proteins. This dysfunction is implicated in neurodegenerative processes. Specifically, reduced UCHL1 activity has been associated with Parkinson's disease, as it contributes to the accumulation of misfolded proteins and impaired mitochondrial function in dopaminergic neurons. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene is central to a pathway involving dynein and dynactin proteins, which are essential for intracellular transport and ciliary function. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. While the described network includes multiple dynein and dynactin subunits, the SOD1 allele's effect is most directly linked to ALS due to its role in copper-zinc superoxide dismutase, an enzyme crucial for neutralizing free radicals. Dysfunctional SOD1 leads to oxidative stress and neuronal death, hallmark features of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, playing a critical role in protecting cells from oxidative damage. Mutations in the SOD1 gene have been implicated in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the misfolding and aggregation of the SOD1 protein, which results in the degeneration of motor neurons in the brain and spinal cord. The pathway described connects SOD1 to several dynein-related proteins involved in intracellular transport and ciliary function, suggesting a possible interaction between oxidative stress and cytoskeletal dynamics in the disease process. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that neutralizes reactive oxygen species. The pathway described involves SOD1 interacting with components of the dynein complex, including DCTN (dynactin subunits) and DNAH, DNAI, DNAL (dynein axonemal components). Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to the accumulation of misfolded SOD1 protein, which is toxic to motor neurons, resulting in progressive degeneration of the motor cortex and spinal cord. The interaction with dynein pathways may relate to the transport and mitochondrial dysfunction often observed in ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves SOD1, which is a copper-zinc superoxide dismutase that normally functions to detoxify reactive oxygen species. In this network, SOD1 interacts with BIP (a chaperone protein) and ATF6 (a transcription factor involved in the unfolded protein response), leading to the activation of DDIT3, which is involved in stress responses. Mutations in the SOD1 gene are strongly associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the degeneration of motor neurons. These mutations typically result in a toxic gain of function of the SOD1 protein, contributing to oxidative stress and neuronal death. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies superoxide radicals. Mutations in SOD1 are implicated in amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive loss of motor neurons. The provided pathway suggests SOD1 interacts with the unfolded protein response (UPR) pathway components, such as BIP (HSPA5) and ATF6, which are involved in endoplasmic reticulum (ER) stress responses. Dysregulation of the UPR, as indicated by the pathway, can lead to neuronal dysfunction and death, further implicating SOD1 in ALS pathology. Thus, the SOD1 allele contributes to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves SOD1, which is associated with oxidative stress, and the unfolded protein response (UPR) pathway through the interaction with ATF6 and DDIT3. SOD1 is a copper-zinc containing superoxide dismutase that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide. Mutations in the SOD1 gene are a major cause of inherited amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations lead to toxic accumulation of misfolded SOD1 protein, contributing to motor neuron degeneration. The UPR pathway, which includes ATF6 and DDIT3, is a cellular response to endoplasmic reticulum (ER) stress and is implicated in neurodegenerative diseases. Therefore, the SOD1 allele contributes to \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when dysregulated, particularly through chromosomal translocations such as the Philadelphia chromosome (t(9;22)), leads to the formation of the BCR-ABL fusion protein. This constitutively active tyrosine kinase drives uncontrolled cell proliferation by activating the downstream signaling pathway: BCR-ABL \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK. This pathway is central to cell growth and survival. When aberrantly activated, it contributes to the development of chronic myeloid leukemia (CML), a type of blood cancer. The continuous activation of this pathway prevents normal cell death and promotes the proliferation of leukemic cells. Therefore, the biological effect of the ABL1 allele in this context is the promotion of CML.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase. Mutations or chromosomal translocations involving ABL1, such as the Philadelphia chromosome resulting from the fusion of BCR and ABL1, lead to the production of the BCR-ABL fusion protein. This protein is constitutively active and drives uncontrolled cell proliferation, a hallmark of chronic myeloid leukemia (CML). The activation of the BCR-ABL pathway leads to the downstream activation of the RAS-RAF-MEK-ERK signaling cascade, promoting cell survival and proliferation. This aberrant signaling is central to the development and progression of CML.\n\n\\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that, when aberrantly activated\u2014such as through the BCR-ABL fusion protein\u2014leads to uncontrolled cell proliferation and survival. This fusion protein is a hallmark of chronic myeloid leukemia (CML), a type of blood cancer characterized by the presence of the Philadelphia chromosome. The BCR-ABL fusion activates downstream signaling pathways, including the RAS/RAF/MEK/ERK cascade, promoting tumorigenesis. This altered signaling disrupts normal cellular control, contributing to the development and progression of CML.\n\n\\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, specifically in the context of the described pathway, contributes to the development of gastrointestinal stromal tumors (GIST). Mutations in the KIT gene, a receptor tyrosine kinase, can lead to constitutive activation of the KIT protein, which in turn activates downstream signaling components such as GRB2, SOS, RAS, RAF, MEK, and ERK. This results in uncontrolled cell proliferation and survival, which are hallmarks of GIST. These tumors most commonly occur in the stomach or small intestine and are often driven by activating mutations or gene duplications in KIT. \n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway is involved in signal transduction through the RAS-RAF-MEK-ERK cascade, which regulates cell growth, survival, and differentiation. Mutations in the KIT gene can lead to constitutive activation of this pathway, causing uncontrolled cell proliferation. This is a known mechanism in several cancers, particularly gastrointestinal stromal tumors (GISTs), where KIT mutations are frequently observed. These mutations often result in the activation of downstream effectors such as RAS, RAF, MEK, and ERK, promoting tumor growth and progression.\n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT gene encodes a receptor tyrosine kinase that plays a critical role in cellular signaling pathways involved in proliferation and survival. Mutations in KIT, particularly those leading to constitutive activation, can result in uncontrolled cell growth. In the provided pathway, KIT activates GRB2, SOS, RAS, RAF, MEK, and ERK, which are key components of the RAS-RAF-MEK-ERK signaling cascade. This cascade is frequently dysregulated in cancer. Mutations in KIT that lead to its constitutive activation contribute to the development of certain cancers, particularly gastrointestinal stromal tumors (GISTs). These mutations are often found in the juxtamembrane domain of KIT and result in ligand-independent activation of the receptor, promoting tumorigenesis.\n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 gene encodes cyclin-dependent kinase 4, which, when activated by cyclin D (CCND1, CCND2, or CCND3), phosphorylates the tumor suppressor protein RB1. This phosphorylation inactivates RB1, allowing E2F transcription factors (E2F1, E2F2, E2F3) to promote the expression of genes required for DNA synthesis and cell cycle progression. Mutations or overexpression of CDK4 can lead to uncontrolled cell proliferation by continuously inactivating RB1, thereby disrupting normal cell cycle regulation. This aberrant pathway is commonly observed in certain cancers, particularly those involving the RB1 pathway. The persistent activation of E2F leads to unchecked cell division, contributing to tumorigenesis. This genetic aberration is frequently associated with retinoblastoma and other cancers where RB1 function is compromised.\n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided pathway illustrates a key regulatory mechanism in the cell cycle, particularly in the G1 to S phase transition. The network involves cyclin D (CCND1, CCND2, CCND3) and CDK4 forming a complex that phosphorylates RB1 (retinoblastoma protein), leading to the release of E2F transcription factors (E2F1, E2F2, E2F3), which activate genes required for DNA synthesis. Dysregulation of this pathway, especially through overexpression or activation of CDK4, can lead to uncontrolled cell proliferation. This is a hallmark of cancer. Mutations or amplifications in CDK4 are associated with various cancers, most notably melanoma, where they contribute to tumor progression by promoting uncontrolled cell division. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the regulation of the cell cycle, specifically the G1 to S phase transition. CDK4, when activated by cyclin D (CCND1, CCND2, or CCND3), phosphorylates RB1, leading to its inactivation. This allows E2F transcription factors to activate genes required for DNA replication. Mutations in CDK4, particularly those that result in constitutive activation, can lead to uncontrolled cell proliferation. This is a hallmark of cancer. Specifically, mutations in the CDK4 gene are frequently observed in melanoma and other cancers. These mutations often involve the R24C or R24H substitutions, which prevent the normal inhibitory effect of the CDK inhibitor p16INK4a, leading to dysregulated cell cycle progression. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in autophagy and the ubiquitin-proteasome system. In the given pathway, SQSTM1 acts downstream of PINK1 and PRKN, which are key components of the mitochondrial quality control pathway. Mutations in SQSTM1 have been associated with neurodegenerative disorders, particularly amyotrophic lateral sclerosis (ALS). These mutations can disrupt the normal function of SQSTM1, affecting the clearance of damaged mitochondria and leading to the accumulation of toxic proteins in neurons. This contributes to neuronal dysfunction and degeneration.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in the ubiquitin-proteasome system and autophagy. It is part of the PINK1-PRKN pathway, which is central to mitochondrial quality control. Mutations in SQSTM1 have been associated with neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Specifically, a missense mutation in SQSTM1, such as the E315K variant, has been identified as a risk factor for familial ALS. This mutation may impair the function of SQSTM1, disrupting its role in autophagy and leading to the accumulation of misfolded proteins, which contributes to neuronal dysfunction and death. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 gene encodes sequestosome 1, a protein involved in autophagy and the ubiquitin-proteasome system. In the provided pathway, SQSTM1 interacts with PINK1 and PRKN, which are central to mitochondrial quality control. Mutations in SQSTM1 have been associated with neurodegenerative disorders. Specifically, mutations in SQSTM1 are known to contribute to amyotrophic lateral sclerosis (ALS). These mutations can disrupt autophagic processes, impairing the clearance of damaged mitochondria and leading to neuronal dysfunction and degeneration.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe described pathway begins with the amyloid beta precursor protein (APP), which is cleaved to generate Abeta, a key component in the pathogenesis of Alzheimer's disease. The cascade described includes activation of the extrinsic apoptotic pathway through FAS, FADD, and CASP8, leading to mitochondrial outer membrane permeabilization via BID, BAX, and BAK1. This results in the release of cytochrome c, activation of APAF1, and subsequent caspase activation (CASP9 and CASP3), culminating in apoptosis. This pathway is significantly implicated in neurodegenerative processes, particularly in Alzheimer's disease, where APP mutations and abnormal Abeta accumulation contribute to neuronal death and cognitive decline.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP gene (amyloid beta precursor protein) is central to the amyloidogenic pathway, which is implicated in Alzheimer's disease. The given pathway outlines a sequence of events starting with APP, leading to the production of Abeta, which can trigger apoptosis via the extrinsic and intrinsic pathways, ultimately leading to caspase 3 activation and cell death. This cascade is associated with neuronal degeneration observed in Alzheimer's disease. The accumulation of Abeta peptides is a hallmark of Alzheimer's pathology, contributing to the formation of amyloid plaques and neurofibrillary tangles. Thus, alterations or overactivity in the APP pathway may exacerbate these pathological features, promoting neurodegeneration and cognitive decline.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is central to the amyloid cascade hypothesis of Alzheimer's disease. The pathway described outlines a sequence of molecular events initiated by APP, leading to the production of Abeta peptides, which trigger extrinsic and intrinsic apoptotic pathways via FAS and mitochondrial pathways involving BAX, BAK1, and CYCS, ultimately leading to caspase activation and apoptosis. This apoptotic cascade contributes to the neurodegeneration observed in Alzheimer's disease. The accumulation of Abeta plaques and the subsequent apoptotic processes are key pathological features of the disease. Therefore, this APP allele contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, specifically in the context of the described pathway involving PI3K, PIP3, AKT, and BAD, is associated with the activation of the PI3K/AKT signaling cascade, which promotes cell survival and proliferation. Mutations in KIT that lead to its constitutive activation are linked to several diseases, most notably Gastrointestinal Stromal Tumor (GIST), a type of sarcoma. These mutations result in uncontrolled signaling through the pathway, contributing to tumorigenesis. \n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT gene encodes a receptor tyrosine kinase involved in cell growth and differentiation. Mutations in KIT can lead to constitutive activation of the PI3K/AKT pathway, enhancing cell survival and proliferation. This pathway is crucial in the development of certain cancers, particularly those involving aberrant signal transduction. Mutations in KIT and associated genes like PIK3CA, AKT1-3, and BAD are commonly observed in gastrointestinal stromal tumors (GISTs), contributing to tumor development and progression. These mutations result in uncontrolled cell growth, resistance to apoptosis, and tumor progression. \n\n\\boxed{Gastrointestinal Stromal Tumor}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT proto-oncogene encodes a receptor tyrosine kinase involved in the activation of the PI3K/AKT signaling pathway, which regulates cell survival, proliferation, and differentiation. Mutations in KIT can lead to constitutive activation of this pathway, promoting uncontrolled cell growth. This aberrant signaling is implicated in several diseases, most notably gastrointestinal stromal tumors (GISTs), where KIT mutations are frequently observed. These mutations prevent normal receptor inactivation, leading to persistent signaling through PI3K, PIP3, AKT, and downstream effectors like BAD, which inhibits apoptosis. This contributes to tumor development and progression.\n\n\\boxed{Gastrointestinal Stromal Tumor (GIST)}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway illustrates a sequence involving mitochondrial apoptosis. SOD1 is an antioxidant enzyme that normally neutralizes superoxide radicals. In this context, the SOD1 allele appears to influence BCL2, a protein that inhibits apoptosis. Downstream, BAX and BAK1 promote apoptosis by releasing cytochrome c, which activates APAF1 and the caspase cascade. If SOD1 is dysfunctional or mutated, it may lead to oxidative stress and dysregulation of apoptosis. This disruption in the apoptotic pathway is commonly associated with neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Mutations in SOD1 are a known cause of familial ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves mitochondrial-mediated apoptosis, starting with SOD1, which is a superoxide dismutase that normally detoxifies reactive oxygen species. In this context, the SOD1 allele appears to be involved in a regulatory interaction affecting the BCL2 family of proteins, which are key regulators of apoptosis. When BCL2 is inhibited or not active, BAX and BAK1 are activated, leading to the release of CYCS (cytochrome c), which activates APAF1 and initiates the caspase cascade through CASP9 and CASP3. This cascade ultimately leads to apoptosis. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. These mutations may disrupt the normal function of SOD1, leading to increased oxidative stress and apoptosis of motor neurons.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a sequence of events leading to apoptosis, starting with the SOD1 gene, which is involved in the detoxification of reactive oxygen species. Mutations in SOD1 are known to cause a form of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. These mutations can lead to misfolding and aggregation of SOD1, which may trigger mitochondrial dysfunction and subsequent apoptosis. This is reflected in the pathway through the activation of pro-apoptotic factors such as BAX and BAK1, leading to cytochrome c release and caspase activation. Therefore, this SOD1 allele contributes to the neurodegenerative disease ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the MEN1 gene, which encodes menin 1, a tumor suppressor protein. MEN1 is part of a network that interacts with KMT2A (a histone methyltransferase) and CDKN1B and CDKN2C (cyclin-dependent kinase inhibitors). Mutations in MEN1 are the cause of Multiple Endocrine Neoplasia type 1 (MEN1), a hereditary disorder characterized by the development of tumors in endocrine glands such as the parathyroid, pituitary, and pancreatic islets. These mutations typically lead to loss of function of the MEN1 protein, resulting in uncontrolled cell proliferation and tumor formation. The involvement of CDKN1B and CDKN2C, which regulate the cell cycle, supports the role of MEN1 in controlling cell growth. \n\n\\boxed{Multiple Endocrine Neoplasia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves the MEN1 gene, which encodes menin 1, and interacts with KMT2A (lysine methyltransferase 2A), suggesting a role in epigenetic regulation. The pathway also includes CDKN1B and CDKN2C, which are cyclin-dependent kinase inhibitors involved in cell cycle control. Mutation or dysfunction of MEN1 is a well-known cause of Multiple Endocrine Neoplasia type 1 (MEN1), a hereditary syndrome characterized by the development of tumors in endocrine glands, such as the parathyroid, pituitary, and pancreas. The interaction with KMT2A and CDKN genes implies a mechanism involving chromatin remodeling and cell cycle regulation, which may contribute to tumor formation. \n\n\\boxed{Multiple Endocrine Neoplasia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway defined by the network (MEN1*+KMT2A) // (CDKN1B,CDKN2C) involves tumor suppressor genes associated with cell cycle control and chromatin remodeling. MEN1 encodes menin, a protein involved in tumor suppression and chromatin regulation. Mutations in MEN1 are known to contribute to Multiple Endocrine Neoplasia type 1 (MEN1), a hereditary syndrome characterized by the development of tumors in endocrine glands, such as the pituitary, parathyroid, and pancreatic islet cells. The interaction with KMT2A, CDKN1B, and CDKN2C underscores the role of this pathway in regulating cell proliferation and DNA repair, with dysregulation leading to tumorigenesis. Thus, mutations in the MEN1 allele are primarily linked to the development of Multiple Endocrine Neoplasia type 1.  \n\\boxed{Multiple Endocrine Neoplasia type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is the WNT/\u03b2-catenin signaling pathway, crucial for cell proliferation and differentiation. A mutation in APC, which normally functions to degrade \u03b2-catenin, leads to its accumulation. This results in the activation of TCF/LEF transcription factors, which upregulate the expression of target genes such as BIRC5, MYC, and CCND1, promoting cell proliferation and survival. Such a loss-of-function APC allele is a well-established driver in colorectal cancer, where it contributes to uncontrolled cell growth and tumor formation.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described is part of the Wnt/\u03b2-catenin signaling cascade. The APC gene is a key negative regulator in this pathway. A mutation in APC, such as a loss-of-function allele, leads to the stabilization of CTNNB1 (\u03b2-catenin), which then translocates to the nucleus and activates the TCF/LEF transcription factors. This results in the upregulation of target genes like BIRC5, MYC, and CCND1, which promote cell proliferation and tumorigenesis. This dysregulation is a hallmark of colorectal cancer. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway describes the Wnt/\u03b2-catenin signaling cascade. The APC gene acts as a tumor suppressor in this pathway. A mutant APC allele (APC*) is unable to effectively bind \u03b2-catenin (CTNNB1), leading to its stabilization and translocation to the nucleus. There, it interacts with TCF/LEF transcription factors to activate the expression of downstream target genes such as BIRC5, MYC, and CCND1, which promote cell proliferation and survival. This aberrant activation of the Wnt/\u03b2-catenin pathway is a hallmark of colorectal cancer. Therefore, the APC allele contributes to the development of $\\boxed{\\text{Colorectal Cancer}}$."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that detoxifies superoxide radicals. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), also known as Lou Gherig's disease. These mutations lead to the misfolding and aggregation of SOD1, which is toxic to motor neurons, causing their degeneration. The pathway described involves the ubiquitin-proteasome system, which is responsible for degrading misfolded or damaged proteins. DERL1, a component of the endoplasmic reticulum-associated degradation (ERAD) pathway, may interact with SOD1 to target it for proteasomal degradation. Dysfunctional proteasome activity, as indicated by the listed proteasome subunits, can exacerbate the accumulation of toxic SOD1 aggregates, contributing to neurodegeneration in ALS.  \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes DERL1 and the 26S proteasome, which is central to protein degradation. SOD1, or superoxide dismutase 1, is a key enzyme in the detoxification of reactive oxygen species. Mutations in SOD1 have been strongly linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. This pathway may be involved in the degradation of misfolded or damaged proteins, including SOD1 itself, and disruptions in this process could contribute to the accumulation of toxic protein aggregates that are implicated in ALS pathogenesis.\n\n\\boxed{Amyotrophic lateral sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals to hydrogen peroxide and oxygen, playing a critical role in protecting cells from oxidative damage. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described involves the proteasome system, which is responsible for degrading misfolded or damaged proteins. In the context of SOD1-related ALS, mutant SOD1 proteins may become misfolded and aggregated, overwhelming the proteasomal degradation system, leading to neuronal dysfunction and death. Thus, the SOD1 allele contributes to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 (superoxide dismutase 1) gene is central to a pathway involving dynein and dynactin proteins, which are essential for cellular trafficking and ciliary function. Mutations in SOD1 are primarily associated with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that leads to the loss of motor neurons. These mutations result in the production of misfolded SOD1 proteins, which accumulate in motor neurons, causing toxicity and eventual cell death. While the specific network detailed includes genes involved in dynein and dynactin function, the direct biological effect of the SOD1 allele in this context is related to the development of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene, located on chromosome 21, encodes superoxide dismutase 1, an enzyme that helps neutralize free radicals. When mutated, SOD1 contributes to the misfolding and aggregation of the protein, leading to the degeneration of motor neurons. This is a key factor in the pathogenesis of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The SOD1 mutations are implicated in a significant subset of familial ALS cases, where the malfunction of SOD1 disrupts neuronal function and results in progressive muscle weakness and paralysis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene is a key component of the oxidative stress response pathway, and mutations in this gene are associated with amyotrophic lateral sclerosis (ALS). In the given genomic pathway, SOD1 is connected to various dynein and dynactin complex components that are involved in cellular transport and ciliary function. These interactions suggest that SOD1 may influence neuronal transport and function, which are compromised in ALS. Therefore, the SOD1 allele contributes to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is involved in synaptic function and has been implicated in neurodegenerative processes. The pathway described involves SNCA interacting with VMAT2 (encoded by SLC18A2), a vesicular monoamine transporter responsible for transporting monoamines into synaptic vesicles. Dysregulation of this interaction may disrupt normal neurotransmitter packaging and release. Abnormal accumulation of alpha-synuclein, particularly in the form of fibrillary inclusions, is a hallmark of Parkinson's disease. This pathological accumulation is associated with neuronal dysfunction and death, especially in dopaminergic neurons of the substantia nigra. The SNCA allele in question, through its interaction with VMAT2, may contribute to the pathogenesis of Parkinson's disease by impairing normal synaptic function and promoting the formation of neurotoxic alpha-synuclein aggregates.  \n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is involved in synaptic function and regulation of neurotransmitter release. In the given pathway, SNCA interacts with VMAT2 (encoded by SLC18A2), a transporter responsible for moving monoamines into synaptic vesicles. Mutations or overexpression of SNCA can lead to the accumulation of misfolded alpha-synuclein, contributing to neurodegeneration. This is a hallmark of Parkinson\u2019s disease, where abnormal alpha-synuclein aggregates form Lewy bodies in dopaminergic neurons, leading to cellular dysfunction and death. The interaction with VMAT2 may further impair monoamine packaging, exacerbating neuronal loss. Thus, the SNCA allele contributes to the pathogenesis of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes the alpha-synuclein protein, which is involved in the regulation of synaptic vesicle trafficking and neurotransmitter release. In the provided pathway, SNCA interacts with VMAT2 (encoded by SLC18A2), a vesicular monoamine transporter responsible for packaging monoamines into synaptic vesicles. Dysregulation of this interaction may lead to impaired synaptic function. Abnormal accumulation of alpha-synuclein is a hallmark of Parkinson's disease, contributing to the degeneration of dopaminergic neurons in the substantia nigra. This pathology is also observed in other neurodegenerative disorders such as dementia with Lewy bodies. The SNCA allele, particularly mutant forms, is a significant genetic contributor to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an essential enzyme in the urea cycle. It catalyzes the synthesis of N-acetylglutamate, a necessary activator of carbamoyl-phosphate synthase 1 (CPS1), another key enzyme in the urea cycle. Defects in the NAGS gene lead to a deficiency in N-acetylglutamate, which in turn inhibits CPS1 activity. This impairment disrupts the urea cycle, preventing the effective removal of ammonia from the body. The resultant buildup of ammonia can be toxic, especially to the central nervous system. This condition is known as N-acetylglutamate synthase deficiency, a rare autosomal recessive disorder. The pathway is defined by Glu (glutamate) leading to NAGS, which produces NAG, which activates CPS1. A defective NAGS allele therefore contributes to the disease $\\boxed{\\text{N-acetylglutamate synthase deficiency}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an essential enzyme in the urea cycle. The pathway described involves the synthesis of N-acetylglutamate (NAG), which is a required activator for carbamoyl-phosphate synthase 1 (CPS1), another key enzyme in the urea cycle. A deficiency or mutation in NAGS leads to a lack of NAG, impairing CPS1 activity and disrupting the urea cycle. This results in the accumulation of ammonia in the blood, causing hyperammonemia. The condition is known as NAGS deficiency, a rare inborn error of metabolism that leads to severe neurological damage if untreated. \n\n\\boxed{NAGS deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an essential enzyme in the urea cycle. It catalyzes the production of N-acetylglutamate, a required activator for carbamoyl-phosphate synthase 1 (CPS1), another key enzyme in the urea cycle. A mutation in the NAGS gene leads to a deficiency in N-acetylglutamate, impairing the activity of CPS1 and disrupting the urea cycle. This results in the accumulation of ammonia in the blood, a condition known as hyperammonemia. The disease caused by this deficiency is N-acetylglutamate synthase deficiency, which is a rare autosomal recessive disorder and a form of inherited metabolic disorder affecting the urea cycle.\n\n\\boxed{N-acetylglutamate synthase deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves SOD1, which is linked to BIP (HSPA5), ERN1, and XBP1. This suggests a role in the unfolded protein response (UPR) within the endoplasmic reticulum. SOD1 is a copper-zinc superoxide dismutase that normally detoxifies superoxide radicals. Mutations in SOD1 are associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. These mutations lead to protein misfolding and aggregation, activating the UPR, which is reflected in the pathway through ERN1 and XBP1. The pathway indicates that SOD1 dysfunction can trigger ER stress responses, contributing to cellular toxicity in motor neurons. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an antioxidant enzyme that neutralizes superoxide radicals. Mutations in SOD1 are implicated in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The provided pathway involves SOD1, which may influence endoplasmic reticulum (ER) stress response through interactions with BIP (a chaperone protein) and ERN1 (a sensor of ER stress), leading to activation of XBP1, a transcription factor involved in the unfolded protein response. Dysregulation of this pathway due to mutant SOD1 may exacerbate ER stress and contribute to neuronal dysfunction and death, hallmarks of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves SOD1, which is a key player in the mitochondrial antioxidant defense system. Mutations in the SOD1 gene are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described includes interactions with ER stress-related proteins (ERN1, XBP1, and HSPA5), suggesting a link between SOD1 dysfunction, oxidative stress, and endoplasmic reticulum stress, all of which are implicated in ALS pathogenesis. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS-PI3K-AKT signaling pathway, contributes to uncontrolled cell proliferation and survival by activating downstream effectors such as PI3K, PIP3, and AKT, which in turn phosphorylate and inactivate BAD, a pro-apoptotic protein. Mutations in NRAS that lead to constitutive activation of this pathway are commonly associated with various cancers, particularly melanoma, leukemia, and solid tumors. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS-PI3K-AKT signaling cascade, which plays a central role in cell survival, proliferation, and growth. NRAS is a key oncogene in this pathway, and its activation can lead to uncontrolled cell growth. Mutations in NRAS, particularly in the G12, G13, or Q61 residues, are known to cause constitutive activation of the RAS protein, leading to continuous signaling through PI3K and AKT, which suppresses apoptosis (as seen with BAD inactivation). This dysregulated signaling contributes to the development of several cancers, including melanoma, leukemia, and certain solid tumors. Given the involvement of NRAS in this pathway, the biological effect of an NRAS allele with activating mutations is the promotion of tumorigenesis.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the RAS family members NRAS and KRAS activating PI3K, leading to PIP3 production and subsequent AKT activation. AKT phosphorylates BAD, inhibiting apoptosis. Mutations in NRAS, particularly in this pathway, can lead to constitutive activation of the PI3K/AKT signaling cascade, promoting cell survival and proliferation. This aberrant signaling is commonly observed in various cancers, notably melanoma, where NRAS mutations are a known driver. These mutations contribute to tumorigenesis by disrupting normal apoptosis and growth control mechanisms.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, plays a central role in the p53 pathway, which is crucial for DNA repair, apoptosis, and cell cycle regulation. Mutations in TP53 can lead to the loss of its tumor-suppressing function, resulting in uncontrolled cell proliferation and genomic instability. This pathway includes target genes like CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, all involved in responding to DNA damage and inducing apoptosis. Loss of TP53 function is commonly associated with a variety of cancers, particularly Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome characterized by a high risk of developing multiple types of malignancies, including breast cancer, osteosarcoma, and leukemia. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene, located on chromosome 17, is a tumor suppressor gene that regulates the cell cycle and induces apoptosis in response to DNA damage. The pathway network includes downstream targets such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which are involved in DNA repair, cell cycle arrest, and apoptosis. Mutations in TP53 can lead to loss of function, impairing its ability to respond to DNA damage and prevent uncontrolled cell division. This contributes to the development of various cancers, particularly Li-Fraumeni syndrome, a hereditary condition that predisposes individuals to multiple types of cancer. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene encodes the tumor suppressor protein p53, which is crucial for maintaining genomic stability and preventing cancer. It regulates cellular responses to DNA damage, including apoptosis, cell cycle arrest, and DNA repair. Mutations in TP53 can lead to loss of function, impairing these protective mechanisms and increasing the risk of various cancers. In the given pathway, TP53 regulates genes involved in DNA repair (DDB2, POLK), apoptosis (BAX, BAK1), and cell cycle arrest (CDKN1A, GADD45). Dysfunctional TP53 can result in uncontrolled cell proliferation and tumor development. Specifically, germline mutations in TP53 are associated with Li-Fraumeni syndrome, a hereditary cancer predisposition disorder characterized by a high incidence of multiple types of cancers, including breast cancer, leukemia, and sarcomas.\n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway describes a genomic interaction where the PARK7 gene (DJ1) influences the activation of TP53, which in turn leads to the expression of DUSP1. PARK7 is associated with Parkinson's disease, as mutations in this gene can lead to degeneration of dopaminergic neurons, a hallmark of the disease. The described pathway suggests that PARK7 plays a role in cellular stress response and DNA repair, which are critical in preventing neurodegeneration. Therefore, the biological effect of this PARK7 allele is its contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves PARK7 (DJ1), TP53, and DUSP1. PARK7 is associated with Parkinsonism and acts as a redox-sensitive protein that may influence cellular stress responses. Its interaction with TP53 suggests a role in DNA damage response and apoptosis. DUSP1 is a regulator of MAP kinase signaling, potentially modulating stress responses and inflammation. Dysfunction in this pathway may lead to impaired stress response and increased susceptibility to neurodegeneration. The involvement of TP53 highlights a potential link to cancer, but the primary association with PARK7 is with neurological disorders. Given PARK7's known role, the biological effect is primarily linked to a neurodegenerative condition.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the gene PARK7 (DJ1), which encodes a protein associated with Parkinson's disease. The network suggests that under certain conditions (DJ1*), TP53 activates DUSP1, which is involved in cellular stress responses. Mutations in PARK7 have been implicated in early-onset Parkinson's disease, suggesting that this allele may contribute to the neurodegenerative disorder by disrupting normal cellular functions and stress responses. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway, as described, involves a series of molecular interactions leading from FGFR3 to the activation of MYC, a key transcription factor involved in cell growth and proliferation. Dysregulation of FGFR3 signaling has been implicated in various diseases, particularly when it leads to constitutive activation of downstream effectors such as RAS and RAF, promoting uncontrolled cell growth. This pathway's activation is strongly associated with certain types of cancer. Specifically, activating mutations in FGFR3 are commonly found in bladder cancer and some types of leukemia. These mutations can lead to the persistent activation of the pathway, contributing to tumorigenesis.\n\n\\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway described involves a signaling cascade leading to the activation of the MYC transcription factor, which regulates cell proliferation and survival. Mutations in FGFR3 are known to cause aberrant signaling, often leading to uncontrolled cell growth. This pathway is frequently implicated in various cancers, particularly those involving the RAS/RAF/MEK/ERK (MAPK) signaling axis. The presence of this FGFR3 allele, which activates downstream effectors like SOS, RAS, RAF, MEK, and ERK, suggests a role in promoting tumor development. Specifically, this type of pathway dysregulation is commonly associated with bladder cancer, where FGFR3 mutations are frequently observed. \n\n\\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway described is a signaling cascade associated with the RAS/RAF/MEK/ERK (MAPK) pathway, which regulates cell proliferation, differentiation, and survival. Mutations in FGFR3 are known to cause aberrant activation of this pathway, leading to uncontrolled cell growth. This is a hallmark of several cancers, including bladder cancer, multiple myeloma, and some types of leukemia. Specifically, activating mutations in FGFR3 are strongly implicated in bladder cancer, where they contribute to tumor initiation and progression. These mutations often result in constitutive activation of the FGFR3 signaling pathway, promoting cell survival and proliferation.\n\n\\boxed{Bladder Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene encodes a receptor tyrosine kinase involved in the RET/PI3K/MTOR signaling pathway. Mutations in RET, particularly in the context of this pathway, can lead to constitutive activation of downstream effectors such as PI3K, AKT, and MTOR, promoting cell proliferation and survival. This dysregulation is implicated in several diseases, notably multiple endocrine neoplasia type 2 (MEN2), which includes medullary thyroid carcinoma, pheochromocytoma, and parathyroid hyperplasia. RET mutations are also associated with familial medullary thyroid carcinoma and, in some cases, non-MEN2-related thyroid cancer. These mutations typically result in gain-of-function changes that drive tumorigenesis.\n\n\\boxed{Multiple Endocrine Neoplasia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET gene is a proto-oncogene that, when mutated, can lead to uncontrolled cell growth and division. In the provided pathway, RET activates the PI3K/AKT/mTOR signaling cascade, which is crucial for cell survival, proliferation, and metabolism. Mutations in RET that constitutively activate this pathway can drive tumorigenesis. RET mutations are particularly associated with medullary thyroid carcinoma (MTC), a type of endocrine tumor. These mutations may also be linked to other cancers and hereditary syndromes, such as multiple endocrine neoplasia type 2 (MEN2). The activation of the PI3K/AKT/mTOR pathway through RET is a known driver of tumorigenesis in these conditions.\n\n\\boxed{Medullary Thyroid Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene is a receptor tyrosine kinase involved in the RET/PI3K/PIP3/AKT/MTOR signaling pathway. Activating mutations in RET lead to constitutive activation of this pathway, promoting uncontrolled cell growth and survival. This aberrant signaling is implicated in the development of multiple endocrine neoplasia type 2 (MEN2), including medullary thyroid carcinoma (MTC), pheochromocytoma, and parathyroid hyperplasia. Additionally, RET mutations have been associated with congenital hypothyroidism and some cases of thyroid cancer. These mutations bypass normal growth control mechanisms, contributing to tumorigenesis.\n\n\\boxed{Multiple Endocrine Neoplasia Type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 (profilin 1) is a key regulator in actin dynamics, influencing the conversion of monomeric actin (G-actin) to filamentous actin (F-actin). Mutations in the PFN1 gene have been associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. These mutations can lead to altered cytoskeletal dynamics, impaired axonal transport, and increased vulnerability of motor neurons to stress and degeneration. The involvement of PFN1 in the actin pathway underscores its critical role in maintaining neuronal integrity and function.\n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 (profilin 1) is essential for actin filament dynamics by promoting actin polymerization and regulating the conversion of monomeric actin to filamentous actin. Mutations in PFN1 have been associated with a rare neurodegenerative disorder known as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Specifically, certain PFN1 alleles, such as those with missense mutations, can lead to the accumulation of pathological proteins and disrupt neuronal function, contributing to the pathogenesis of these diseases. \n\n\\boxed{Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PFN1 gene encodes profilin 1, a protein involved in actin dynamics, which is essential for the formation of actin filaments. In the context of the actin pathway (Actin(monomeric) \u2192 PFN1* \u2192 Actin(filamentous)), mutations in PFN1 can disrupt the normal polymerization of actin, affecting cellular processes such as motility, division, and structure. Specifically, a pathogenic PFN1 allele is associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. This contribution to ALS is linked to the role of PFN1 in maintaining neuronal integrity and proper cytoskeletal function.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex, which is involved in the production of amyloid-beta peptides. The pathway described includes PSEN1 and PSEN2 as initiators, leading to calcium dysregulation and subsequent apoptosis via the intrinsic mitochondrial pathway. Dysfunctional PSEN1 can lead to abnormal processing of amyloid precursor protein, resulting in accumulation of amyloid-beta, a hallmark of Alzheimer's disease. This pathway's involvement in apoptosis also supports its role in neurodegeneration. Therefore, mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex involved in the processing of amyloid precursor protein (APP), leading to the production of amyloid-beta peptides. Accumulation of these peptides is a hallmark of Alzheimer's disease. The provided pathway shows that PSEN1 and PSEN2 mutations can lead to dysregulation of calcium homeostasis, mitochondrial dysfunction, and ultimately apoptosis via the intrinsic pathway involving CYCS, APAF1, and caspases. This chain of events is implicated in neurodegenerative processes. Therefore, mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe provided genomic pathway involves PSEN1 and PSEN2, which are known to be involved in the processing of amyloid precursor protein (APP). This processing leads to the production of amyloid-beta peptides, which are central to the pathogenesis of Alzheimer's disease. The pathway includes calcium release from the endoplasmic reticulum (RYR3), mitochondrial calcium uptake (MCU), and eventual mitochondrial permeability transition pore (MPTP) activation, leading to cytochrome c release and activation of the caspase cascade, culminating in apoptosis. This sequence of events is implicated in neuronal death and is characteristic of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitination of proteins, particularly in the ubiquitin-proteasome system. Mutations in PRKN are associated with early-onset, autosomal recessive Parkinson's disease. The pathway involving PRKN, PLCG1, IP3, and ITPR suggests a role in calcium signaling, which is critical for neuronal function. Disruption of this pathway could lead to impaired calcium homeostasis, contributing to neurodegeneration. This genetic pathway is crucial for maintaining cellular health, and its dysfunction has been implicated in neurodegenerative disorders. Therefore, the biological effect of this PRKN allele is primarily linked to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and degradation of proteins. Mutations in PRKN are associated with autosomal recessive juvenile parkinsonism, also known as PARK2. This pathway involves calcium signaling through PLCG1, IP3, and ITPR receptors, which play a role in intracellular signaling and neuronal function. Dysfunction in this pathway could potentially contribute to neurodegenerative processes. However, the primary disease linked to PRKN mutations is Parkinson's disease, specifically early-onset forms. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination of misfolded or damaged proteins. In the provided pathway, PRKN initiates a cascade leading to PLCG1 activation, which generates IP3, triggering Ca\u00b2\u207a release from the endoplasmic reticulum via ITPR receptors. Dysregulation of this pathway may disrupt intracellular calcium homeostasis, a process implicated in neurodegeneration. Mutations in PRKN are strongly associated with autosomal recessive juvenile parkinsonism, also known as Parkinson disease 7 (PARK7). This condition is characterized by early-onset Parkinsonism, with symptoms such as tremor, rigidity, and bradykinesia. The role of PRKN in mitochondrial quality control and autophagy further supports its involvement in neurodegenerative disorders.\n\n\\boxed{Parkinson disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is associated with Huntington's disease (HD) when mutated. HD is a neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. The pathway described involves components of the mitochondrial respiratory chain, specifically complex III (CxIII) and cytochrome c (CytC), suggesting a link between mitochondrial dysfunction and the disease mechanism. Altered HTT function may disrupt mitochondrial integrity and energy production, contributing to neuronal death. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the pathogenesis of Huntington's disease (HD). Mutations in HTT, particularly the expansion of CAG repeats, lead to the production of a toxic mutant huntingtin protein. This protein accumulates in neurons, particularly in the brain, causing progressive degeneration of nerve cells. The network provided involves components of the mitochondrial respiratory chain, specifically Complex III (CxIII) and the cytochrome c (CytC) pathway. These components are crucial for oxidative phosphorylation and apoptosis regulation. The interaction between HTT and these mitochondrial proteins may disrupt normal mitochondrial function, contributing to energy deficiency and neuronal apoptosis, hallmark features of HD. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes the huntingtin protein, which is central to the pathogenesis of Huntington's disease. This neurodegenerative disorder is caused by a CAG trinucleotide repeat expansion in the HTT gene, leading to the production of a mutant huntingtin protein with an abnormally long polyglutamine tract. This toxic protein accumulates in neurons, causing cellular dysfunction and progressive neuronal loss, particularly in the basal ganglia and cerebral cortex. The provided pathway elements, such as CxIII and CytC, are components of the mitochondrial respiratory chain, suggesting that mitochondrial dysfunction may be a downstream consequence of mutant huntingtin. This contributes to the energy deficit and oxidative stress observed in Huntington's disease.\n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele in this genomic pathway contributes to the activation of the RAS-RAF-MEK-ERK signaling cascade, a key driver in cell proliferation and survival. Mutations in RET, particularly in the tyrosine kinase domain, can lead to constitutive activation of the RET receptor, which in turn continuously activates downstream signaling. This uncontrolled activation is implicated in the development of multiple endocrine neoplasia type 2 (MEN2) and medullary thyroid carcinoma (MTC). These conditions are characterized by the growth of tumors in endocrine tissues, such as the thyroid. RET mutations are also associated with other familial cancer syndromes and sporadic cancers.\n\n\\boxed{Medullary Thyroid Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene is a key player in the RET-RAS-RAF-MEK-ERK signaling pathway, which is critical for cell growth and survival. Mutations in the RET gene, particularly those leading to its constitutive activation, can drive uncontrolled cell proliferation and are associated with multiple endocrine neoplasia type 2 (MEN2), including medullary thyroid carcinoma and pheochromocytoma. These mutations often result in the RET protein being constantly active, even in the absence of its normal ligands, thereby stimulating downstream signaling pathways. This aberrant signaling contributes to tumor development and progression.\n\n\\boxed{Multiple Endocrine Neoplasia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, as part of the RET\u2192RAS\u2192RAF\u2192MEK\u2192ERK signaling pathway, contributes to uncontrolled cell growth and proliferation when mutated. RET is a receptor tyrosine kinase that, when aberrantly activated\u2014often due to gain-of-function mutations\u2014leads to constitutive activation of downstream effectors like RAS, RAF, MEK, and ERK. This persistent activation promotes cell survival, proliferation, and differentiation, which are hallmarks of cancer. Mutations in RET are particularly associated with medullary thyroid carcinoma (MTC), a type of endocrine tumor that originates in the thyroid. Additionally, RET mutations are implicated in other conditions such as multiple endocrine neoplasia type 2 (MEN2) and congenital hypothyroidism. These mutations disrupt normal signaling regulation, leading to oncogenic transformation. \n\n\\boxed{Medullary Thyroid Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphoinositide 3-kinase (PI3K), which is a key component of the PI3K/AKT/mTOR pathway. Mutations in PIK3CA can lead to constitutive activation of this pathway, promoting cell growth, survival, and proliferation. This dysregulation is frequently observed in various cancers, including breast, colon, and endometrial cancers. The activation of the PI3K/AKT/mTOR pathway through PIK3CA mutations contributes to tumor development and progression. Therefore, the biological effect of a PIK3CA allele with activating mutations is to enhance the growth and survival of cancer cells.\n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which is a key component of the PI3K/AKT/mTOR pathway. Mutations in PIK3CA are frequently observed in various cancers, including breast, colorectal, and endometrial cancers. These mutations often result in constitutive activation of the PI3K pathway, leading to increased cell proliferation, survival, and resistance to apoptosis. The pathway's activation is associated with oncogenic transformation and tumor progression. Consequently, PIK3CA mutations contribute to the development of multiple types of cancer. \n\n\\boxed{Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PIK3CA gene encodes the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which is a key component of the PI3K/AKT/mTOR signaling pathway. Mutations in PIK3CA, such as the E545K and H1047R variants, lead to constitutive activation of this pathway, promoting cell proliferation, survival, and growth. This dysregulation is commonly observed in various cancers, including breast, colorectal, and endometrial cancers. The activation of downstream effectors like AKT, MTOR, and S6K enhances protein synthesis and cell cycle progression, contributing to tumor development and progression.\n\n\\boxed{Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the PRKN gene, which encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. This system is crucial for protein degradation and cellular quality control. Mutations in PRKN are associated with autosomal recessive early-onset Parkinson's disease. The pathway components, such as UBCH7/8 and alpha-synuclein (SNCA), are also implicated in Parkinson\u2019s disease pathology. Dysfunction in this ubiquitination pathway can lead to the accumulation of misfolded proteins, such as alpha-synuclein, contributing to neurodegeneration. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitination and subsequent degradation of proteins. Mutations in PRKN are associated with autosomal recessive early-onset parkinsonism, a neurodegenerative disorder characterized by motor dysfunction, including tremors, rigidity, and bradykinesia. This pathway involves ubiquitin conjugating enzymes (UBCH7/8) and alpha-synuclein (SNCA), which are linked to the pathogenesis of Parkinson's disease. The presence of the PRKN allele suggests a role in ubiquitin-proteasome system dysfunction, contributing to the accumulation of misfolded proteins and neuronal degeneration, particularly in dopaminergic neurons. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin protein ligase involved in the ubiquitin-proteasome system, which is critical for protein degradation. Mutations in PRKN are a leading cause of early-onset Parkinson's disease (PD), specifically autosomal recessive juvenile Parkinsonism (PARK2). These mutations often result in loss-of-function of parkin, leading to impaired mitochondrial function, increased oxidative stress, and neuronal degeneration, particularly in dopaminergic neurons of the substantia nigra. This leads to the characteristic motor symptoms of Parkinson's disease. The presence of PRKN in this pathway, along with ubiquitin conjugating enzymes UBE2L3 and UBE2L6, and SNCA, highlights its role in the ubiquitination and degradation of alpha-synuclein, a key protein in PD pathology.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene is central to the mitochondrial quality control pathway, working with PRKN (parkin) and MFN1/2 to maintain mitochondrial health. Mutations in PINK1 are associated with autosomal recessive early-onset Parkinson's disease. PINK1 is involved in the recognition of damaged mitochondria, initiating their clearance through mitophagy. When PINK1 is dysfunctional, damaged mitochondria accumulate, leading to neuronal degeneration. This pathway is crucial for neuronal survival and function.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene is a key component of the mitochondrial quality control pathway, working in conjunction with PRKN (parkin) and MFN1/2 (mitofusin 1/2) to maintain mitochondrial integrity. Mutations in PINK1 lead to impaired mitochondrial function, including defects in mitophagy, which is the process of removing damaged mitochondria. This results in the accumulation of dysfunctional mitochondria, leading to neuronal degeneration. PINK1 is located on chromosome 1, and the pathway it defines is crucial for maintaining mitochondrial health. Mutations in PINK1 are associated with autosomal recessive early-onset parkinsonism, a neurodegenerative disorder characterized by motor dysfunction and loss of dopaminergic neurons. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 gene is a key component of the mitochondrial quality control pathway, working in conjunction with PRKN (parkin) and MFN1/2 (mitofusins) to remove damaged mitochondria through a process called mitophagy. Mutations in PINK1 are associated with autosomal recessive Parkinson's disease. These mutations impair the ability of PINK1 to phosphorylate parkin, which is essential for the degradation of damaged mitochondria. This leads to the accumulation of defective mitochondria, resulting in neuronal dysfunction and degeneration, particularly in dopaminergic neurons of the substantia nigra. This pathway is crucial for maintaining mitochondrial health and cellular function, and its disruption is a major cause of hereditary Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex involved in the production of amyloid-\u03b2 peptides. Mutations in PSEN1 are strongly associated with early-onset Alzheimer's disease. In the provided pathway, PSEN1 activates GSK3B, which phosphorylates target proteins, and this activity regulates the function of KIF5 and KLC proteins, which are involved in intracellular transport. Disruption of this pathway due to PSEN1 mutations can lead to pathological accumulation of amyloid-\u03b2, a hallmark of Alzheimer's disease. Therefore, the biological effect of this PSEN1 allele is the contribution to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPSEN1 (presenilin 1) is a key component of the gamma-secretase complex, which is involved in the proteolytic cleavage of the amyloid precursor protein (APP). This pathway produces amyloid-beta peptides, whose accumulation is a hallmark of Alzheimer's disease. The provided pathway illustrates a regulatory interaction where PSEN1 activates GSK3B, which in turn modulates the activity of KIF5 and KLC proteins involved in intracellular transport. Mutations in PSEN1 are strongly linked to early-onset Alzheimer's disease, leading to abnormal amyloid-beta processing and neurodegeneration. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the proteolytic cleavage of amyloid precursor protein (APP). The pathway described suggests that PSEN1 influences GSK3B, which in turn regulates the kinesin motor complex (KIF5 + KLC). This interaction could affect intracellular transport and trafficking, processes critical for neuronal function. Mutations in PSEN1 are strongly associated with early-onset Alzheimer\u2019s disease, as they lead to abnormal processing of APP, resulting in increased production of amyloid-beta peptides, which are a hallmark of Alzheimer\u2019s pathology. Thus, the PSEN1 allele contributes to the development of $\\boxed{Alzheimer's disease}$."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPSEN1 (presenilin 1) is a key component of the gamma-secretase complex, which is involved in the proteolytic processing of the amyloid precursor protein (APP). This processing generates amyloid beta (A\u03b2) peptides, which are central to the pathogenesis of Alzheimer's disease. The mutation or altered function of PSEN1 can lead to increased production of A\u03b242, a highly aggregative form of A\u03b2, contributing to the formation of amyloid plaques in the brain. These plaques, along with neurofibrillary tangles, are hallmark features of Alzheimer's disease. Given its role in A\u03b2 production, PSEN1 mutations are strongly associated with early-onset familial Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene is a key component of the gamma-secretase complex, which is involved in the processing of amyloid precursor protein (APP). The provided pathway suggests that PSEN1 activates GSK3B, which in turn modulates the kinesin motor complex (KIF5 + KLC). This pathway may be associated with the regulation of intracellular transport and signaling. Mutations in PSEN1 are strongly linked to early-onset Alzheimer's disease, contributing to the accumulation of amyloid-beta plaques. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves PSEN1, which is a key component of the gamma-secretase complex responsible for the cleavage of amyloid precursor protein (APP). This cleavage generates amyloid-beta peptides, whose accumulation is a hallmark of Alzheimer's disease. PSEN1 mutations are strongly associated with early-onset Alzheimer's disease, as they lead to increased production of toxic amyloid-beta 42. The network includes GSK3B, which is involved in tau phosphorylation, another key feature of Alzheimer's pathology. KIF5 and KLC proteins are components of the kinesin motor complex, which may be involved in the intracellular transport of APP and other proteins. Thus, dysfunction in this pathway contributes to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a major cause of autosomal recessive juvenile Parkinson's disease (PD). The pathway described includes UBE2L3 and UBE2L6, which are ubiquitin-conjugating enzymes that work with PRKN in ubiquitination, and PAELR, which interacts with PRKN in mitophagy. Dysfunction in this pathway, particularly due to PRKN mutations, impairs the clearance of damaged mitochondria and leads to the accumulation of toxic proteins, contributing to neuronal degeneration in Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of autosomal recessive juvenile Parkinson's disease (PD). The pathway described involves ubiquitin conjugating enzymes (UBCH7/8) and the E3 ligase PRKN, which together regulate protein degradation. This is critical for mitochondrial quality control and neuronal survival. Disruption of this pathway due to PRKN mutations leads to impaired mitophagy, accumulation of damaged mitochondria, and neurodegeneration, particularly in dopaminergic neurons. This contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in the ubiquitin-proteasome system. Mutations in PRKN are a common cause of early-onset autosomal recessive Parkinson's disease. Parkin functions in mitochondrial quality control by tagging damaged mitochondria for degradation through mitophagy. Loss-of-function variants in PRKN disrupt this process, leading to the accumulation of damaged mitochondria and subsequent neuronal degeneration, particularly in dopaminergic neurons of the substantia nigra. This pathway, involving ubiquitin conjugating enzymes (UBCH7/8) and ubiquitin ligase (PRKN), along with PAELR and GPR37, highlights the role of ubiquitination in neurodegeneration.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway highlights the involvement of the APP gene, which encodes the amyloid beta precursor protein, in a sequence leading to the production of amyloid-beta (Abeta). This is a key component in the pathogenesis of Alzheimer's disease. The cascade involves NMDA receptors, calcium influx, mitochondrial calcium uptake via MCU, and ultimately mitochondrial permeability transition, which can lead to the release of cytochrome c, a marker of apoptosis. These events are closely associated with neurodegeneration and the hallmark features of Alzheimer's disease, such as amyloid plaques and neurofibrillary tangles. Therefore, this APP allele contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway illustrates a sequence involved in Alzheimer's disease pathology. The APP (amyloid beta precursor protein) gene encodes a protein that, when cleaved, produces Abeta, a key component of amyloid plaques. These plaques are a hallmark of Alzheimer's disease. The pathway shows how Abeta activates NMDAR, leading to increased intracellular Ca2+ levels, which promotes mitochondrial Ca2+ uptake via MCU. This leads to mitochondrial dysfunction and the opening of the MPTP, releasing CYCS and initiating apoptosis. This cascade of events is strongly associated with neuronal death and cognitive decline seen in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the amyloid precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta), a key player in Alzheimer's disease pathology. Abeta interacts with NMDA receptors (NMDAR), leading to increased intracellular calcium levels, which can dysregulate mitochondrial function through the mitochondrial calcium uniporter (MCU). Excessive calcium in the mitochondria can trigger the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS) and initiating apoptosis. This cascade is implicated in neuronal damage and death, hallmark features of Alzheimer's disease. The genes involved, including NMDAR subunits and mitochondrial calcium transporters, further underscore the role of this pathway in neurodegeneration. Thus, the APP allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TPO (thyroid peroxidase) gene is crucial in the synthesis of thyroid hormones. The provided pathway illustrates the role of TPO in the oxidation of iodide and tyrosine to form monoiodotyrosine (MIT) and diiodotyrosine (DIT), which are then coupled to form triiodothyronine (T3) and thyroxine (T4) within thyroglobulin (TG). Mutations in the TPO gene can impair this process, leading to congenital hypothyroidism. This condition results from the inability to produce sufficient thyroid hormones, which are essential for normal growth, development, and metabolism. If left untreated, it can cause intellectual disability and other serious developmental issues. Therefore, the biological effect of a defective TPO allele is congenital hypothyroidism.\n\n\\boxed{Congenital Hypothyroidism}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TPO gene encodes thyroid peroxidase, a key enzyme in thyroid hormone synthesis. In the given pathway, TPO* (likely a mutant or dysfunctional TPO allele) impairs the iodination of tyrosine residues on thyroglobulin (TG), which is essential for the production of thyroid hormones T3 and T4. This disruption in hormone synthesis leads to hypothyroidism. The inability to properly iodinate and cleave thyroid hormones from TG results in insufficient thyroid hormone availability, contributing to congenital hypothyroidism, a condition often detected at birth and requiring lifelong thyroid hormone replacement therapy.\n\n\\boxed{Congenital Hypothyroidism}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TPO gene encodes thyroid peroxidase, an enzyme critical in the synthesis of thyroid hormones. In the provided pathway, TPO* likely represents a defective or mutant form of TPO. This defective enzyme would impair the iodination of tyrosine residues in thyroglobulin (TG), which is essential for producing thyroxine (T4) and triiodothyronine (T3). Without proper TPO function, the conversion of iodide and tyrosine into MIT and DIT, and subsequently into T3 and T4, cannot proceed effectively. This leads to reduced production of thyroid hormones, resulting in hypothyroidism. A TPO deficiency is a known cause of congenital hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormones from birth.\n\n\\boxed{Congenital Hypothyroidism}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involves the urea cycle, critical for ammonia detoxification. NAGS encodes N-acetylglutamate synthase, which produces N-acetylglutamate, an essential activator of CPS1 (carbamoyl-phosphate synthase 1), the rate-limiting enzyme in the urea cycle. A defective NAGS allele impairs N-acetylglutamate synthesis, leading to reduced CPS1 activity and impaired ammonia detoxification. This results in the accumulation of ammonia, causing hyperammonemia. The disease associated with this defect is **N-acetylglutamate synthase deficiency**, also known as **NAGS deficiency**, a rare autosomal recessive disorder. Symptoms include hyperammonemia, neurological damage, and metabolic acidosis if left untreated.\n\n\\boxed{N-acetylglutamate synthase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an essential enzyme in the urea cycle. It catalyzes the synthesis of N-acetylglutamate, a critical activator of carbamoyl-phosphate synthase 1 (CPS1), which is also part of the urea cycle. A defective NAGS allele leads to impaired N-acetylglutamate production, resulting in reduced CPS1 activity. This disrupts the urea cycle, causing the accumulation of ammonia in the blood (hyperammonemia). The condition is known as N-acetylglutamate synthase deficiency, a rare inherited metabolic disorder. It contributes to a disease called **NAGS deficiency** or **N-acetylglutamate synthase deficiency**, which leads to severe neurological symptoms if untreated.\n\n\\boxed{N-acetylglutamate synthase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, which is essential for the synthesis of N-acetylglutamate, a required activator of carbamoyl-phosphate synthase 1 (CPS1) in the urea cycle. A defective NAGS allele impairs the production of N-acetylglutamate, leading to reduced CPS1 activity. This results in impaired ammonia detoxification, causing hyperammonemia. The disorder is known as N-acetylglutamatesynthase deficiency, a rare autosomal recessive urea cycle disorder. \n\n\\boxed{N-Acetylglutamatesynthase Deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is a gene involved in the ubiquitin-proteasome system and is associated with the autophagy pathway through its interaction with the BECN1-containing complex. Mutations in ATXN3 are primarily linked to spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive loss of coordination, muscle stiffness, and other neurological symptoms. The pathway components listed are involved in autophagy, a cellular process crucial for degrading and recycling damaged proteins and organelles. Defects in this pathway can lead to the accumulation of toxic proteins, contributing to neuronal degeneration. Thus, the ATXN3 allele, through its role in autophagy, contributes to the pathogenesis of $\\boxed{\\text{Spinocerebellar Ataxia Type 3 (SCA3)}}$.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is associated with spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This neurodegenerative disorder is characterized by progressive deterioration of the cerebellum and other brain regions, leading to impaired motor coordination, speech difficulties, and oculomotor dysfunction. The pathway described involves autophagy-related genes, which are critical for cellular waste management and maintenance. Mutations in ATXN3, particularly polyglutamine expansions, lead to protein aggregation and dysfunction, contributing to neuronal death. The interaction with autophagy regulators like BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 suggests that altered autophagy may play a role in disease progression. Thus, ATXN3 contributes to the development of spinocerebellar ataxia type 3.  \n\\boxed{Spinocerebellar Ataxia Type 3}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene is involved in the ubiquitin-proteasome system and autophagy pathways. In the given network, ATXN3 interacts with components of the class III phosphatidylinositol 3-kinase (PI3K) complex, which is essential for autophagy initiation. Mutations in ATXN3, particularly those causing polyglutamine expansion, lead to the neurodegenerative disease spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease. This condition is characterized by progressive loss of coordination, muscle rigidity, and other neurological symptoms. The involvement of ATXN3 in autophagy may contribute to the accumulation of misfolded proteins and neuronal dysfunction.\n\n\\boxed{Spinocerebellar Ataxia Type 3}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene encodes a serine/threonine kinase that plays a critical role in the RAS-RAF-MEK-ERK signaling pathway, which regulates cell proliferation and survival. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the kinase, causing uncontrolled cell growth. This aberrant activation of the BRAF- MEK- ERK pathway is implicated in several cancers, most notably melanoma. The provided pathway includes BRAF, which is linked to MEK (MAP2K1 and MAP2K2), and ERK (MAPK1 and MAPK3), highlighting its role in the MAPK/ERK cascade. BRAF mutations are a well-established driver in melanoma and other cancers, contributing to tumor development and progression. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe presence of a specific BRAF allele, particularly the V600E mutation, leads to constitutive activation of the BRAF kinase. This results in continuous activation of the MEK-ERK signaling pathway, which promotes uncontrolled cell proliferation and survival. This aberrant signaling is a hallmark of several cancers, most notably melanoma. The BRAF* -> MEK -> ERK pathway is central to the Ras-Raf-MEK-ERK signaling cascade, and its dysregulation through BRAF mutations is a major driver in the development of melanoma and other cancers like thyroid carcinoma and colorectal cancer. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF gene is a key component of the MAPK/ERK signaling pathway, which is critical for cell growth and differentiation. Mutations in BRAF, particularly the V600E mutation, lead to constitutive activation of the pathway, promoting uncontrolled cell proliferation. This aberrant signaling is commonly observed in various cancers, most notably melanoma. The presence of the BRAF* allele, which may represent a mutation such as V600E, contributes to the development of melanoma by disrupting normal regulatory mechanisms of the MAPK pathway.\n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (smoothened) gene is a critical component of the Hedgehog signaling pathway, which regulates cell growth, differentiation, and tissue patterning. A mutation in the SMO gene can lead to constitutive activation of the Hedgehog signaling pathway, resulting in uncontrolled cell proliferation. This aberrant activation is implicated in the development of basal cell carcinoma (BCC), the most common form of skin cancer. Mutations in SMO are frequently observed in BCC and are also associated with other cancers, such as medulloblastoma and certain types of breast cancer.\n\n\\boxed{Basal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO allele is a key component of the Hedgehog signaling pathway, which is crucial for embryonic development and tissue homeostasis. Mutations in *SMO* can lead to constitutive activation of the pathway, disrupting normal cellular processes. This aberrant signaling has been implicated in various cancers, including medulloblastoma, a type of brain tumor that commonly affects children. Additionally, *SMO* mutations have been associated with basal cell carcinoma and other malignancies. The pathway's dysregulation can also contribute to developmental disorders. \n\n\\boxed{Medulloblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO allele is a key component of the Hedgehog signaling pathway, which plays a critical role in embryonic development and tissue homeostasis. Activation of SMO leads to the inhibition of SUFU and KIF7, allowing GLI proteins to act as transcription factors, thereby upregulating downstream targets like GLI1, PTCH, HHIP, and others. This pathway is also linked to the Wnt signaling cascade, indicating cross-talk between these critical developmental pathways. Dysregulation of SMO activity, such as through constitutive activation, can lead to uncontrolled cell proliferation and tumorigenesis. This is particularly evident in basal cell carcinoma (BCC), a common form of skin cancer, where mutations in PTCH or activating mutations in SMO are frequently observed. These mutations disrupt normal cellular growth control, leading to the development of BCC. Thus, SMO is implicated in the pathogenesis of basal cell carcinoma.\n\n\\boxed{Basal Cell Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP gene encodes the amyloid beta precursor protein, which is central to the amyloid cascade hypothesis of Alzheimer's disease. The pathway described involves the production of Abeta (a peptide derived from APP) and its interaction with the cytochrome c oxidase (COX) complex, which is part of the electron transport chain in mitochondria. Abeta accumulation can lead to mitochondrial dysfunction, as suggested by its inhibitory effect on COX activity, which in turn affects cellular respiration and energy production. This mitochondrial impairment is implicated in neuronal damage and is a hallmark of Alzheimer's disease. Thus, the APP allele contributes to the pathogenesis of Alzheimer's disease through the accumulation of Abeta and subsequent mitochondrial dysfunction.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP (amyloid beta precursor protein) gene is located on chromosome 21 and is central to the amyloidogenic pathway, where it is cleaved to produce \u03b2-amyloid peptides. These peptides accumulate and form plaques, a hallmark of Alzheimer's disease. The pathway described\u2014APP* \u2192 Abeta \u2192 CxIV \u2192 H2O\u2014reflects the production of amyloid beta and its interaction with the cytochrome c oxidase subunit IV (CxIV), which is part of the electron transport chain in mitochondria. This interaction may lead to mitochondrial dysfunction, oxidative stress, and neuronal damage. The accumulation of Abeta and its toxic effects on neuronal function are strongly linked to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APP gene encodes the amyloid beta precursor protein, which is central to the amyloid cascade hypothesis of Alzheimer's disease. The pathway described involves the production of Abeta, a peptide that accumulates in plaques in the brain. This accumulation is a hallmark of Alzheimer's disease. The other COX genes are components of the cytochrome c oxidase complex, which is part of the electron transport chain in mitochondria. The effect of the APP allele, particularly in the context of Abeta production, contributes to the development of Alzheimer's disease by disrupting normal neuronal function and leading to neurodegeneration. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a role in various cellular processes, including cell proliferation, differentiation, and survival. When activated by ligands such as neuregulins (NRG1-4), ERBB4 participates in signal transduction pathways that regulate development and function in multiple tissues. Mutations or aberrant activation of ERBB4 can lead to dysregulated signaling, contributing to disease. Specifically, alterations in the ERBB4 pathway have been implicated in the development of certain cancers, including breast cancer and schizophrenia. However, the most directly associated disease with ERBB4 dysfunction is schizophrenia.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase involved in various cellular processes, including neuronal development and signaling. When functioning normally, it plays a role in modulating responses to neuregulins (NRG1-4), which are ligands that bind to ERBB4. Mutations or aberrant expression of ERBB4 have been implicated in several diseases. Specifically, dysregulation of the ERBB4 signaling pathway has been associated with schizophrenia. Studies suggest that ERBB4 may be involved in synaptic plasticity and neural circuitry, and its disruption could contribute to the pathophysiology of schizophrenia. Thus, the ERBB4 allele contributes to the risk and development of schizophrenia.\n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that is part of the ErbB family, and it interacts with neuregulins (NRG1-4) as ligands. This pathway is involved in various cellular processes, including neuronal development, survival, and differentiation. Mutations or dysregulation of ERBB4 have been implicated in several neurodevelopmental and psychiatric disorders. Specifically, ERBB4 has been associated with schizophrenia, as studies have identified genetic linkage and functional disruptions in this gene in patients with the disorder. The biological effect of this ERBB4 allele may involve altered signaling in neural circuits, contributing to the pathophysiology of schizophrenia. \n\n\\boxed{Schizophrenia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway defined involves ATXN1 interacting with RORA and KAT5, which in turn regulate ITPR1, SLC1A6, and GRM1. ATXN1 is a known causative gene for spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. These downstream targets are involved in calcium signaling and neurotransmitter function, which are disrupted in ataxia. The interaction of ATXN1 with these genes likely contributes to the pathogenesis of SCA1 by perturbing normal neuronal signaling and function.\n\n\\boxed{Spinocerebellar Ataxia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given pathway involves ATXN1, a gene associated with spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder. ATXN1 interacts with RORA and KAT5, leading to the activation of ITPR1, SLC1A6, and GRM1. These downstream genes are involved in calcium signaling, glutamate transport, and neurotransmitter receptor function, all of which are critical in neuronal function. Dysregulation in this pathway due to mutant ATXN1 could disrupt normal neuronal signaling and contribute to neurodegeneration. \n\n\\boxed{Spinocerebellar Ataxia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe given genomic pathway involves ATXN1, a gene associated with spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder. ATXN1 is a transcriptional co-repressor that, when expanded, leads to misfolding and aggregation, causing neuronal dysfunction. The pathway shows interactions with RORA and KAT5, which are involved in transcription and chromatin remodeling, suggesting ATXN1's role in modulating gene expression. Downstream targets include ITPR1, SLC1A6, and GRM1, which are involved in calcium signaling and glutamatergic transmission, processes crucial for neuronal function. The dysregulation of these processes may contribute to the progressive degeneration of cerebellar neurons, a hallmark of SCA1.\n\n\\boxed{Spinocerebellar Ataxia Type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that functions as a tumor suppressor. In the provided pathway, CDKN2A activates the p53 pathway by inhibiting MDM2, which in turn stabilizes TP53. Activated TP53 upregulates CDKN1A, which inhibits the CDK4/6-cyclin D complex, preventing the phosphorylation of RB1. This maintains RB1 in its hypophosphorylated state, which represses E2F activity, thus halting the cell cycle. A mutation or deletion in CDKN2A can disrupt this pathway, leading to uncontrolled cell proliferation. Such alterations are commonly associated with melanoma and other cancers. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a cyclin-dependent kinase inhibitor that plays a critical role in cell cycle regulation and tumor suppression. When mutated or inactivated, CDKN2A can lead to uncontrolled cell proliferation. In the given pathway, CDKN2A negatively regulates MDM2, which in turn regulates TP53. TP53 is a central tumor suppressor that activates CDKN1A, which inhibits cyclin D and CDK4/6, preventing the inactivation of RB1. RB1, when active, represses E2F transcription factors, which are involved in cell cycle progression. Loss of CDKN2A function can disrupt this regulatory network, leading to unchecked cell division and tumor formation. This pathway is commonly altered in melanoma and various other cancers. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved in cell cycle regulation. In the provided pathway, CDKN2A negatively regulates the MDM2-TP53-CDKN1A axis and directly inhibits CDK4/6, which phosphorylates RB1 to release E2F. Loss or mutation of CDKN2A disrupts this regulatory network, leading to uncontrolled cell proliferation and genomic instability. This contributes significantly to the development of melanoma and other cancers. The loss of CDKN2A function is a well-established oncogenic event, often found in melanoma, neuroendocrine tumors, and certain hematologic malignancies. \n\n\\boxed{Melanoma}"]]